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ABSTRACT 
 
Children born with HIV in the 1980s and 1990s are surviving into adolescence 
and adulthood, due to the availability of highly active antiretroviral therapy (HAART).  
Growing up with a chronic and stigmatized disease presents considerable challenges as 
young people explore their sexuality, develop relationships, and take steps to become 
independent and productive adults.  Adherence to HAART is an essential and life-long 
practice for the maintenance of health and longevity.  For adolescents born with HIV, a 
daily medication schedule is one aspect of disease management that also includes medical 
visits, HIV status acceptance, bouts of illness, and disclosure of  HIV status to others.     
 This research uses a framework of medical ecology to explore the personal, socio-
familial, and medical contexts in which perinatally HIV-infected adolescents, as 
competent social actors, navigate the complexities of HIV disease management.  It 
examines personal behaviors and attitudes, family dynamics, peer relationships, and 
health care structures and relationships that affect their adherence to HAART. 
 A key finding of this study was increased agency and adaptation to HIV among 
adolescents who learned their diagnosis earlier in life and whose caregivers demonstrated 
acceptance of HIV and support for the adolescents.  They were able to adhere to their 
medication regimens, despite busy schedules, non-disclosure to friends, and treatment 
fatigue, and also had a somewhat better understanding of the medical aspects of HIV and 
HAART. Yet all of the adolescents had gaps in their understanding of clinical indicators 
and viral resistance, and the relationship between adherence and HIV transmission.    
 viii 
 This deficit in a medical conceptualization and understanding of HIV and its 
ramifications is another important finding of this study.  The adolescents’ notions and 
actions regarding HIV disease, based on social, cultural, and medical norms and 
interactions within their environment, have a significant impact on the natural history of 
HIV.  The level and consequent infectiousness of HIV as it responds to medications, 
mutates in their absence, and multiplies or is suppressed, depends on the individual’s 
strict adherence to medications and attention to medical details, and affects HIV 
transmission to the individual’s sexual partners.  From both an individual medical and a 
public health perspective, an understanding of the ramifications of adherence and non-
adherence to HAART is crucial.  Early acceptance and understanding of HIV increase the 
possibility of successful medication adherence and overall disease management.   
  In order to facilitate perinatally-infected adolescents’ disease management and adherence 
to medications, it is recommended that the process of disclosure of HIV diagnosis to the child 
begin early so that the child is fully aware by the age of ten.  The acceptance of HIV in the family 
and clear-cut roles and responsibilities for disease management should be facilitated by ongoing 
instruction and counseling.  Adolescents should be given thorough, if basic, instruction on the 
medical aspects of HIV, and should be encouraged to have friends, and especially sexual partners, 
accompany them to their clinic visits.  This will encourage greater understanding of HIV and 
perhaps lead to less stigmatization of HIV and those living with HIV.  Finally, providers and 
adolescent patients should construct a partnership in which their individual models of disease 
management are integrated and power and responsibility are appropriately shared. 
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CHAPTER 1: INTRODUCTION 
 
Research Rationale 
 The development and availability of highly active antiretroviral therapy 
(HAART) have improved health and prolonged life for people infected with the human 
immunodeficiency virus (HIV).  Children born with HIV in the 1980s and 1990s are now 
reaching adolescence and adulthood, something that was inconceivable before the advent 
of HAART and the highly effective class of drugs known as protease inhibitors. In fact, 
older children and adolescents are now the largest percentage of infected children (CDC 
2009).  Growing up with HIV poses complex problems as young people begin to explore 
their sexuality, develop relationships, and take steps to become independent and 
productive adults. Adolescence is a life stage fraught with change, growth, excitement, 
and confusion, and the added complication of a serious, chronic, and stigmatized disease 
presents huge challenges for youth as they grow and mature personally and socially.   
Studies note that many HIV-infected adolescents have not been raised to learn the 
typical responsibilities of adolescence and adulthood, since more attention was given to 
making their presumably short lives as happy and carefree as possible (Wiener, Mellins, 
et al. 2007; Battles and Wiener 2002).  Since the odds of survival into adulthood have 
improved,  it is now critical to consider the special medical circumstances and social 
issues of young people HIV-infected since birth, in order to enhance their healthy 
development.   
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Adherence to HIV medication regimens is an essential and life-long practice for 
the maintenance of health and longevity.  For adolescents perinatally infected with HIV, 
a daily medication schedule is one of many medical issues that also include regular 
medical visits, bouts of illness, developmental problems, acceptance of HIV status, and 
the ongoing decisions about disclosing one’s HIV status to others.  Living with a chronic, 
stigmatized disease is such a big challenge that parents and other caregivers often refrain 
from disclosing the diagnosis to the children for as long as possible.  At the same time, as 
these children enter adolescence and begin to exercise independence and explore their 
sexuality, their need to be aware of and understand their disease intensifies.  Since 
perinatally infected youth are generally receiving health care regularly, the health care 
setting is one venue in which their sexual health and development, responsible behavior, 
medication adherence, and disclosure of HIV status are addressed.  Disclosure of status, 
both to an infected person and by an infected person to others, is a sensitive issue even 
for the individual who is equipped with the social, economic, and emotional resources to 
manage its consequences.  For adolescents embarking on the exploration of relationships, 
sexuality, and independence, the issues of disclosure, acceptance, and responsibility 
related to HIV can be heavy burdens that affect their health behaviors, including 
medication adherence. 
For perinatally infected young people, the development of autonomy, whether the 
emphasis is on separating from parents (loss) or on achieving independence (gain) 
(Beyers et al. 2003), is a complex issue affected by the “unexpected futures” (Domek 
2006: 1367) they now have, and by the efforts of parents to keep them from the normal 
trajectory of growing up and from the knowledge of their disease (Battles and Wiener 
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2002).  Autonomy as competence (Beyers et al. 2003) may also be challenged by a 
complicated family dynamic where one or more members are also HIV-infected and 
might die, or have died (Fielden et al. 2006).  Knowing that AIDS has taken family 
members or severely burdens the family may affect how much the young person can 
believe in his own abilities to act, plan, and thrive (Steele et al. 2007:62).  The identity-
culture dialectic that defines adolescents presages their approach to disease management.  
Their responses, which are shaped by their “socioculturally mediated capacity to act” or 
agency (Ahearn 2001:112) in response to their HIV disease, become salient now that they 
are moving from childhood toward adulthood. 
For perinatally-infected adolescents, this transition is complicated by the 
integration of an HIV identity from which they may, at times, distance themselves 
because they do not want to be associated with adults who were infected through 
stigmatized behaviors (Kang et al. 2008).  The contradictory discourse of the child 
(Brannen 1996:115) as, on the one hand, a dependent and incompetent individual whose 
agency is ignored and, on the other hand, a child who is expected and encouraged to 
comply with medical instructions, points to the need for approaching the child, and 
especially the adolescent, as a more active participant or partner in the undertaking of 
tasks and construction of meaning normally thought of as resting in the adult domain.   
The capability and level of participation or partnership in their health care must be 
evaluated for each adolescent.  Maintenance of viral suppression has been problematic in 
adolescents with behaviorally-acquired HIV, and points to the need to evaluate 
adolescents for treatment readiness (Dodds et al 2003:44; Merzel et al. 2008:984), and 
better prepare teens with HIV for the life-long, sometimes difficult medication regimens 
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(Murphy et al. 2005).  Perinatally-infected adolescents, while accustomed to taking 
medications, may nonetheless require similar groundwork as they become aware of their 
diagnosis and take control of their medication regimens.  Since the effect of living with 
HIV since birth may be somewhat delayed maturity and treatment fatigue (Merzel 2008), 
this groundwork may result in the adolescent’s taking control of her medications 
gradually or at an older age (Schwartz and Drotar 2006).   
 Because adolescents with perinatally-acquired HIV have been prescribed 
antiretroviral therapy from an early age, they are likely to have some resistant strains of 
HIV (Mullen et al. 2002).  It is also possible that they were infected with a resistant strain 
carried by their mothers (Delaugerre et al. 2007).  An additional, important distinction of 
HIV, among other chronic conditions, is that it is an infectious disease, and can be 
infectious even during long symptom-free periods.  Moreover, the antiretroviral drugs are 
very unforgiving if not adhered to strictly (Fisher et al. 2006).  For these reasons, 
adherence is extremely important; it makes a lower viral load and thus reduced risk of 
HIV transmission to sexual partners more likely, and it also reduces the risk of further 
resistance to the adolescent’s current and future regimens.  The adolescent’s HAART and 
viral resistance history notwithstanding, it is of utmost importance for these adolescents 
to understand and practice good adherence, both for their own health and for current and 
future sexual partners. 
Situating the Research 
Perinatal HIV in the United States   
 In the United States, fewer and fewer babies born to mothers with HIV are 
themselves HIV-infected, due to more widespread HIV testing of pregnant women and 
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the administration of antiretroviral therapy to mothers and babies (Buchanan and 
Cunningham 2009).  Figure 1.1 shows the increase and decrease of perinatal AIDS cases 
from 1985 to 2007 in the United States.  With the advent of combination antiretroviral 
therapy and the development and availability of new medications, more reported cases 
were presenting as HIV-infected, having not progressed to AIDS.  For this reason, the 
CDC began reporting HIV cases separate from AIDS cases in 1998, though the HIV 
numbers represent only those states that had instituted HIV case reporting (CDC 1998).  
  
Figure 1.1 Reported U. S. Perinatal AIDS and HIV Cases, 1985-2007  
 Slide Source: cdc.gov 
  
 As of 2008, about 8,500 perinatal AIDS cases have been reported in the United 
States (CDC 2008).  As of 2007, there were about 7,550 perinatally infected individuals 
believed to be living with HIV/AIDS (CDC 2008).  Of these persons with HIV or AIDS, 
about one-third were under 13 years old (CDC 2008).  Many of them are now expected to 
survive through adolescence and into adulthood.  Thus, an understanding of how 
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perinatally-infected children and adolescents cope with HIV as they mature continues to 
be important for those providing services to them. 
Perinatal HIV in Florida 
 In Florida, perinatal HIV infection rates have followed national trends.  Figure 1.2 
shows the cases of perinatal HIV/AIDS in Florida from 1977 to 2008.  The perinatal 
transmission rate in Florida is now below 2% (FDOH 2009).  Through 2009, there was a 
cumulative total of 2,356 perinatal HIV/AIDS cases in Florida, of which 76% were 
Black, 13% were Hispanic, and 9% were White (FDOH 2009).                                            
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Figure 1.2 Florida Perinatal Cases by Diagnosis Year         Slide Source: FL Dept. of Health 
  
The increased life expectancy of person with HIV/AIDS is evident in the 
perinatally-infected cohort, among whom there are now individuals nearing 30 years of 
age.  At the same time, there are currently between 550 and 600 children under the age of 
13 living with perinatally acquired HIV in Florida.  Figure 1.3 shows the distribution of 
1,475 persons living with perinatal HIV or AIDS in Florida through 2009.  Through 
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8/31/10, there were 1,479 persons with perinatal HIV/AIDS presumed to be living in 
Florida (http://www.doh.state.fl.us/disease_ctrl/aids/trends/msr/2010/MSR0910.pdf). 
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Research Participants and Methodology 
 
 The participants in this research study were recruited from the Florida Family 
AIDS Network (FAN), a federally-funded program which targets and provides clinical 
and social supportive services for women, infants, children, and families infected and 
affected by HIV/AIDS.  Seventeen individuals were enrolled from among the perinatally-
infected adolescents aged 13 to 24 in FAN.  A semi-structured interview was conducted 
with each adolescent, who also completed a short medication and adherence 
questionnaire.  In addition, one focus group of biological mothers of infected children 
was conducted, and five clinicians who provide care to children and adolescents in FAN 
were interviewed. 
   Qualitative studies of medication adherence among people with HIV are 
underrepresented in the adherence literature (Beusterien et al. 2008; Sankar et al 2006).  
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The qualitative methodology used in this study of adolescents with perinatally-acquired 
HIV is an acknowledgment of the complexity of young people’s lives, and the methods 
employed allowed a range of questions to be posed – not just what a person does, but 
why, how, where, and when (Lehoux et al. 2006:2092).  This qualitative research allowed 
the young people to express themselves on issues that were of extreme importance to 
their lives and their health. 
 The study’s focus on the perinatally-infected adolescent in his or her social and 
cultural environment is embedded in the theoretical frameworks of medical ecology and 
childhood studies.  Medical ecology places the individual at the center of proximal and 
more distal contexts that interact with each other and variously influence the individual 
(Steele et al. 2007). The proximal niche has direct effects on the child’s agency, meaning 
making, and behaviors, and childhood studies focuses on children as independent 
members of culture and society, with their own subculture and capacity to formulate 
meanings during their interactions within this subculture (Bluebond-Langner and Korbin 
2007). 
Purpose of the Research 
Adolescence is the stage at which individuals begin to explore their sexuality and 
independence.  Perinatally-infected HIV-positive adolescents are becoming sexually 
active and assuming greater responsibility for their disease management.  Many 
adolescents with HIV are not engaging in safer sex and strict medication adherence, and 
this combination can increase the risk of HIV transmission to sexual partners (Letourneau 
et al. 2010; Quinn et al. 2000).  In addition, adherence interruptions or medication refusal 
increases the risk of viral resistance and poorer health outcomes. 
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 This research was designed to explore the personal, socio-familial, and clinical 
contexts in which perinatally infected adolescents navigate the complexities of living 
with HIV as they move toward adulthood and physical and emotional maturity.  In 
particular, the study examined adolescents’ medication adherence, and identified, 
compared, and analyzed personal behaviors and attitudes, family dynamics, peer 
relationships, and health care structures and relationships that affect their ability and 
willingness to comply with the instructions of their antiretroviral medication regimens. 
 These findings were used to propose measures that adolescents and their 
caregivers, medical practitioners, social service providers, and others in the adolescents’ 
medical/ecological environment could implement to improve the health-related behaviors 
of adolescents. Recommendations for addressing the support, coping, and care of parents 
and other caregivers, the procedures and interactions of health care encounters, policy 
making, and ancillary service delivery were also proffered as a result of the findings of 
this study. 
Research Site 
 The perinatally infected adolescents who participated in this research study were 
enrolled in the Florida Family AIDS Network (FAN), a program funded by a Ryan White 
Treatment Extension Act federal grant and administered at the University of South 
Florida College of Public Health.  This grant targets women, infants, children, and 
families infected and affected by HIV/AIDS, and funds primary and specialty HIV care   
at five clinical sites and social supportive services at two case management agencies in 
the Tampa Bay area.  The study participants were either patients at one of the clinics or 
received services at one of the case management agencies, and were specifically recruited 
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at the University of South Florida Pediatric Clinic in Tampa, Tampa Hillsborough Action 
Plan in Tampa, or AIDS Service Association of Pinellas in St. Petersburg.    
 Currently, FAN serves 163 clients with perinatally acquired HIV.  Of these, 130 
are between the ages of 13 and 24, and are categorized as adolescents.  At the time of this 
study, 90 of these adolescents were receiving their care at the USF pediatric clinic, where 
the majority of the study participants were recruited.  Two physicians and three nurse 
practitioners provided the clinical care for these adolescents, and they were interviewed 
for this study.  Adolescents also had access to the services of a nurse educator, social 
worker, medical case manager, and licensed clinical social worker at this clinic. 
Research Questions 
Since it is essential that perinatally infected adolescents, like all individuals with 
HIV disease, follow a strict medication regimen to ensure continued health and survival, 
this study focused on adherence and its meaning in HIV disease management.  The 
relationships between adherence and viral load and between viral load and HIV 
transmission risk also compelled an examination of adolescents’ perceptions of risk with 
regard to sexual behavior.  Therefore, the two primary research questions that this 
research addressed were: 
Question 1: What factors obstruct or promote medication adherence for 
perinatally-infected adolescents?  What cultural and social factors influence 
their decisions about adherence? 
Question 2: How do perinatally-infected adolescents perceive adherence to 
their medication regimens? 
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A secondary area of inquiry involved adolescents’ current and future sexual relationships 
and activity, and shapes the third research question:   
Question 3: How do perinatally-infected adolescents conceive of and  
situate sexual activity and sexual relationships within their HIV disease  
management? 
Research Hypotheses 
 The theoretical framework of medical ecology demands that the research 
questions be contextualized within the personal, social, cultural, and medical 
environments of the participants, and these contexts are assumed to have an impact on 
adherence behavior and sexual risk-taking behavior.  Thus, the hypotheses that this study 
tested were: 
H1: The active participation of the adolescent in his or her health care and 
treatment plan, and the level of trust in his or her health care providers have 
 an influence on the adolescent’s understanding of the importance of 
 adherence and his or her acceptance of adherence responsibility. 
H2: The lack of family stability (e.g., loss of parents or siblings to HIV) 
and peer support adversely influences adolescents’ adherence.  
H3: The timing and circumstances of disclosure to the individual have an 
impact on their subsequent adherence behavior. 
H4: Health status has an influence on an adolescent’s adherence.  Very 
healthy or very ill individuals are more likely to stop taking their medicine,  
or to take it sporadically. 
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Full Disclosure: Positionality and the Researcher 
 This research was undertaken by an individual who shares the HIV diagnosis with 
her participants.  My HIV-positive status was the motivating force behind my interest in 
and focus on HIV/AIDS in my academic and professional work.  While my experience 
with HIV and disease management, from transmission risk and diagnosis to adherence 
and disclosure, has been different from that of the adolescents with perinatally-acquired 
HIV in this study, it was important to recognize my position of commonality with them 
regarding living with an incurable disease and attending to a daily medication regimen.  
My position as an HIV-infected individual allowed me to move into their HIV experience 
and back again into my researcher position, but it also had the potential to influence the 
relationships, analysis, and recommendations that were part of the research process.  
While it was not my intention to insert my experience and HIV identity into the research, 
I did remain cognizant of the standpoint from which I approached the research (Hendrick 
2000). It seemed fair to allow both the study participants and any readers of the final 
research product access to this knowledge. 
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CHAPTER 2: LITERATURE REVIEW 
 
 HIV disease has become a chronic condition with the introduction and availability 
of highly active antiretroviral therapy (HAART).  Like most chronic health conditions, 
HIV disease entails management that is life-long and physically, emotionally, 
economically, and socially burdensome.  Added to these challenges is the continued 
stigmatization of HIV and its sufferers.  For young people with perinatally acquired HIV, 
the ongoing and sometimes difficult medical management of the disease is coupled with 
the physical, cognitive, and social development of childhood and adolescence, which 
effects a challenging lived experience for the children themselves as well as for their 
families. 
 The role of anthropology in the study of HIV and AIDS has long been recognized 
in the development of “analytical perspectives which transcend conventional host-vector 
epidemiology” (El-Bayoumi and Morsy 1993:1). Anthropologists have engaged in 
research aimed at elucidating the meaning of AIDS in particular cultural contexts 
(Marshall and Bennett 1990) and the subjective experience of AIDS in different social 
and cultural environments (Alcano 2009; Whyte 2009).  As HIV disease has evolved into 
a chronic condition in which individuals can experience long periods of good health, 
anthropological examination of the sick role (Crossley 1998) and clinician and patient’s 
differing chronic illness models take on added significance (Hunt and Arar 2001; Sobo 
1999).  For the perinatally infected children now entering adolescence and young 
adulthood, these constructed models of HIV disease, which encompass infectiousness, 
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prevention, and transmission, as well as ongoing care and treatment adherence, become 
salient as they endeavor to exercise agency as independent actors, especially in their 
intimate relationships (Hay 2010; Fernet et al. 2011). 
Chronic Stigmatized Disease 
 
While most chronic illnesses or conditions can be difficult to manage, due to their 
life-long and limiting sequelae, an illness, disability, or other condition that is chronic and 
also stigmatized can be demoralizing, and may require additional resources for effective 
management.  It not only causes suffering in individuals with many different health 
conditions or disabilities, but it is complicit in reducing the effectiveness of the public 
health system in addressing and containing certain diseases, including AIDS (Van Brakel 
2006: 307).  There are many health conditions that, judged at the social level, impose a 
“spoiled identity” upon the sufferer (Goffman 1963), such as Hansen’s Disease (leprosy), 
epilepsy, AIDS, and various types of mental illness (for a review of the stigma of these 
and other conditions, see Van Brakel 2006).  Numerous studies have been published on 
these conditions, and have enumerated the specific social obstacles that result from 
bearing the stigma of the disease.  The inferior, disgraceful, or unacceptable qualities of a 
person with a stigmatized condition have been examined at an individual and micro-
social level, which reveals the effects on and responses of the stigmatized individual 
(Link and Phelan 2001:366), but others have emphasized the social and cultural 
determinants of stigma (Kleinman et al. 1995; Link and Phelan 2001).  Studies of the 
lived experience of the sufferer in his or her social and cultural environment emphasize 
both the varied manifestations of stigma and the interactionist and contextual 
underpinnings of stigmatizing attitudes and behavior (Moneyham et al.1996).  It is crucial 
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to understand these influences on the lived experience of stigma in order to address the 
health-related responses that may stem from the stigma people feel or fear. 
Stigma has been attached to a wide variety of actions and conditions other than 
illness (Link and Phelan 2001:363-4), but it has been extensively directed at a large and 
changing group of illnesses and disabilities over time (Sontag 2001; Van Brakel 2006).  
The attributes of, reactions to, and outcomes of the stigmatized condition have generally 
been negative, constraining, and segregating, both to the sufferers and to the social actors 
around them.  There are typically four attributes that define a stigmatized condition:  
1) the individual is responsible for his or her condition; 2) the condition is unchangeable 
or fatal; 3) there is a danger of contagion; and 4) the condition is apparent to others 
(Herek 1999:1105-6).  While the latter three attributes have lost some legitimacy since 
the advent of highly active antiretroviral therapy (HAART), the first continues to have 
potency for people living with HIV (Lekas et al. 2006:1172).       
The responses to stigma by the sufferers, particularly due to the cultural ideas of 
blame, punishment, immorality, taboo, and sin (Douglas 1991; Kopelman 2002; Nack 
2002) that attach to their conditions, range from moral anxiety, guilt, and shame (Das 
2001) to secrecy, denial, and isolation (Herdt 2001; Scambler 2009).  The outcomes of 
these responses have personal and public health implications, which include ignoring 
prevention messages, delaying health care, developing other complicating conditions 
(opportunistic infections, depression, etc.), refusing to adhere to medication regimens, 
and increasing the chances of spreading disease (Carr and Gramling 2004; Weiss et al. 
2006), in addition to the socio-political consequences, such as discrimination, exclusion, 
and violence (Herdt 2001; Nicolas and Schilder 1997).  In addition to the effects of 
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stigma on those suffering from such conditions, stigmatizing attitudes can prevent the 
larger society from seeking health advice, practicing safe behaviors, and importantly in 
the case of AIDS, getting tested (Valdiserri 2002; Heijnders and Van Der Meij 2006). 
While the focus of my research was on individual disease management, it is 
important to recognize that stigmatized diseases like AIDS have their roots in social 
structures of inequality and marginalization, and the unequal distribution of power 
(Farmer 1999; Lekas et al 2006; Parker and Aggleton 2003; Scambler 2006).  In 
particular, the view of AIDS from its beginnings in the early 1980s has been one of a 
disease of outsiders and/or the powerless, invoking responses of “us” versus “them,” 
(Devine et al. 1999; Gilmore and Somerville 1994), in which AIDS does not concern the 
dominant, powerful majorities, but rather particular marginalized groups.  The views of 
the powerful center maintain the social norms that stigmatize certain groups and certain 
conditions.  Tewksbury and McGaughey refer to stigmatization as a “metaphorical 
vaccine” (Tewksbury and McGaughey 1997:53) since it is seen as “metaphorically 
removing or destroying its source” (Gilmore and Somerville 1994:1342).  It is also 
conceived as an act of “symbolic violence” that reinforces the existing unequal social 
structure (Lekas et al. 2006:1166).  In general, health is an important component of one’s 
identity, and is “sustained in part through the creation of ‘unhealthy’ others,” who are 
separate and dangerous (Crawford 1994).  This attitude and the results of this social 
structure find their way into the identities and actions of those afflicted (Ciambrone 2003) 
and also into the relationships of stigmatized individuals with health care providers and 
with other institutional agents (Taylor 2001).  The stereotypes associated with 
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stigmatized conditions are internalized by both the stigmatized and the stigmatizing (Fife 
and Wright 2000; Lekas et al. 2006: 1184). 
 The global distribution of HIV infection is heavily skewed toward the poorer 
nations (Parker 2002) and in the United States, HIV has disproportionately affected 
marginalized (Holtgrave and Crosby 2003) and minority populations, particularly African 
Americans (Oramasionwu et al. 2009).  Globally, 90% of HIV/AIDS cases occur in the 
less developed nations, most in sub-Saharan Africa, where 80% of AIDS-related deaths 
have occurred (Bancroft 2001).  Figure 2.1 shows the distribution of HIV/AIDS globally.  
In the United States at the end of 2007, African Americans accounted for almost half of 
all people living with HIV and 45% of new infections in 2006 (CDC 2010).  Figures 2.2 
and 2.3 illustrate the ethnic distribution of HIV/AIDS and rates of infection in the United 
States. 
 
 
 
 
 
 
 
 
 
 
      Figure 2.1 Global Distribution of HIV/AIDS, 2009                 Source: who.int 
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Figure 2.2 Persons Living with AIDS, by Ethnicity, United States, 2008    
Source: cdc.gov 
 
The figure below illustrates the disparity in HIV infections among ethnicities by 
showing the rate of infection in each ethnic population. 
 
 
 
 
 
 
 
 
  Figure 2.3 Rates of HIV Infection by Ethnicity, United States, 2008    
  Source: cdc.gov 
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The genesis of this disproportionate burden of HIV in communities of color, and 
in particular, among African Americans, has been traced to a combination of factors that 
embed HIV risk in social, economic, and environmental structures (Lane et al. 2004).  
Residential segregation and high rates of incarceration have led to conditions in which 
concurrent sexual partnerships are common and women’s power to negotiate their 
relationships may be diminished (Lane et al. 2004).  This social organization increases 
the chances of HIV transmission. Disparities in health insurance coverage and access to 
health care have also been implicated in higher rates of HIV in certain ethnic 
communities (Chu and Selwyn 2008).  Finally, social capital and income inequality have 
also been correlated with rates of HIV, where more social capital is associated with lower 
HIV rates and greater income inequality is associated with higher HIV rates (Holtgrave 
and Crosby 2003).  Social capital has been variously defined and measured, but is 
essentially resources and benefits that result from social cooperation (Holtgrave and 
Crosby 2003; Beaudoin 2009).  The benefits of social capital to health, however, have 
been shown to be mediated by income, and are significantly diminished among low-
income Blacks (Beaudoin 2009).  Thus, it is crucial to recognize and examine underlying 
socioeconomic conditions and their effect on health outcomes, including HIV 
transmission rates. 
The social structural barriers to a good quality of life, parity in health care, and 
dignified treatment have led many with stigmatized CHC to challenge the status quo and 
foster the integration of their illness into their identity, undergo a transformation of 
ideals, and embrace a positive meaning of their condition in their lives (Thorne and 
Paterson 1998:175).  The responses of stigmatized individuals are thus varied, depending 
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on their particular circumstances and possession of social and economic capital, and are 
“shaped by the relative power of the stigmatized and the stigmatizer” (Link and Phelan 
2001: 380).  The responses are personal and political, in that they are aimed at adapting to 
the personal circumstances of illness as well as resisting and challenging the societal 
norms that have made certain conditions moral and social burdens (Anspach 1979; cited 
in Taylor 2001). Many works have moved toward an examination of the opportunities for 
positive change, empowerment, transformation (Aujoulat et al. 2008; Mohammed and 
Thombre 2005; Farber et al. 2003; Baumgartner 2002), and “more optimistic analytic 
frames” that allow the person to maintain an unspoiled identity and anticipate a more 
affirmative future (Thorne and Paterson 1998:175).  The theoretical perspective of 
chronic illness as a “biographical disruption” (Bury 1982) has been redirected in many 
studies toward thinking of chronic illness as more biographically integrative and adaptive 
(Carricaburu and Pierret 1995; Farber et al. 2000; Baumgartner 2002).  Chronically ill 
people who are able to move beyond stigma and adapt to their illness can reconcile 
themselves to its presence and regain a healthy sense of body and self (Charmaz 1995). 
Whether a chronic illness and its associated stigma are seen as threats or as 
opportunities, upon diagnosis or upon disclosure (in the case of HIV-infected children), 
people must confront this permanent presence in their lives.  While they as individuals 
construct the meaning of their illness or disability, the meaning and the ensuing new 
illness identity, indeed any identity, “is shaped by external or social interactions” (Kralik 
et al. 2003:13), “both past and present social processes” (Fife 2005:2132).  The 
incorporation of the illness identity has different effects on the lived experience and sense 
of self of the individual, and the identity can take different forms (Baumgartner 2007).  
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The illness identity may be paramount and embraced (Baumgartner 2007:920); it may be 
socially disruptive and require a renegotiation of identity status with others (Mathieson 
and Stam 1995).  Some individuals will be their illness and others will consider the 
illness just one part of who they are (Bartos and McDonald 2000).  The new identity may 
be maintained, altered, denied, suppressed, or surrendered to, but adaptation is considered 
a necessary part of coping with the condition and ensuring a quality of life and health 
(Charmaz 1995).  The particular response to the chronic stigmatized disease is 
determined by the social and cultural context of the individual, and the meaning that he or 
she attaches to the illness and the particular mode of incorporation of illness into his or 
her identity will determine how he or she will manage the everyday aspects – medical, 
social, personal – of the disease (Bartos and McDonald 2000).  It is important to examine 
the factors that allow and facilitate the incorporation of the illness identity and the 
adaptation process in ways that promote a positive outlook in the present, one that allows 
for the realistic anticipation of the future through the setting of goals (Schwartz and 
Drotar 2006).  
The variation in adaptive measures taken toward the presence of a chronic disease 
necessitates an exploration of the variation in the cultural context of the individual and in 
the social environment in which he or she acts and interacts.  The cultural context, 
including the beliefs and norms surrounding illness, influences the particular meaning 
that a person develops and attaches to his or her illness (Fife 1994:310).  An 
understanding of the particular sociocultural variables which encourage and support 
“found meaning,” that is, a positive explanation that reconciles “ the world view and the 
self view” (Thompson and Janigian 1988, cited in Fife 1994:310), is important for 
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disease management, since it is the adaptation to and acceptance of the chronic condition 
that facilitates the fulfillment of ongoing medical requirements, including regular medical 
visits and adherence to medications and other medical directives.  The discovery of 
meaning and the incorporation of the illness identity, however that is manifested, into the 
self, are tasks requiring effort that may be especially challenging for adolescents, since 
they are developmentally at the point where they are grappling with the identities that 
will constitute their adult selves. 
Adolescence and Perinatally Acquired HIV Infection 
  
Perinatally-infected adolescents are embarking on a new phase both in their lives 
and in the “trajectory” (Alonzo and Reynolds 1995:303) of their disease.  Though they 
have lived their entire lives with an illness that requires frequent medical visits and daily 
medication, many of them are just learning their diagnosis as they enter adolescence.  For 
these adolescents, the ill self is habit (Charmaz 2002), but the HIV-positive self is not.  
While perinatally-infected youth are familiar with illness, that is, the lay experience of 
being sick, it is only upon disclosure that they are really able confront their disease as a 
clinical phenomenon (Kleinman et al. 1978). This knowledge will then change the illness 
experience. This new information, as well as the new phase of adolescence, elicits 
responses to the illness: making sense of their disease (meaning making), integrating an 
HIV identity into their emerging adult selves, and exercising agency as increasingly 
independent persons. With this new knowledge, they confront the cultural definitions of 
HIV and AIDS, which now pertain to them.  They must embark on a quest to discover 
what HIV means to them, and in a culture where the definition of AIDS provokes 
stigmatizing associations and labels (Kang et al. 2008; Rao et al. 2007 ), the quest for 
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meaning, identity, and agency may be arduous and psychosocially demanding (Battles 
and Wiener 2002; Dodds et al. 2003; Kang et al. 2008). 
Meaning, Identity, and Agency   
 Meaning making, identity development, and agency all occur within the context 
of people’s cultural systems, which in turn “are human creations, continually recreated 
and reimagined by individuals with diverging experiences and motives” (Buckser 2008: 
168).  Meaning is an individual dynamic construction that is embedded in the person’s 
particular social and cultural context (Fife 1994:315; Thorne 1999:400), so the ill person 
may assign different meanings to the illness as his or her experience varies in changing 
contexts.  The meaning of illness refers to the individuals’ “unique perceptions of the 
world as they know it and the ways in which they perceive the [illness] event redefining 
their world, their place in that world, and therefore their personal identity” (Fife 2005: 
2133).  Fife’s (1994:311) schema of meaning construction in the face of illness integrates 
these questions of meaning, identity, and agency which individuals face when they learn 
they have a serious illness, and she further argues that meaning comprises two 
conceptualizations, self meaning and contextual meaning, which are dialectically related 
(Fife 1994) and allow individuals to situate their illness experience in a context that gives 
their illness identity and social situation integrity. 
Fife (1994; 2005) is cited in some detail because her conceptualization of 
meaning in illness provides a framework for attaching meaning to the illness both as 
personal, lived experience and as socially and culturally constructed event.  The personal 
meaning becomes the basis for the establishment of a new, added, or changed identity, 
and this meaning is influenced by the meaning attached to the condition in the wider 
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sociocultural context.  Further, if we conceive of culture as shifting rather than static 
(Taylor 2007), then it not only influences but is influenced by the personal meanings and 
lived experience of its members, as they go about “the remaking of moral meanings and 
the reframing of the ontology of suffering” (Kleinman et al. 1995:1321).  This dialectic 
may be particularly salient in the case of highly stigmatized conditions, like AIDS, as 
members of a social and cultural community assume a “flawed identity” (Hosek et al. 
2002:356) because of stringent negative cultural definitions and connotations, but may 
then contest the outsider status that this identity imposes in an effort to foster cultural 
change and resume normal, accepted membership status. 
The meaning of a chronic, even stigmatized, condition can be positive or 
negative, and is unique to the individual, conditioned as it is by personal attributes, social 
factors, and experience (Kang et al. 2008:232).  Since the factors influencing meaning 
making are variable, meaning can change (Thorne 1999).  For adolescents with 
perinatally-acquired HIV, the factors that shape the meaning of HIV, in addition to 
stigma, include the life-long nature of their illness, the time and manner of disclosure, the 
secrecy and fear surrounding the illness, the burden of HIV on other family members, 
family loss, social capital (Sawyer et al. 2007:1485), delayed development, economic and 
other social problems, and membership in or association with marginalized populations 
(Domek 2006; Fielden et al. 2006; Hosek et al. 2005; Kang et al. 2008; Ledlie 2001; New 
et al. 2007; Rehm and Franck 2000).   
 The coalescence during adolescence of culture, identity formation, and the onset 
of autonomy will have a marked effect on how HIV-infected adolescents manage their 
disease.  Culture describes not only the beliefs and values that are attached to health and 
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illness in general and to HIV in particular, but also to the symbolic interactions that the 
adolescents engage in with peers, family, community, and health care system.  Identity 
includes, in addition to a myriad of roles vis-à-vis others, the HIV/AIDS identity 
(Baumgartner 2007), because HIV disease will always be a part of the adolescent’s life. 
How the person integrates this disease identity will have an impact on how he or she 
responds to the medical factors involved in lifelong disease management – adherence, 
disclosure, illness episodes, medical routines, and overall attention to healthy living. The 
development and incorporation of the illness/disease identity also has implications for 
psychosocial wellbeing. 
For any adolescent, the construction of meaning and identity is novel and 
potentially confusing.  For the adolescent with HIV, as with other chronic illnesses, 
identity development can be negatively impacted by the illness (Hosek et al. 2002).  
Perinatally-infected adolescents nearing adulthood have been shown to have difficulty 
with their HIV identity because they do not want to be associated with the adults who 
were infected behaviorally through stigmatized behaviors such as drug use or 
homosexual activity (Kang et al. 2008). The denial or avoidance of the HIV identity is 
one of the stages of the developing adolescent identity, where one has not explored, 
acknowledged, or accepted the HIV identity as part of the self (Hosek et al. 2002).  The 
individual at this stage of identity development, when he or she has not yet adjusted to 
the illness identity, manifests a coping strategy that is emotion-centered (LeBlanc et al. 
2003), whereas adolescents at the other end of this identity development continuum 
exhibit problem-centered coping (LeBlanc et al. 2003), and have reached an acceptance 
of their HIV identity that allows them to think more about the future (Hosek et al. 2002).  
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Denial or avoidance coping has been shown to have negative consequences on both 
physical and mental health among adults, adolescents, and children with chronic illness 
(Dahlbeck and Lightsey 2008).  
 It is also important to note that the illness identity may be more salient at certain 
times. As with adults, adolescents find that their illness, as well as their life experience in 
general, takes center stage at certain times and fades into the background at others.  
Paterson’s (2001) metastudy of chronic illness experience, revealed that illness and 
wellness perspectives can and do switch places, with illness coming to the fore as a result 
of mitigating medical or social circumstances.  When the circumstances change, the 
wellness perspective may shift forward.  Whether the illness or the wellness perspective 
dominates any given time depends not only on aspects of the illness, but also on the 
salience of socioecological circumstances, such as poverty, racism, violence, family 
problems, and stigma (Kang et al. 2008).  Adolescents with perinatal HIV have shifted 
between periods of illness and periods of wellness throughout their lives, but it is during 
adolescence that their psychosocial, developmental, medical, and family changes will 
affect their own approach, not their caretakers’ approach, to their illness.  The shifting 
perspectives of illness/wellness during the confusing time of adolescence influence the 
decisions that these young people are now beginning to make for themselves.  This 
shifting identity will have implications for whether, when, and how adolescents comply 
with medical directives, including medication adherence, discussed in greater detail 
below. 
For perinatally infected young people, the development of autonomy is a complex 
issue affected by the “unexpected futures” (Domek 2006:1367) they now have, and by 
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the efforts of parents to delay the normal course of growth and maturity as well as 
knowledge of their disease (Battles and Wiener 2002).  Autonomy as competence 
(Beyers et al. 2003) may also be challenged by a complicated family dynamic where one 
or more members are also HIV-infected and might die, or have died (Fielden et al. 2006).  
Knowing that AIDS has taken family members or severely burdens the family may affect 
how much these young people can believe in their own abilities to act, plan, and thrive 
(Steele et al. 2007:62).  The identity-culture dialectic that defines adolescents presages 
their approach to disease management.  Their responses, which are shaped by their 
“socioculturally mediated capacity to act” or agency (Ahearn 2001:112) in response to 
their HIV disease, become salient now that they are moving from childhood toward 
adulthood.  
Ahearn’s pared down and direct definition of agency fits well with adolescents 
whose independent actions and the reasoning behind them are now taking shape.  The 
cultural influences around them contribute to their construction of the meaning of HIV 
and to the identity they are developing in the face of this chronic, stigmatized disease. 
These influences, coupled with the particular HIV identity that has emerged, will 
determine the types of actions they take in dealing with their disease.  Two of the more 
problematic areas of the adolescent experience of living with a chronic condition are the 
social stigma attached to their condition and anticipating and preparing for the future 
(Kang et al. 2008; Rehm and Franck 2000: Schwartz and Drotar 2006).  Adolescence is a 
stage during which individuals value normalcy and want to fit in and establish 
independent social relationships (Fielden et al. 2006: LeBlanc et al. 2003).  It is also the 
time of nascent independence when young people begin to make decisions that have the 
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power to affect their futures. They are aware of growing up and becoming adults, so part 
of their focus is on that future adulthood.  These challenges – stigma and future goals – 
significantly shape and are shaped by the chronic disease experience during adolescence, 
and translate into agentive1 decisions about and patterns of adherence and disclosure 
(Kang et al. 2008). 
Adherence to Medications   
 Stigma is one of the cultural notions that, in Ahearn’s (2001) words, mediate the 
capacity to adhere to medications and to disclose one’s status to others. The negative 
effects of stigma lead to non-adherence and failure to disclose because secrecy is seen as 
the best defense against stigmatizing attitudes and actions (Brown et al. 2000; Rao et al. 
2007) and the surest way to appear normal.  Preparation for adulthood and the setting of 
goals, which adolescents begin to address independently, may be a source of ambivalence 
for youth with perinatal HIV, because they may not been raised with an eye on the future 
and they may have witnessed shortened futures in the death of a family member (Brown 
et al. 2000; Merzel et al. 2008). This uncertainty of the future may lead to difficulties in 
the transition to adulthood (Battles and Wiener 2002: Hosek et al. 2002) and affects how 
they perceive and manage adherence.  In addition, if adolescents live with biological 
mothers, then their problems with adherence may reflect the mother’s own difficulties in 
accepting her disease and taking medications every day (Cunningham et al. 2006:44).   
On the other hand, if a child’s mother has a positive attitude about the future and the 
medications that make that future possible, this, too, may be felt by the child (Hammami 
et al. 2004). 
                                                 
1
 I opt for Ahearn’s choice of the adjectival form of agency (Ahearn 2001:110) 
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The capacity to act in response to one’s HIV disease is noted consistently in the 
literature as being affected by the medical ecological context of the young person (Brown 
et al 2000; Williams et al. 2006; Steele et al. 2007).  In addition to stigma and personal 
constructions of the future, the agency of the adolescent with perinatal HIV within the 
domain of HIV disease management is influenced – either facilitated or constrained – by 
local meanings, that is, the culture of HIV (Brown et al. 2000; Baumgartner 2007), HIV 
medications (Belzer et al.1999), family dynamics (Pontali 2005), the health care system 
(Dodds et al. 2003), and health care relationships (Pontali 2005).  Medication adherence 
is highlighted in HIV disease management because it is currently the only action shown 
to improve and extend a person’s life, but even more importantly, because HIV 
medications are very unforgiving if adherence is not virtually perfect.  The risk of HIV 
resistance to medications escalates when patients fall below 95% adherence (Veinot 
2006:265).  This is equivalent to forgetting a dose fewer than two days a month.  In the 
clinical tradition, adherence to HIV medications is essential and may seem incontestable, 
but clinicians often fail to recognize that “pills have symbolic power in addition to active 
ingredients” (Trostle 2000:40).  The cultural background of the adolescent and his or her 
family and community determines the goals that are set with regard to managing his or 
her disease (Schwartz and Drotar 2006), and may not coincide with the health care 
provider’s goals for the patient.  Anthropologists have examined how differences in the 
provider and patient’s understandings of illness and disease influence both health care 
interactions and the patient’s health behaviors (Hunt and Arar 2001; Wong and Ussher 
2008).   
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 Non-adherence to medications may be intentional or unintentional.  Bauman 
(2000) outlines the risk factors for chronic illness in general.  While unintentional non-
adherence seems to be more prevalent, HIV-positive people do sometimes make the 
decision to stop their medications.  Perinatally-infected adolescents may be especially 
unwilling to continue taking their medications, because of the disruptiveness of the 
regimen and because they are weary of both taking the medicine and enduring the side 
effects (Bauman 2000). Unintentional non-adherence is more complicated – and more 
dangerous for people with HIV – because many factors outside of the individual interfere 
with the desire or at least the willingness to adhere.  Adherence has been shown to be 
poorer among adolescents than among adults and younger children (Merzel et al 2008: 
977).   
 The illness identity that incorporates meanings and values, and the disease 
management informed by this identity, develop in and are shaped by several contexts: the 
personal (cognitive, emotional), the social, the cultural, and the medical.  Adherence, 
specifically, is dependent upon the adolescents themselves, their family and peer group 
dynamics, the medical aspects of HIV disease and highly active antiretroviral therapy 
(HAART), and the health care system and provider relationships (Pontali 2005).  For 
adolescents just beginning to take control of their medication regimens, adherence as a 
patient-centered activity requiring active personal effort can be an onerous task.  On the 
individual level, depression has been associated with non-adherence to HIV medications 
(Murphy et al. 2005).  One of the factors that may predispose perinatally-infected 
children and young people to depression and other psychosocial distress is the loss or the 
threat of loss of family members to AIDS.  In addition to the difficult adjustment after 
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such loss, there is the added burden of “disenfranchised grief,” during which stigma 
keeps children from speaking openly about the reason for their parent’s or sibling’s death 
(Battles and Wiener 2002:162).    
Maintenance of viral suppression has been problematic in adolescents with 
behaviorally-acquired HIV, and points to the need to evaluate adolescents for treatment 
readiness (Dodds et al 2003; Merzel et al. 2008), and better prepare teens with HIV for 
the life-long, sometimes difficult medication regimens (Murphy et al. 2005).  Perinatally-
infected adolescents, while accustomed to taking medications, may nonetheless require 
similar groundwork as they become aware of their diagnosis and take control of their 
medication regimens.  Since an effect of living with HIV since birth may be somewhat 
delayed maturity (Sherr et al. 2009), this groundwork may result in the adolescent’s 
taking control of his or her medications gradually or at an older age (Schwartz and Drotar 
2006).   
For some young people, taking medications reminds them of their HIV status or 
seems unnecessary since they feel well (Murphy 2003).  Taking medications for an 
incurable disease may also elicit thoughts of their own, perhaps imminent, death, which is 
psychologically and emotionally daunting for a teenager (Dodds et al. 2003).  The 
perinatally infected have the added menace of medication fatigue (Merzel et al. 2008).  
As mentioned earlier, an emotion-centered response to HIV may lead to poorer 
adherence.  Finally, a huge problem noted by many young people is a logistical one, in 
which schedules and activities lead them to forget, not have medications with them, be 
unable to take them because they were busy, or not want others to see them taking their 
medications (Murphy et al. 2003). 
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In terms of the medical aspects of HIV and HAART, the chronic nature of HIV 
disease management may begin to affect the perinatally-infected adolescent’s sense of 
normalcy.  Disease symptoms and opportunistic infections that require hospitalization 
may be a fact of life, and the complexity and tolerability of the medication regimen and 
frequent medical appointments and directives may interfere with the individual’s 
activities.  As adolescents develop autonomy, they may express opposition to care and 
treatment by resisting caregivers’ oversight (Merzel et al. 2008) or by rebelling against 
doctors’ orders (Hammami et al. 2004: Veinot et al. 2006).  Those adolescents with a 
sense of control over their health behaviors tend to achieve better adherence (Hammami 
et al. 2004).  In particular, since they will have already been on medications for years as 
they reach adolescence, there is the possibility that they have changed regimens more 
than once due to treatment failure, and the current regimen may be complex and difficult.  
HIV medication regimens are generally composed of at least three different drugs, and 
may involve complicated scheduling.  Adverse effects may also be severe enough to 
interrupt normal day-to-day activities, and will be a reason to forgo a dose (Belzer et al. 
1999).  While forgetting pills, whether intentionally or unintentionally, may be due to the 
young person’s developmental abilities, it may also be the result of the “lack of 
compatibility of the antiretroviral regimen with daily activities” (Pontali 2005: 140). 
Family Dynamics   
 The unique characteristic of HIV disease for the perinatally-infected child or 
adolescent is its presence in the family – an infected mother, and possibly also a father 
and siblings with HIV.  Like genetic conditions transmitted from parent to child, perinatal 
HIV causes guilt, but unlike other transmitted diseases, HIV can and often does leave the 
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infected and uninfected child orphaned or with a mother compromised by the disease 
(Lee and Fleming 2003).  There is also the family experience of stigma that accompanies 
an HIV diagnosis (Bogart et al. 2008), as well as the social and economic inequalities that 
underlie the HIV experience in many families (Castro and Farmer 2005).  For this reason, 
there are many family configurations for the perinatally infected child – living with 
biological parents, foster parents, related kin, such as grandmothers, and adoptive 
families (Linsk and Mason 2004; Theall et al. 2004; Cohen 1994; Caldwell et al. 1992).  
The family situation has implications for the adolescent’s success at adherence, because it 
introduces complex dynamics between infected members and between infected and non-
infected members (Rehm and Franck 2000).   
The relationship between the adolescent and his or her parent or other caregiver 
has an influence on how he or she will adhere to medications.  An HIV-positive parent’s 
attitude toward his or her own adherence may be important for how the adolescent adapts 
to this aspect of disease management (Pontali 2005; Williams et al. 2006), and studies 
have shown that HIV-positive caregivers’ own adherence to medications and retention in 
health care may be affected by their attitudes toward medications, distrust of health care 
institutions, and poor relationships with their health care providers (Beer et al. 2009; 
Beach et al. 2006).  Thus, the family’s overall attitudes toward their health care must be 
explored. 
  Strategies and “adherence partnerships,” in addition to open communication, 
facilitate adherence in the sometimes hectic schedules of daily living (Merzel et al. 
2008:981).  Open communication between caregivers and health care providers can also 
have a positive effect on the young person’s adherence, and the inclusion of family 
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members in the management of disease is vital from some cultural standpoints (Brown et 
al. 2000).  At the same time, culture at the family and societal level may dictate secrecy 
and silence when it comes to a child’s knowledge of his or her diagnosis and involvement 
in his or her health care (Lipson 1993; 1994).  Studies show that biological parents differ 
from unrelated caretakers in how they transfer responsibility and disclose the diagnosis to 
the child (Ledlie 1999).  A family-centered, multi-disciplinary approach acknowledges 
the importance of the family and the culture of the patient, and has shown positive impact 
on disease management (Brown et al. 2000:85). 
  The relationship of the primary caregiver to the HIV-infected child (Ledlie 
1999), the social environment and support of the family (New et al. 2007), and the 
cultural beliefs that guide behavior all influence how an adolescent learns of his or her 
HIV diagnosis, and adjusts to the responsibility for his or her health and adherence to 
medications (Bikaako-Kajura et al. 2006).         
Health Care Relationships   
 The final influence on HIV management and medication adherence is the health 
care system and the practitioner-patient relationship (Hammami et al. 2004; Pontali 
2005).  The health care system can be a convenient environment to navigate or it can 
confound the patient at every turn (Dodds et al. 2003), and the degree of availability, 
accessibility, affordability, and cultural appropriateness of health care services 
determines the degree to which patients are able and willing to comply with medical 
counsel.  For the adolescent transitioning from pediatric to adult care, the new health care 
system can provoke considerable anxiety and lead to suboptimum compliance or falling 
out of care (Wiener et al. 2007).  A transition team made up of clinical and psychosocial 
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practitioners, family members, and the adolescent can ease the move to adult care by 
engaging in planning and counseling with the young person before the transition occurs 
(Kang et al. 2008; Pontali 2005). 
The adolescent’s health care team is crucial to the success of the young person’s 
management of HIV disease, both by providing the necessary information for correct 
adherence to often complicated regimens and by providing the support that young 
patients need (Pontali 2005).  Perinatally-infected patients have been in care throughout 
their lives, and the relationships they have with these team members can be some of the 
more stable relationships in their lives.  However, as the children moves into adolescence, 
the health care provider may also be viewed as the authority who poses demands on them 
and, from this perspective, does not acknowledge their lived reality and leaves them with 
no control over their actions. This position of the health care provider can be a huge 
barrier to adolescents’ successful disease management (Dodds et al 2003:43). 
The expression of agency as a form of resistance to collective representations 
(Das 2001) of a particular chronic health condition is one way that afflicted persons can 
cope with their condition, especially if it carries stigma, and can gain a measure of 
control that seems to be in the hands of society and the health care system.  Agency as 
resistance can be directed at stigma, and thus lead to better adherence and disclosure, 
since individuals contest the stigma and act as valuable beings, without shame.  
Conversely, agency can be exercised as resistance to compliance and adherence, as 
patients attempt to gain a sense control that too often seems situated with the practitioners 
and with the medications that interrupt their lives (Kourrouski and Lima 2009; Childs and 
Cincotta 2006).  Responses to this resistance can be found in refining compliance issues 
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so that the patient shares the decision making with the practitioner.  This means involving 
the young person in the design of his or her care.  Adherence and other management 
issues are fluid (Williams et al. 2006), as are the illness/wellness identities (Paterson 
2001), and these vary according to the adolescent’s personal and social concerns, as well 
as his or her medical issues.  Health care providers must recognize that adherence may 
sometimes sink low on the list of an individual’s priorities, and it is in collaborating on 
setting medical goals (Schwartz and Drotar 2006) that conflict between compliance and 
other lived experiences can be minimized.  Adherence in adolescents seems to be 
positively affected by a warm, trusting relationship with their health-care providers 
(Pugatch et al. 2002).  
The establishment of goals by the growing child may not have been encouraged 
by family or health care providers when survival beyond childhood was not probable.  
Now that children are becoming adolescents, and adolescents are becoming adults, it may 
be helpful to approach compliance as empowerment (Aujoulat et al. 2008), so that the 
young people feel that they have a stake in their health care and have the ability to 
perform the compliance activities successfully.  This approach, in which there are goals 
and collaboration, must be considered in the context of the adolescent’s cultural identity 
and developmental level.  For all adolescents, but especially for those with chronic and 
stigmatized conditions, the desire to be normal is paramount.  Normalcy is a social 
construct, communicated among peers, and it is also defined culturally (Taylor et al. 
2008:3088), so it is important for the health care team to be aware of the cultural 
influences that guide their patients in integrating their disease management with the other 
facets of their lives.   
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 Despite the thousands of studies of compliance (Trostle 2000) that have been 
published in the last several decades, complete adherence to medications remains difficult 
to attain (DiMatteo 2004), and difficult to measure (Simoni et al. 2003; Wiener et al. 
2004).  In addition, adherence itself is defined individually, and it is often conceived and 
assessed differently by the patient and by the practitioner.  For the patient, as Trostle 
(2000) noted, taking medications is more than the instructions given by the doctor; taking 
pills has many meanings within the context of the adolescent’s life, and these meanings 
determine how those pills are taken and how important the person considers his or her 
adherence.  The discord brings up the definitions of adherence and compliance, and the 
loci of power and control that inhere in those definitions.  Trostle (2000) and many others 
accept Haynes’s definition of medical compliance as “the extent to which the patient’s 
behavior...coincides with medical or health advice” (Haynes 1979, quoted in Trostle 
2000:38).  The word ‘adherence’ is often used in this definition, and the two terms are 
used interchangeably.  Fawcett (1995; cited in Trostle 2000) made the distinction 
between the two words, suggesting that adherence is being faithful to the medication 
plan, whereas compliance evokes conforming to the practitioner’s instructions.  The 
distinction is trivial if one argues that the medication plan, after all, is given to the patient 
per the practitioner’s instructions, and the authority in any case rests with the practitioner.  
 Trostle maintains that adherence is an ideology, and as such, judges the patient’s 
adherence behavior “in terms of imposed professional expectations” (Trostle 2000:41; 
emphasis added).  It is the power exercised in the practitioner-patient relationship, and 
the efforts, if any, that are made to establish trust and collaboration in this relationship 
that have implications for the way in which the patient accepts and acts upon the 
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information shared during the medical encounter.  For adolescents attempting to establish 
autonomy in decision making, this power relationship may be especially precarious.  
They also may feel reticent about being truthful with providers because of the power the 
provider wields, not only to instruct but also to rebuke (Rao et al. 2007:32). Researchers 
have addressed this issue by looking at an empowerment-based approach to adherence 
(Aujoulat 2008; Veinot et al. 2006) and at the patient as partner in the provider-patient 
relationship (Thorne and Paterson 1998).  Not only would a more collaborative medical 
encounter and ongoing relationship distribute power in a more meaningful way for the 
patient, but it would also provide the opportunity for the provider to learn about what 
medication means to the adolescent, beyond its “active ingredients” (Trostle 2000).  With 
the ever-common problem of less than optimum adherence, the need to examine what 
disease, medication, adherence, and wellness mean in the everyday lived experience of 
perinatally-infected, HIV-positive adolescents is as great as ever.  For this group of 
children on the brink of adulthood, which is an unexpected but current reality, this effort 
to understand and help improve their lives by making disease self-management 
something they believe they are capable of engaging in efficiently, is an obligation that 
cannot be delayed. 
 Disclosure of HIV Diagnosis   
 Parents, caretakers, and health care providers face the complex task of revealing 
to perinatally infected children the nature and name of their illness, and there is wide 
variation among these adults on when and how disclosure should occur.  Before the era of 
HAART, children were not expected to survive beyond childhood or early adolescence, 
and so parents often could not (in the case of infants) or opted not to identify the disease 
 39
to their child (Domek 2006).  Since combination antiretroviral therapy has improved both 
the quality and length of life, that option is no longer feasible, though many parents often 
delay disclosure for years (Abadia-Barrero and LaRusso 2006).  The issues and attitudes 
involved in disclosure to a perinatally infected child are personal, social, emotional, and 
cultural, and will determine whether a parent or caretaker chooses to disclose in early or 
late childhood (Wiener et al. 2007:157). 
 Parents and other caretakers report reasons for and against disclosing to the HIV-
infected child, particularly at a young age.  Most commonly, they maintain that children 
are too young to understand the diagnosis, would share the information impulsively and 
inappropriately, might have negative emotional reactions, might experience psychosocial 
harm (depression, social stigma, etc.), and in the case of biological parents, would be 
angry with them (Vaz et al. 2010:248; Wiener et al. 2007:156).  A small percentage in 
one study expressed the wish to protect the child’s innocence (Wiener et al. 1996, cited in 
Waugh 2003:170).  On the other hand, they have appreciated the importance of 
disclosure when adherence to medications becomes problematic, the child is approaching 
puberty and possible sexual activity, and in general because the child needs to know how 
to protect others from infection (Vaz et al. 2010:250; Wiener et al. 2007:156).  The 
disclosure issue, however, not only addresses the child’s readiness to accept the 
diagnosis, but is a function of the parent or caregiver’s emotional readiness to impart this 
information and deal with the subsequent reactions and questions (Waugh 2003:170).  In 
particular, children living with biological parents or related kin are known to be disclosed 
to less often than their counterparts living with unrelated caregivers (Ledlie 1999), the 
biological parents or relatives being reticent to address the parents’ history of HIV 
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infection and their role and associated guilt in the child’s infection (Ledlie 1999; Lipson 
1993).  Mothers also may not disclose for reasons of denial or possible negative reactions 
from partners and family (Mitchell et al. 2008:45). 
 The American Academy of Pediatrics recommends disclosure to school-age HIV-
infected children in a manner that takes into account the individual child’s cognitive 
development and social context (Wilfert et al. 1999). The practice of openness about 
illness in children with cancer became common in the 1970s, when survival rates 
increased and children’s rights were being noted and discussed (Wiener et al. 2007:155-
6).  However, open communication may be more difficult with HIV than with cancer, due 
to the continuing stigma associated with HIV, maternal guilt, and the complicated issue 
of HIV as a disease of the family, all of which characterize HIV and differentiate it from 
other chronic childhood diseases (Lesch et al. 2007; Wiener et al. 2007; Cohen 1994).  
Studies have nonetheless shown that young children understand the concepts of illness 
and death (Bibace and Walsh 1980; Bluebond-Langner 1978; Lipson 1993), and are 
aware of their conditions even if parents are silent about them (Wiener et al. 2007).  In 
addition to children’s knowledge of and attention to what is happening to them, there is 
the possibility that children will overhear their diagnosis being named and discussed by 
medical providers (Instone 2000:242), and that it is better for them to learn their 
diagnosis through a deliberate process planned and undertaken by parents, caretakers, and 
medical providers (Lesch et al. 2007). 
  The psychosocial effects of disclosure to children are inconclusive across many 
studies and report a range of psychosocial and emotional effects (including a lack of 
effect [Instone 2000]) of disclosure and nondisclosure (Wiener et al. 2007), though a 
 41
longitudinal study of perinatally-infected children found no significant difference in the 
quality of life of these children before and after disclosure (Butler et al. 2009).  Some 
children report that they felt sadness and worry upon hearing their diagnosis, and others 
responded with “a quiet acceptance” (Oberdorfer et al. 2006:285), but there were also 
positive aspects to disclosure (Vaz et al. 2010) and perhaps a greater willingness to make 
health care decisions (Lesch et al. 2007).  Of special significance is the positive 
correlation between full disclosure of HIV status to children and adherence to 
medications (Bikaako-Kajura et al. 2006).   
 The prevalence of nondisclosure of HIV status to children is widespread, with 
similar outcomes from studies in Europe (Thorne et al. 2000), Brazil (Abadia-Barrero and 
LaRusso 2006), France (Funck-Brentano et al. 1997), India (Arun et al. 2009), South 
Africa (Kouyoumdjian et al. 2005), Thailand (Oberdorfer et al. 2006), and the United 
States (Flanagan-Klygis et al. 2002; Lester et al. 2002; see Wiener et al. 2007 for a 
review). While nondisclosure may be part of a cultural and social environment that 
dictates silence and secrecy (Hejoaka 2009), it serves to ensconce the child’s illness 
experience in “an embarrassing private world and becomes a shameful characteristic of 
the self” (Abadia-Barrero et al. 2006:40).  The disclosure of HIV status, on the other 
hand, clarifies and legitimizes for the child the lifelong experience of seeing doctors, 
taking medicines, and being sick, thereby reducing anxiety and confusion and, over time, 
providing a sense of relief and normalcy (Abadia-Barrero et al. 2006:37).  With 
disclosure of their disease, children were shown to understand their health condition 
better (Gerson et al. 2001), which could lead to the child’s exercising autonomy and more 
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successfully “attempting to achieve cognitive mastery over their bodies and lives” 
(Lipson 1993:8).   
 Disclosure is a complicated venture, embedded in the larger, ongoing family story 
of HIV, and many have suggested that it not be a discrete event but rather a process, an 
ongoing dialogue (Lipson 1993).  The benefits of  processual disclosure to school-age 
children convey the idea that it is not so much “whether, or even when, but how to speak 
with children about any disease” (Lipson 1993:8; emphasis in original).  The content of 
the discussion must certainly coincide with the child’s cognitive ability, and involves 
more complex explanations as the child gets older.  However, partial disclosure or false 
attribution of the child’s illness, which are very common among caregivers (Arun et al. 
2009; Oberdorfer et al. 2006; Funck-Brentano et al. 1997) can violate trust, cause 
suspicion and anxiety when questions remain unanswered, and lead to rebellion through 
non-adherence (Bikaako-Kajura et al. 2006).  On the other hand, children rated trust very 
highly as a reason for disclosure (DeMatteo et al. 2002).   
 Health care providers often favor disclosure earlier in the child’s life than  parents 
or other caregivers deem appropriate (De Baets et al. 2008; Klitzman et al. 2008).  Thus, 
the process of disclosure may clash with a family’s cultural perspectives and social 
standpoint, so health care providers need to be aware of the dilemmas which preclude 
disclosure that many of their families face (Lipson 1994).  Despite the differences in 
when disclosure should occur, many caregivers voice their desire for support and input 
from providers during the disclosure process (Myer et al. 2006).  The “developmental 
illness experience model” presented by Abadia-Barrero et al. (2006) and the 
characterization of disclosure as an “ongoing and dynamic” process (Ledlie 1999:148) 
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reflects the importance of recognizing the increasing maturity and cognitive development 
in children, the unique but changing sociocultural factors, family issues and caregiver 
needs, and the gradual nature of understanding what AIDS means to the child and the 
family (Abadia-Barrero 2006).  The process approach to disclosure can also include the 
health care providers, who often have long, trusting relationships with perinatally 
infected children.  The dialogue between caregivers and providers “may resolve the 
tension between caregivers’ and healthcare workers’…divergent understanding of 
disclosure and views of the child” (Lesch et al. 2007:815) and help them prepare for the 
ongoing dialogue that both the caregivers and the clinicians will have with the child. 
 In addition to the social, medical, and emotional reasons for disclosing the HIV 
diagnosis to children, there has been increasing attention given to the right of the child to 
know his or her diagnosis and thus begin to learn the personal and public health 
ramifications of successful HIV disease management (Wiener et al. 2007).  The efforts to 
protect a child from the disturbing revelation of his or her incurable, stigmatized disease 
are counterbalanced by the ethical exigencies that take into account the child’s desire for 
answers and capabilities to exercise responsibility (Lipson 1993, 1994).  Three broad 
ethical issues surrounding disclosure of an HIV diagnosis to children are the consensus 
on when to disclose, the competing rights of parents and children, and the health 
ramifications for both child and society (Klitzman et al. 2008).  These complex issues 
entail conflicting opinions and rights – health care provider versus parent, parent versus 
child, and child versus society – which must be addressed on a case by case basis.  
Approaching disclosure as an ongoing process, with the collaboration of parents and 
health care providers, can provide needed time to address these issues and form a 
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consensus on what is best for the particular child and family.  Blasini et al. (2004) 
developed a disclosure model comprised of pre-disclosure education sessions for 
providers, caregivers, and children, a disclosure event, and post-disclosure sessions.  The 
model takes into account the different conceptualizations of disclosure by providers and 
parents, and encouraged partnerships among all parties (Blasini et al. 2004:183).  
Anthropology and Childhood Studies 
 Children and childhood have been studied by anthropologists since the 
discipline’s beginnings in the late 19th and early 20th centuries.  Books and monographs 
contain details of the place of children in kinship relations, child rearing and socialization 
practices, and initiation rituals, among other topics. (LeVine 2007).  The focus on 
children, as social actors, with their own points of view, did not, however, begin to 
develop until the 1920s and 1930s.  Margaret Mead, well known to scholarly and popular 
audiences, conducted research with children and adolescents (Mead 1928, Mead 1932; 
Bateson and Mead 1942), in which she looked at children’s thought, adolescent 
development, and interpersonal relationships. One of the stumbling blocks in the early 
anthropological studies of children as learners of culture was the dependence on 
psychology for developmental theories of the child, which as LeVine notes, were 
“unreliable, as one developmental theory followed another into the trash heap of history” 
(LeVine 2007:249).  In addition to the loss of credibility, a difficulty with many 
psychological theories was that they did not acknowledge cultural differences and 
influences, but rather considered stages of cognitive development, moral development, 
and attachment, for example, to be universal (LeVine 2007:250).  Toren goes further still 
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in implicating “the notion of the child as an a-social, a-historical individual…in the 
various psychological and anthropological theories of cognition” (Toren 1993:471). 
Subsequent anthropological research saw the move away from dependence on 
psychological theories of stages of development and cognitive structures, though 
Hardman acknowledged the benefit of including a “formal list of analytical notions” 
(Hardman 1973:516) qua Piaget and Levi-Strauss. Then in the 1950s and 1960s, John and 
Beatrice Whiting and colleagues developed and carried out comparative ethnographies 
known as the Six Cultures Study (Whiting 1963; Whiting and Whiting 1975), which was 
“systematic naturalistic observation of children…in their routine ‘behavior settings’” 
(LeVine 2007:253).  The importance and value of studying children in their own right 
gained some traction from the 1960s onward; nonetheless, Hardman, in 1973, was asking 
“Can there be an anthropology of childhood?” and proposing the exploration of 
children’s worlds as more than just training for adulthood (Hardman 1973:501). 
 The 1980s and 1990s saw this shift in the study of children and childhood to an 
even greater emphasis on the children as autonomous beings, not just “adults in the 
making” (Brannen 1996:114).  The 1989 United Nations Convention on the Rights of the 
Child (UNCRC) underscored the stature and separateness of the child, and his or her 
human rights and needs for protection (United Nations 1989). The recognition of the 
child as creative cultural actor as well as the influence of environmental variation on 
childhood together moved anthropology into a new paradigm of childhood studies that 
saw its genesis in the 1980s (James 2007). 
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General Conceptualizations 
Children may have been regarded as just part of a larger kinship group, or a stage 
on the way to adulthood, but what anthropologists did recognize through ethnographic 
study was that sociocultural norms were dependent on environment and that childhood 
environments exhibited wide cultural variation (LeVine 2007:248).  The new childhood 
studies of more recent decades have focused on the child’s environment as a culture 
separate from the dominant adult culture and the child as an autonomous social actor. 
This called into question the idea of childhood as a liminal stage (James et al. 1998:198) 
and young children as precultural or presociological (James et al. 1998).  The idea of 
children “as empty buckets filling up with culture” was thus rejected, and participation of 
children in research was emphasized, so that data was gleaned from children themselves 
(Benthall 1992:1). The acknowledgement of children’s contributions led not only to a 
new anthropology of children, but also to a more comprehensive anthropological lens on 
culture (Bluebond-Langner and Korbin 2007:242). 
This bold turn in childhood studies meant that children were approached as 
independent members of culture and society, with their own subculture and capacity to 
formulate meanings during their interactions within this subculture (Bluebond-Langner 
and Korbin 2007).  Toren (1993) argues that children’s acts and ideas, and the meanings 
they construct, are socially mediated, historically situated, and based in experience, and 
are distinct from, and can even be oppositional to, the meanings of adults.  In order to 
examine the context and experience of children as they not only acquire but also create, 
transform, and challenge culture (Kyratzis 2004; Toren 1993), their voice and status are 
highlighted (James 2007; James et al. 1998).  The currency of the notion of children as 
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articulate talkers and formulators of meaning is demonstrated in studies and theoretical 
discussions, such as talk and social competence (Hutchby 2005), talk and peer culture 
(Kyratzis 2004), adolescent talk (Baker 1984), and the importance of listening to 
children’s voices in research (Roberts 2000).  The status of children refers to their present 
selves, as opposed to their slowly but continuously developing selves growing toward 
adulthood.  This duality in childhood – being and becoming – is discussed further below.   
The emic perspective of children in anthropological and other social science 
research aims to counter the longstanding powerlessness and silence of children in social 
life. By designing research in which children can be heard, their voices not being 
“silenced, suppressed, or ignored” (James 2007:261), the study of culture and social 
organization can be enriched by the information gained from the standpoint of the child 
(James et al. 1998:31).  At the same time, the child’s perspective fosters social 
understanding, recognizes the child’s right to expression, and can serve as a basis for 
policy. (McKechnie and Hobbs 2004).  However, this approach to a socially active 
childhood and to the child’s standpoint, which James et al. (1998) define in four 
sociological types of varying autonomy and power ascribed to children, raises the 
prospect of overgeneralization by glossing over the individual and cultural diversity 
among children and childhoods (James et al. 1998:30-1; James 2007). This 
homogenization of childhood can be prevented by the participation of children as co-
researchers and with particular anthropological methods of inquiry.  These are discussed 
in Chapter 3, as will the use of children’s voices and the issue of representation (James 
2007).  In addition, the medical ecology framework can mitigate such false homogeneity 
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as it places children in particular contexts and highlights specific social interactions 
within those contexts.  This framework is discussed below.   
While one of the foundations and aims of the anthropology of childhood is to 
dispel the notion of the immature child (Toren 1993), and to demonstrate the competence 
of the child as social actor and culture creator, it is important to recognize that childhood 
is fluid (James et al. 1998:203-4), children change rapidly, and their lived experience 
occurs within and is affected by a social structure that includes adults and adults’ 
influences.  With regard to children’s experience of illness, the notion of fluidity extends 
to the child’s wellbeing (Crivello et al. 2009), and therefore, his or her management of 
disease may likewise be fluid. The duality of being a child in time and place and 
becoming older as one moves toward adulthood is addressed by scholars of childhood 
studies, who attempt to contrast, rank, balance, and assimilate them. Uprichard insists on 
assimilation, that “children and childhood are always and necessarily ‘being and 
becoming’” (Uprichard 2008:303; emphasis in original).  She notes that children 
themselves are aware of both statuses and she argues that each shapes the other 
(Uprichard 2008).   
Despite Uprichard’s concern that in focusing on the being child, the “temporality 
of the ‘becoming’ child has…been lost” (Uprichard 2008: 306), anthropologists and other 
social scientists have maintained this focus as a counterpoint and corrective to past 
structures and conceptions  that presented the child as objects rather than subjects 
(Christensen and James 2000), natural as opposed to cultural (Jenks 1996; LeVine 1998; 
Panter-Brick 1998), incompetent (James et al. 1998), and waiting (Qvortrup 2004). 
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Childhood Studies and Management of Chronic Stigmatized Disease 
The idea of being and becoming in childhood raises two issues which are germane 
to the study of adolescents’ management of perinatally-acquired HIV: the agency-
vulnerability dichotomy and temporality.  The new childhood studies, including the 
anthropology of childhood, reject a hard structural determinism and mere social 
reproduction in children, and instead emphasize the child as a competent social actor 
capable of producing a separate childhood culture (Jenks 1996; James et al. 1998) as well 
as interacting with adult culture and, in so doing, transforming, challenging, and learning 
from it. James and James present a model, based on Mary Douglas’s grid-group matrix of 
social organization (Douglas 1973, cited in James and James 2004:53), whereby the 
production and reproduction of childhood occur in time and space.  It comprises Law, 
which they define as normative, mediative, culturally-reflective  
processes and mechanisms of regulation that exist in all societies, both 
religious and secular…comprising a system of principles and practices 
that underpin the social construction of a wide range of behaviours, 
attitudes, beliefs and relationships…[and] defines the rights and 
responsibilities of, and therefore the relationships between, citizens in 
any given cultural and political context. (James and James 2004:49) 
 
The Law is situated between, as it were, the social space that is structure, and social 
action, which is agency, and mediates the process by which structure and agency affect 
and are affected by the other (James and James 2004:57).  The model allows for 
variations in children as actors, both as particular members of particular societies and as 
members of a human group with certain similarities, and for the existence of plural 
childhoods as structures, similarly ranging from the particular to the general (James and 
James 2004:58-60). 
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 The growing prominence of childhood and children as distinct entities in 
particular societies (and at the level of more global structures, e.g., the UNCRC) at this 
particular moment is evident in the more visible and influential roles of children, and 
reflects changes in the social order and cultural practices (McKechnie and Hobbs 2004).  
The UNCRC (1989) is one such action.  In all societies, the cultural, economic, political 
and social contexts provide the particular nexus for responses about, toward, for, and by 
children.  The social changes and the social continuities, in addition to the regulations 
which mediate the social order, are controlled by adults (James and James 2004:25), so 
the agency of children necessarily involves the interaction between adults and children, 
and the uneven power relations between them. For example, the power of adults is 
questioned by Woodhead (1990) in his rejection of the characterization of children’s 
needs as straightforward observable facts by authoritative adults.  This way of looking at 
needs dismisses the particularities and competencies of children. It is within these adult-
child relationships that the child’s vulnerability appears in a paradoxical coexistence with 
agency.  This mix is perhaps more dialectical in nature than paradoxical, as the child’s 
agency is a reaction and a response to vulnerability that accompanies a particular stage of 
childhood.  Aside from the most common areas of interaction, the family and the school, 
the health care system serves as a setting for adult-child connection and communication, 
and the sick child is one example of the coexistence of agency and vulnerability. 
   Perinatally-infected children’s vulnerability stems from their status as children, 
their sick role, and their compliance with the adult professional medical sphere. It is this 
idea of compliance, as a judgment of a patient’s behavior with regard to professional 
expectations, which keeps authority safely within the hegemonic walls of medicine and 
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the adult world (Trostle 2000). Thus, the perspective of the HIV-positive adolescent, as 
well as his or her individually-shaped management, can demonstrate the active role and 
precise meanings that adolescents develop in response to their illness.  The health care 
provider’s understanding of the patient’s perspective is a necessary step in the forging of 
a partnership in health care treatment that spreads rights, responsibilities, and power 
among the participants and may ostensibly lead to better management and better health.  
This recognition of agency in health management helps to reduce the adolescent’s 
vulnerability. 
 The concepts of being and becoming in childhood raise two additional issues that 
are relevant to the lives and disease management of HIV-infected adolescents, 
particularly those infected at birth. These are temporality and embodiment, which are 
experienced uniquely by children and in childhoods, and must be examined by looking at 
the child or adolescent’s autonomous culture (Crivello et al. 2009; Hirschfeld 2002:613).  
Both are sociocultural constructions as well as physical realities, and are experienced by 
adolescents and children in ways that are distinct from adult conceptions and experiences.  
For the chronically ill child or adolescent, there may be developmental and psychosocial 
effects that stem from the constant presence of illness.  For the HIV-infected child in 
particular, the disease may result in reduced height and weight, as well as delayed 
pubertal development (Buchacz et al. 2003), which can alter both temporal and embodied 
experience.  The fact that HIV and other diseases, disorders, and disabilities are physical 
conditions has often obscured the social and cultural meanings and the different ways that 
they can be experienced, and the different cultures that children, including ill children, 
construct apart from adult culture (Hardman 1973). In Davis et al.’s approach to children 
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with disabilities, “overcoming the unitary notion of the disabled child” (Davis et al. 
2000:206) permits the revealing of structure-agency interactions and changes that 
children effect in their particular environment (Davis et al. 2000).  Time and 
embodiment, and their meanings, are two such phenomena that children with HIV are 
shaped by and which they in turn reshape as they experience life with HIV. 
The importance of time in childhood is revealed in expressed attention to age, 
constructions of age grades and age classes cross-culturally, and its future orientation 
(James and Prout 1990).  In addition, the passage of time during childhood shows 
evidence of ongoing developmental changes, and the social meanings of these changes, 
as well, shift over time (Toren 1993:462) and across cultures (Hockey and James 2003: 
4-5). The process of ageing and the passage of time are thus “qualitatively” experienced, 
and childhood “is less a fact of nature and more an interpretation of it” (James et al. 
1998:62).  Ethnography has revealed very different experiences of ageing, where, for 
example, the demarcation of childhood/adulthood is made by parenthood or betrothal 
rather than by chronological age (James et al. 1998:63).  Rites of passage and initiation 
rituals are also social and cultural acts that symbolically indicate the end of childhood and 
the entry into adulthood, a process of ageing and change that are not necessarily evident 
without the rituals (Hockey and James 2003:46-7).   
The future orientation of time in childhood may be especially problematic for 
adolescents with perinatal HIV.  Many of these young people were not expected to have a 
future, so they may not have a strong sense of “becoming” adults.  They may not see how 
their past and present relate to their future (Uprichard 2008), or they may see who they 
are as what they may never become.  The generational relationships, which differentiate 
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children from adults (James et al. 1998:66), must also be explored, for the fractures in 
these age links through untimely death may also affect the adolescent’s sense of time.  
How these adolescents construct and attach meaning to their pasts and presents, and those 
of their parents, becomes salient when we explore their attitudes toward medication 
adherence.  Adherence to antiretroviral therapy is the only means of giving HIV-positive 
individuals the opportunity at a future, but these children, who have been ill all of their 
lives but now know their diagnosis, may not envision a future at all.  Thus, adherence 
may seem nonsensical, and their present needs may be all that concern them.  On the 
other hand, some of these adolescents may see medication as their last-ditch effort at a 
possible future, and therefore practice adherence faithfully.  The meaning of time and 
ageing, and their conceptualizations of the future may also have implications for their 
emergent sexuality; the effects of risky sexual behavior, for them and for their partners, 
are in the future, and this may or may not have meaning for them.  Whether or not they 
engage in risky sexual behavior, adolescents are developing a sexual identity and 
perspective on sex, and making decisions based on these developments (James and James 
2004:155), so it is essential to know their perspectives and the elements that constitute 
their adolescent culture in order to address their health-related implications.  The 
chronicity (from birth, in this case), gravity, and stigma of HIV, therefore, necessitate an 
examination of perinatally-infected adolescents’ perspectives on time, in the culture that 
they create in the present, which may be very different because of their experience living 
with HIV.   
Health care providers have a key role in the lives of perinatally infected youth.  
They have been involved in some of their patients’ lives continually since birth.  As 
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medical care providers, they necessarily see the patient’s future as a priority in their 
decisions about care and treatment, and thus the child’s everyday experience are 
considered, if at all, only for their future consequences (James et al. 1998:74).  The 
disagreement between provider and patient, and the noncompliance of the patient may be 
the consequence of the routine view that children are incompetent and of value as 
“potential” adults rather than of interest as actual children.  The success of medicine often 
risks seeing patients’ success in terms of survival, that is, the future, rather than quality of 
life, that is, the present. The structure of time and the interpretation of the future also 
figure into adolescents’ transition from pediatric to adult health care (Pontali 2005). 
Pediatric HIV health practitioners in FAN acknowledge the difficulty of this change in 
their patients’ lives, and their understanding of the temporal currents of these lives and of 
how these patients view this transition may facilitate a process by which the integration 
into adult care is made.   
As we have seen, the theoretical basis of the new childhood studies is the child as 
competent social actor, meaning maker, and cultural author, viewed from the perspective 
of the emic present where agency and structure are balanced (Prout 2000:3). This design 
is underpinned by a social constructionism and, as will be argued below, by the medical 
ecology in which the perinatally-infected adolescents are situated.  It also argues against a 
strict biological determinism and structuralism that sees children as prisoners of their 
physical and psychological stage in life, developing gradually until the attainment of the 
freedom of adulthood.  That said, children, like the rest of us, are embodied beings, and 
while it is the theoretical view presented here that social and cultural variations fashion a 
heterogeneity of children and childhoods (and vice versa), one must recognize that the 
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lived experience of all young people is an embodied experience, and the experience of 
the body has effects on the person’s lived experience.  In addition, illness, health, and 
disease are physically as well as socially experienced phenomena.  Thus, the exploration 
of adolescents’ meanings and management of HIV may benefit from an exploration of 
how the “body (and its processes of change) forms an entity that is experienced 
and…interpreted by different actors in different social and cultural contexts” (Prout 
2000:3-4).  The notion of the chronically and seriously ill child summons up 
vulnerability, to which many in the new childhood studies object, at least as a wholly 
biologically determined state.  Rather, as Christensen argues, vulnerability is a culturally 
and socially constructed status which, particularly in childhood illness, consigns the child 
to dependence upon adult caregivers and ignores his or his knowledge and experience of 
illness (Christensen 2000:38).  Bluebond-Langner demonstrates quite convincingly in her 
poignant study of terminally ill children that they are very aware of what is happening to 
them, and very knowledgeable about their illness and its treatment (Bluebond-Langner 
1978).   
For the HIV-positive adolescent, physical and physiological changes in the body, 
opportunistic infections, and medication side effects are all part of the illness experience.  
The benefits and drawbacks of antiretroviral therapy are part of the fluidity of wellbeing, 
and their impact on the youth’s social and embodied identity may in turn affect their 
decision making with regard to adherence and other disease management activities.  The 
vulnerability and incompetence, along with the associated dependence that adults, 
including health care practitioners, often attribute to young people are constructions of 
childhood that lead adults to interact with children authoritatively and protectively, 
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effectively blocking the centrality and visibility of children’s agency with regard to their 
bodies (Prout 2000) and interfering with or complicating their disease management. 
The contradictory discourse of the child (Brannen 1996:115) as, on the one hand, 
a dependent and incompetent individual whose agency is ignored and, on the other hand, 
a child who is expected and encouraged to comply with medical instructions, points to 
the need for approaching the child, and especially the adolescent, as a more active 
participant or partner in the undertaking of tasks and construction of meaning normally 
thought of as resting in the adult domain.  The puzzlement of the stage and status of 
adolescents with HIV, and perhaps especially those with perinatally acquired HIV, raises 
the issues of transitionality and liminality that define these young people.  Adolescence 
can be seen as a liminal space where the individual is no longer a child but not yet an 
adult.  Rites of passage in many cultures mark this transition (Hockey and James 2003).  
The sick person, and in particular, one with a chronic illness, may also be liminally 
identified, for the Parsonian sick role, with its limits and roles in the sickness stage and 
the recovered health stage, is not complete (Crossley 1998:508).  The chronically ill, 
while never relinquishing their illness, nonetheless can spend extended periods of time in 
good health and are expected to fulfill responsibilities associated with good health 
(Crossley 1998:508). For perinatally infected adolescents, the period of liminality may 
include an acute phase, in which the person is overwhelmed by the diagnosis of HIV, and 
an enduring phase, which sees the person as perhaps healthy but always HIV-positive 
(Little et al. 1998) Therefore, the experience of HIV may be a source of confusion for the 
young people and for those around them.  It may, however, also be a conceptual time and 
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space where their competence as social actors and creativity in culture making is evident, 
as they occupy this way of being uniquely.  
This liminality may extend to the context of the health care system and provider-
patient encounter, where the representations of the sick child remove the child in his or 
her socially and physically lived experience and replace him or her with 
“‘technodressing’ [or] the generation of mathematical symbols which represent the 
corporeal body” (Place 2000:176).  The HIV-infected adolescent or child becomes his or 
her viral load and CD4 count; his or her life outside of the clinic is the number of 
medications and their schedule and dosage. 
Research Ethics: Ethics and Research with Children 
 
Research with children and adolescents is considered ethically challenging 
because of their characterization as vulnerable.  Children possess less cognitive ability, 
less lived experience, and less power vis-à-vis adults.  Their need for protection in a 
variety of situations is recorded in the United Nations Conventions on the Rights of the 
Child (1989). Their rights are duly noted in this document as well.  The involvement of 
children in research requires a search for balance between these needs and rights.  The 
theoretical perspective that guides the anthropology of children characterizes children as 
agentive, competent, social actors, whose participation in and contribution to cultural 
systems is important and necessary to study. Yet, historically, the researcher has been in 
control of the research design, methodology, direction, and analysis, so that the power 
and contribution of children (and indeed adults) to the process and outcomes of research 
can be and are perceived to be inferior or minimal compared to that of the researcher. 
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In order to approach research in an ethical manner, in which the interests of the 
participants are discerned and legitimated, evaluated and addressed, it is incumbent upon 
the researcher to examine the issues that make research with young people problematic 
and, in the course of addressing these issues, make informed decisions about the research 
methods that best elicit findings that are acceptable and beneficial to all involved 
(Whiteford and Trotter 2008).  
Research with human subjects has a checkered history.  While remarkable 
breakthroughs in medicine have occurred as a result of such research, it has also been the 
source of horrifying, harmful, and, to those involved, unknown consequences.  In order 
protect participants, define responsibilities, rectify the ills of the past, and safeguard and 
guide all who are involved in research with human subjects, a number of reports, 
strategies, principles, and treatises have been created and introduced to the public and to 
researchers, in the United States and internationally.   
The Nuremberg Code of 1947 resulted from the record of atrocities in World War 
II, in which people were forced into experiments, and the Nuremberg Trials which took 
place after the war (OHSR 1949).  The Code’s principles include securing the research 
participant’s informed consent to take part in the research and the right of the participant 
to end his or her participation at any time.  The World Medical Association adopted the 
Helsinki Declaration in 1964 (WMA 2008).  This is a policy statement that  delineates 
protections of participants in medical research, and addresses the issues of gaining assent 
from those deemed incompetent, presumably including minors (WMA 2008). 
Despite the establishment of the 1947 Nuremberg and 1964 Helsinki ethical 
codes, and other international documents, exploitative and harmful research continued.  
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In the United States, the Willowbrook State Hospital (1956-70), Jewish Chronic Disease 
Hospital (1963), and Tuskegee Syphilis (1932-1972) studies are three examples (UNH 
n.d.) of research that was conducted on both children and adults without their knowledge.  
In 1974, Congress passed the National Research Act, which provided for the creation of 
the National Commission for the Protection of Human Subjects of Biomedical and 
Behavioral Research.  The commission was charged with identifying ethical principles to 
guide federally-funded research; this was published as the Belmont Report in 1979 
(OHSR 1979).  This report explains three basic ethical principles – respect for persons, 
beneficence, and justice – that are considered imperative in research with human subjects,  
as well as the applications of these principles in the carrying out of research. 
The applications of the principles of ethical behavior in research, while relevant to 
adults and children alike, highlight some of the issues of vulnerability and protection in 
research with children. They include informed consent, information, comprehension, 
privacy, and voluntariness, which acknowledge the principle of respect and autonomy; 
assessment of risks and benefits, and the nature and scope of risks and benefits, which 
apply the beneficence principle; and the selection of subjects, which applies justice 
(OHSR 1979).   
Age is one aspect of a person that determines vulnerability, and it is accepted in 
many, if not most, cultures that the young are a vulnerable group (Whiteford and Trotter 
2009:88).  While the ethical guidelines of the American Anthropological Association and 
the Society for Applied Anthropology do not specifically mention children as a group, the 
British Sociological Association contains the phrase, “Special care should be taken where 
research participants are particularly vulnerable by virtue of factors such as age, social 
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status and powerlessness,” but it does not provide details of ‘special care’ (quoted in 
Morrow and Richards 1996:93).  Children are generally vulnerable on all three counts, 
and for children with a serious disease or disability, there may be additional factors 
contributing to the possibility of harm or exploitation. 
The theoretical perspective that will guide my research sees children and 
adolescents as competent social actors, capable of agency in their own social, cultural, 
and medical settings (James et al. 1998).  Their lived experience in their particular 
environment is the basis for understanding how they manage their HIV disease, including 
medication adherence.  This perspective recognizes that power lies with the adolescents, 
both in their lives and in their participation in the research. The acknowledgement of 
power in a group which is generally perceived and treated as powerless adds ethical and 
methodological “complexities and uncertainties to the research process by interposing a 
new actor and thus a new set of social relations into the field” (Christensen and Prout 
2002:482).  The complexities may be addressed by treating the ethical concerns as an 
ongoing process, to be revisited throughout the research study (Helseth and Slettebø 
2004), and by carefully choosing methods that best allow both a smooth process and 
forthright content as a result of the adolescents’ participation.  
The starting point for addressing the ethical issues in research with perinatally-
infected adolescents with HIV/AIDS is thus the same as it would be for research with 
adults.  The participants must be fully informed of the research and of what their 
participation will entail, their understanding must be established, and their informed 
consent to participate must be freely given.  For those who are not at the age of consent, 
assent must be obtained, which is taken to be “affirmative agreement” and not just 
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“failure to object” (DHHS 2005), and informed consent given by parents or other 
responsible caregivers.  The youth must also be made aware of their right to withdraw 
from the study at any time and their prerogative to refuse to engage in any part of the 
research.  These are all aspects of the principle of respect for persons, and includes 
respecting the participant’s autonomy.  An important theoretical basis of this study is the 
standpoint of the child or adolescent as an autonomous, meaning-making individual, yet 
one with certain vulnerabilities (Balen et al. 2006:44). This somewhat ambiguous 
standpoint of children in research necessitates that their voices be heard (Balen et al. 
2006:44). The protection of vulnerable populations during the research process may be 
achieved through a partnering relationship in which children can be heard during each 
phase of the research and thus have ownership of the data (MacNaughton and Smith 
2005:116).  Making judgments of each adolescent’s competencies, willingness, and 
comfort may be more easily discerned through the forging of these relationships. In 
addition, the choice of methods will also reflect the attention that is given to protecting 
the young people.   
The second ethical principle, beneficence, requires that research confer benefits, 
and is sometimes paired with the avoidance of maleficence or the causing of harm.  This 
is intended to guide research design, data collection, and presentation of findings in ways 
that will benefit participants or others in society while doing no harm.  The benefits to 
participants are linked to the third principle, justice, by tapping children and adolescents 
for research in the first place.  In attempting to protect them because of the traits that 
render them vulnerable (age, inexperience, powerlessness), children have often been 
excluded from studies in which their presence and participation would provide key 
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insights and results that only their perspective can reveal.  For the adolescents living with 
perinatally acquired HIV, parents, caregivers, medical providers, and other adults can 
provide information that is significant, but they cannot tell us what it is like to be fifteen 
and HIV-positive.  The invitation to participate in research about their own disease 
management is a sign of respect, an opportunity for beneficence, and indeed an act of 
justice that need not be missed if the young people are approached and included from the 
perspective that they know, they analyze, they devise, they create, and they manage, and 
they can convey their experiences competently and cogently.  The seriousness and 
urgency of optimum medication adherence, in terms of managing HIV in the present and 
for the future of these adolescents and others around the world, demand that they be 
included in research, for their perceptions will contribute to filling in the gaps that 
currently exist in improving adherence (Mullender et al. 2002: cited in Balen et al. 
2006:31). The findings and subsequent interventions may be felt by the participants 
themselves, may have ramifications for children born with HIV elsewhere, and may 
indeed be a matter of life or death. 
As with any research with human subjects, particularly qualitative research, the 
problems for participants and ethical dilemmas for the researcher cannot be totally 
anticipated and avoided at the outset (Murphy and Dingwall 2007), and in research that 
involves the lived experience of a serious, chronic, stigmatized disease like HIV, the 
potential for distress certainly exists.  One must be aware and prepared for the situations 
in which the effects of an interview or other exercise are negative (Nicolas and Schilder 
1997:88).  The Florida Family AIDS Network is a multi-agency, comprehensive system 
of care, and the availability of social workers, mental health professionals, and other 
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clinical personnel is built into and supported by the network, and provided a safety net for 
the young people who might have needed or wanted counseling during the research 
project. 
Medical Ecology 
 The research on children with HIV and their adjustment to and management of 
HIV disease is varied in its findings.  Some studies show children with HIV having 
greater psychosocial problems than healthy counterparts, while others do not show any 
variation (Steele et al. 2007).  Adherence issues may be successfully addressed by some 
adolescents and consistently problematic for others.  The wide variation in findings on 
HIV in children and adolescents seems to point to the variability in children’s social, 
cultural, and medical environments, that is, the social organization and Law (mentioned 
above) that “underpin behaviours,…rights and responsibilities” (James and James 
2004:49).  This supports the necessity of studying perinatal HIV and disease management 
among adolescents from a medical ecological perspective  (McElroy and Townsend 
2009; Panter-Brick 1998; Steele et al. 2007).  The experiences of the adolescent, as they 
occur in and are part of his or her social and cultural environment, can highlight the 
heterogeneity of these experiences and responses to illness (Hunt and Arar 2001).  This 
framework places the HIV-positive adolescent at the center of proximal and more distal 
contexts that interact with each other and variously influence the child (Steele et al. 
2007). The proximal niche has direct effects on the child’s agency, meaning making, and 
behaviors. 
Two of the more proximal niches in which the adolescent is significantly engaged 
are the family and the peer group.  In following the theoretical perspective outlined above 
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in the anthropology of childhood and the multidisciplinary childhood studies, the child is 
placed center stage as an agentive social actor.  The interactions of the child and his or 
her family members represent one stratum in which the medical, environmental, and 
social influences on the child can be interpreted, keeping in mind that the family is part of 
the larger community and economic and political systems (Novilla et al. 2006).  The 
family is the locus of activities and beliefs related to health, including food and nutrition 
habits, smoking and alcohol use, and physical exercise, in addition to the social factors 
like parent-child relationships, parental controls and protection, and educational and other 
forms of support and encouragement (Christensen 2004).  The family setting as the most 
immediate environment for the child may also extend to the HIV care provider for the 
HIV-positive child, since this person or team is often a continuous and regular presence 
in the child’s life (Ledlie 2001; Merzel et al. 2008). The family and health care providers 
have initial and significant influences on the child’s own health practices and his or her 
attitudes toward illness and illness management. 
The child’s development within the family is examined through the family’s 
activities rather than by the family structure, according to the ecocultural perspective 
(Weisner 2002).  This perspective, which focuses on the family’s “local situation,” 
displays the routines and problems that are part of everyday life, and the specific cultural 
tools that they have at their disposal to deal with the particular environment in which they 
live and act (Weisner 2002).  The focus on activities and family dynamics allows for the 
position of the child as social actor to be highlighted, as the family’s health-seeking 
attitudes and practices shape the developing child (Christensen 2004).  The family of the 
perinatally-infected child is a unique configuration, because the mother is necessarily also 
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HIV-infected, and other family members may be comprised of infected and uninfected 
siblings and father.  In addition, the family may have experienced the deaths of family 
members, and the infected adolescent’s caregivers may be extended family members 
(often a grandmother), foster parents, or other unrelated persons (Cohen 1994).  Health as 
a resource and as a practice may be more or less restricted by the presence of HIV and its 
requirements, and the family dynamic and composition will affect the infected 
adolescent’s wellbeing and experience of HIV disease (Steele et al. 2007).  Some families 
may integrate health-promoting behaviors and attitudes more successfully than others, 
and it is the matrix of personal coping, supportive relationships, competing goals, and 
external mechanisms that determine how a particular family manages health needs and 
indeed how a chronically ill adolescent learns and exercises his or her own health-
promoting behaviors (Christensen 2004). 
A second niche in which the child acts as social and cultural member and which is 
part of the medical ecological space which he or she inhabits is the peer group.  The 
dynamics of the HIV-infected adolescent and his or her peer group include the sharing 
and creation of unique cultural spaces and health practices that affect both the positive 
adolescent and his or her peers.  Adolescents with perinatally-acquired HIV will manage 
their disease according to the allowances and constraints imposed by their own and their 
peers’ schedules, attitudes, and understandings.  They will also practice safe or risky sex 
based not only on knowledge and the influences of family and health care providers, but 
also on the peer culture and relationships in which such activities take place (Battles and 
Wiener 2002; Dodds et al. 2003; Kyratzis 2004). 
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The peer group as cultural space is characterized by children of similar age, and 
peer relationships are largely forged within the context of school.  James et al. submit that 
children’s culture is distinct from adult culture, and “emerges in and through the 
temporal, as well as spatial, interstices of adult social structures,” but this culture is 
constrained, too, by temporal and spatial structures of children’s own lives (James et al. 
1998:75).  They cite in some detail Amit-Talai’s (1995) work with North American 
teenagers, which argues that young people have limited time in which to develop long 
and trusting friendships, and when child and adolescent peer groups are arranged by 
school grade and are thus similar in age, friendships with older or younger individuals are 
nearly impossible (Amit-Talai 1995; cited in James et al. 1998:76).  The age-similar peer 
groups are very different from relationships that form in societies where schooling is or 
was not a social institution, and where children could therefore have contact with and 
learn from people of differing ages and experiences (LeVine 1998).  Children in 
American society create cultures and contribute to social and cultural change, but this 
distinctive peer culture may be problematic in the kinds of knowledge transmission and 
social and personal growth that can occur.  For the child or adolescent with a chronic, 
stigmatized condition like HIV disease, the constraints on the development of peer 
relationships are likely to be greater, because of the time and effort that must be devoted 
to illness management and the developmental delays and psychosocial challenges that 
may be present as a result of both medical and social (family) influences (New et al. 
2007).  These factors, in peer culture generally and in the peer relationships of the 
perinatally infected adolescent, demonstrate a complexity in childhood culture and in the 
navigation of childhood’s temporal and spatial labyrinth, and are implicated in the way 
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that HIV-positive adolescents conflate their illness identity and responsibilities with their 
social identities and interactions.    
The medical ecology perspective demands examination of environmental 
influences beyond the family and peer group.  The child is at the center of an 
environment composed of immediate contacts, situated in the larger sociocultural 
community, all of which are influenced by macro-level social, economic, political, and 
ideological pressures (Steele et al. 2007).  Though the child is a social actor in this 
environment, he or she is also an embodied individual who acts and reacts to biological 
forces in the physical environment.  Part of the HIV-infected individual’s medical 
ecological reality involves his or her infectiousness, the effect of medication adherence 
on the degree of infectiousness, his or her own susceptibility to opportunistic infections 
and to reinfection with a different strain of HIV, and the effects of medication on the 
person’s physical wellbeing and ability to function normally in everyday endeavors 
(McElroy and Townsend 2009; Armelagos et al. 1990).  The human immunodeficiency 
virus is very responsive to antiretroviral therapy, becoming suppressed within weeks of 
therapy onset, and multiplying at the first sign of suboptimum therapy adherence 
(Williams et al. 2006:e1753), yet there is not a one-to-one correlation between adherence 
and health measures (Steele and Grauer 2003:25). It also mutates and becomes resistant 
to medications in response to adherence levels.  The personal, social, and cultural 
resources and stresses that are part of the adolescents’ lived experience affect their ability 
to confront and cope with these aspects of HIV and determine how they manage their 
disease, maintain their health, and safeguards others, especially sexual partners. 
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Resistant HIV, which can be the result of medication non-adherence, can be 
transmitted to sexual partners, so knowledge of resistance and the importance of 
maintaining adherence to stave off resistance and maintain low viremia is an important 
part of the infected adolescent’s disease management (Quinn et al. 2000).  The social and 
biological aspects of successful HIV disease management have implications for public 
health and the increase or reduction of HIV transmission.   
 The medical ecology of HIV disease management places the HIV-infected 
adolescent in an actor-oriented position (Armelagos et al. 1990), encompassing the child 
as social actor espoused by anthropologists and other social scientists of childhood 
studies.  In a medical ecological context,  
health and disease [are situated] in a system of mutually interacting 
organic, inorganic, and cultural environments…[and] are informed  
by the perceptions and social relations of patient, healer, family, and 
community.  Insults can originate from organic, inorganic, and all 
aspects of the cultural environment, and host response to insults entails 
modification or use of resources within all of these environmental 
subsystems. (Armelagos et al. 1990:358) 
 
The perinatally-infected adolescent with HIV, having lived with the virus since birth, has 
had some experience coping with the disease and its sequelae.  However, the individual, 
the disease, the virus, and the social and physical environments are capricious, and 
necessitate adaptive strategies as changes anywhere in the individual’s environment 
occur. Adherence to medications is one such strategy and, in the case of HIV/AIDS, is 
currently the most effective medical strategy once a person has been infected.  In looking 
at the wider AIDS epidemic, behavioral changes are an adaptive strategy aimed at 
preventing infection (Armelagos et al. 1990). 
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 While medication adherence is the most effective health-promoting behavior for 
the HIV-infected individual, there are other adaptive behaviors that can facilitate 
successful adherence.  These are located in the micro-, meso- and macro-systems 
concentrically circling the adolescent (Steele et al. 2007), in which people, community 
situations, and societal economics, politics, and ideology interact and influence the 
individual in his thinking and agency.  If the resources are available at these various 
levels of influence to enable an individual to adopt health-promoting behaviors and 
attitudes, then he or she will thrive in the face of the medical and social obstacles 
presented by life with HIV (McElroy and Townsend 2009:306).  The proximal levels of 
family, health care system, and peer groups have been discussed elsewhere.  At the more 
distal levels, health care accessibility, health policy, economic conditions, and social 
attitudes toward illness are some of the features which influence the actions and 
interactions of the individual and his or her family, social, and medical networks (Pontali 
2005; Steele et al. 2007).  
 In the medical ecology of HIV disease management, the cultural system is 
perhaps the key system affecting perinatally infected adolescents (Armelagos et al. 1990).  
From a clinical and logistical perspective, the young people who are receiving care as 
clients in the Florida Family AIDS Network are provided with the resources to maintain 
their health and minimize some of the previously common adverse effects of the 
medications and of the virus.  However, the cultural system situates their embodied 
experience within their social relationships through the beliefs and other types of 
information that guide them to manage their HIV disease.  Cultural beliefs may facilitate 
or thwart the adolescents’ efforts at successful disease management and subsequent 
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health outcomes.  For example, culture dictates secrecy in some families, yet disclosure 
to peers has been correlated with increased CD4 counts in HIV-infected individuals 
(Sherman et al. 2000).  There are family complexities and economic difficulties that may 
impede regular clinic appointments and secondary health-promoting behaviors such as 
good nutrition.  Whether adolescents are resilient in the face of the insult of HIV depends 
in great part on their cultural resources – their beliefs about self, their social support, the 
importance of and dedication of resources to health that they, their families, and 
communities (and society) defend – for “it is within culture that much of the behavior 
surrounding health and disease is played out” (Armelagos et al. 1990:358).  Medical 
ecology brings together the physical and biological, the social, and the cultural effects of 
HIV, which merge in and around the infected adolescents to determine whether and how 
well they adhere to their medications, manage their disease, and reach an optimum level 
of psychosocial wellbeing and physical health.  
 Health is a multidimensional phenomenon (Novilla et al. 2006:38), and must be 
understood in it temporal and spatial situatedness.  While obstacles to successful disease 
management exist which are beyond the individual’s control, in the proximal but 
especially in the political economic sphere, the possibilities for essential social change 
also exist in collective action (Armelagos et al. 1990:358) that extends beyond and into 
the various social settings of the ecological environment.  However, at the center of the 
overlapping systems and ideologies that comprise this medical ecological environment 
are the perinatally-infected adolescents with HIV disease, who “actively constitute a 
world that is at once the same as, and different from, the world their elders know” (Toren 
1993:463; emphasis in original).  Their goals, resources, capacities, conceptualizations, 
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and experiences are at the heart of the study of adolescent adherence and disease 
management, and as the study of the aids and barriers to optimum disease management is 
pursued, taking into account the myriad ecological factors influencing the lives of these 
young people, it is mandatory to approach these persons as partners in the research, 
recognizing their power and control both in their lives (Armelagos et al. 1990:358) and in 
the research process.  The theoretical perspective adopted by the anthropology of 
childhood and social scientific childhood studies, placed within a medical ecological 
framework, makes this possible.   
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CHAPTER 3:  METHODOLOGY AND RESEARCH ETHICS 
  
The methods used in qualitative research are many, and it is critical to choose 
methods that facilitate the collection of data needed to answer the specified research 
questions.  Since children and adolescents are viewed as competent social actors, and are 
situated in distinctive environments where their personal stories unfold, individual 
interviews will allow the individual voices of the participants to be heard (France 
2004:177).  Since the medical ecology of disease management is the framework for 
examining each adolescent’s beliefs and behaviors, the interviews must be semi-
structured and open-ended to permit the adolescent to discuss those cultural aspects of his 
or her environment and social relations that he or she considers relevant (Sankar et al. 
2006: S59).  Open-ended interviews may also foster feelings of control for the young 
people, who, like women, “still feel powerless, without much to say” (Reinharz and 
Chase 2003: 77).  The open-ended interview is also the setting in which adolescents are 
allowed to sketch out the big-picture issues – living with HIV, growing up and being an 
adolescent with HIV (identity formation), and revealing the problems that arise in 
managing their disease.  It provides the needed latitude for the participant to narrate his or 
her subjective illness experience (Conrad 1990). 
 Interviews with adolescents may include some stumbling blocks.  Adolescence is 
a period of personal and social development, when young people are constructing 
identities and strengthening their sense of self, and if this is especially conflictual for 
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them, they may bring an antagonistic attitude to the encounter with an adult interviewer 
(Weber et al. 1994:43).  Privacy and confidentiality may also be very important for 
youth, who are sensitive to peer influences and may be reticent about sharing certain 
things if they thought peers would find out (Weber et al. 1994:43).  The assurance of 
confidentiality and a location for the interview that is safe may assuage the adolescents’ 
concerns about privacy. 
 Qualitative studies of medication adherence among people with HIV are 
underrepresented in the adherence literature (Beusterien et al. 2008; Sankar et al. 2006).  
Adherence to medication remains a problem across the spectrum of diseases, including 
HIV (DiMatteo 2004), and points to the need to examine the social and cultural contexts 
in which disease management behaviors occur, and which affect if and how these 
behaviors occur.  This qualitative study of adolescents with perinatally-acquired HIV is 
an acknowledgment of the complexity of young people’s lives, and the methods 
employed will allow a range of questions to be posed – not just what a person does, but 
why, how, where, and when (Lehoux et al. 2006:2092).  This qualitative research also 
allows these young people to express themselves on issues that they consider to be 
important in their lives and for their health, and insofar as the data reveal potential areas 
of improvement for their disease management, it is perhaps one of the most ethical things 
we can do for them. 
Role of the Researcher: Reflexivity and Positionality 
 The management of HIV disease that is the focus of this study is an experience 
that I, the researcher, share with the research participants.  While our experiences are not 
identical, this shared phenomenon of living with HIV may have an impact on the 
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collaborative aspect of the research, and allow for identifying dilemmas as they arise.  
The reflexive position of the research will be assumed insofar as it can provide “insights, 
impressions, ideas, and hypotheses…[b]ut insights and impressions are not knowledge; 
they are paths to investigation” (Salzman 2002:808).  The study of adolescents’ 
management of HIV disease is not the study of a middle-aged woman’s HIV disease 
management, but my position as a fellow ‘HIVer’ may facilitate an empathic 
understanding of the factors that help or hinder medication adherence and other health-
promoting behaviors.  The intersubjectivity that obtains from the interactions of the 
researcher and the participants may enrich the data that are collected, but interpretation 
and understanding of the data will reflect empiricism, not reflexivity (Salzman 
2002:808).  It is not my intention to insert my experience and HIV identity into the 
research, but rather to recognize the standpoint from which I approach the research 
(Hendrick 2000).  Likewise, my position as an HIV-infected individual, because of its 
potential influence on the research process, relationships, analysis, and recommendations, 
merits disclosure both to the participants and to any readers of the final research product.  
Identification and awareness of one’s standpoint during the research process, 
particularly that position which is shared with the participants and is the topic of the 
research, is important because that facet could affect how the research is approached and 
how the interviews and other interactions play out.  It could also affect the quality of both 
the data that is ultimately collected and its eventual analysis. One risk that I faced as an 
HIV-infected person is that of projecting, even indirectly, my biases onto the interactions. 
There was also the possibility of positioning myself as the ‘knowing or capable’ HIV-
positive person against the adolescents’ ‘less knowing’ position.  Researchers have 
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addressed the differences that separate adults and children by suggesting various adult 
stances vis-à-vis the children they are studying.  Mandell cites three possibilities in which 
adults position themselves closer to the children’s world in an inverse relationship to the 
authority they wield, the complete involvement in children’s worlds being the “least-
adult” role (Mandell 1988:433). Eder and Corsaro suggest what corresponds to Mandell’s 
intermediate role, in which adults adopt a “form of detachment by avoiding adult roles of 
authority…[and thereby] reduce the inherent power imbalance between adults and 
children” (Eder and Corsaro 1999:527).  The reflexive approach continually reminded me 
of the position I deemed best to occupy, and allowed me to compare it to the position I 
was occupying as the research proceeded.  While I attempted to keep my position, both as 
adult and as HIV-positive person, at a distance from the “empiricist vision” (Gellner 
1988; quoted in Salazar 2002:812) that guided the research, I reflexively recognized my 
role and the effect that it had on my approach and responses.  Reflexivity throughout the 
research process therefore attended to the continual effort I made to give the participants 
primacy and maintain a collaborative partnership in which we shared authority 
(Etherington 2007).   
Reflexivity, as a process throughout the research, is a tool that researchers can use 
to help them to remain aware of ethical issues as they arise; it is achieved by continually 
questioning the ontological and epistemological positions that they take as researchers in 
the research process (Guillemin and Gillam 2004).  It keeps them aware of the 
relationship they have with the research, the participants, the context, and the data at 
every step of the process, so that ethical or other dilemmas can be clearly identified, 
appreciated, and addressed.  One of the ethical dilemmas that are possible in research 
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with young people is the fear or discomfort that these participants may feel in expressing 
themselves, particularly when it involves disagreement or displeasure. In addition to the 
ethical dimension of protecting young research participants, this dilemma has 
implications for the quality of the data.  Reflexively considering the situation involves 
questioning the knowledge and how one comes to know it (Guillemin and Gillam 2004).  
The power relations that exist – adult/child and researcher/participant – do influence the 
research process, and need to be clarified and revisited to ensure a fair and productive 
environment for children (Woodhead and Faulkner 2000).   
There is an ethical conundrum in designing and carrying out research with a 
population considered to possess less power than adults and less power as participants 
than the researcher, while maintaining that this population does possess power and 
competence.  The UN Convention on the Rights of the Child sets out in Article 12 that 
parties to the Convention must  
…assure to the child who is capable of forming his or her own views 
the right to express those views freely in all matters affecting the child, 
the views of the child being given due weight in accordance with the 
age and maturity of the child (UNCRC 1989). 
 
The right to contribute to research, however, opposes to some degree the need for 
protection.  The research process is composed of many steps that suggest varying power 
and partnership arrangement at different stages (Karnieli-Miller et al. 2009).  Thus, for 
example, the selection of methods for a particular project, generally the domain of the 
researcher, might be one of the initial areas of collaboration in which participants voice 
their opinions and preferences regarding possible methods (Hill 2006).  Some 
researchers, in fact, underscore the “child-centredness” of research and children’s 
involvement in “development and implementation of research” (Lewis and Lindsay 2000: 
 77
cited in Balen et al. 2006:31).  Data analysis rests with the researcher, but validation of 
the findings may or may not include participant input (Karnieli-Miller et al. 2009).  The 
structure of the research relationships may be drawn up at the beginning of the study, but 
as with the process of consent (Helseth and Slettebø 2004), power sharing and level of 
participant participation may also need to be renegotiated during the project.  Reflexivity 
on the part of the researcher includes asking herself about her role at different stages, and 
thus her participants’ roles, and revisiting what she wants to know and how she will 
proceed in discovering it (Etherington 2007).   
Florida Family AIDS Network’s Perinatal Clients 
 The Florida Family AIDS Network (FAN) is an HIV/AIDS service program 
comprised of social service and clinical agencies that provide care to women, children, 
and families infected with or affected by HIV and AIDS in Hillsborough and Pinellas 
Counties in west central Florida.  The program is funded by the Ryan White HIV/AIDS 
Treatment Extension Act, Part D, and has been in operation since 1992.  The program 
currently serves about 1200 clients, who receive primary and specialty care at one of five 
clinical sites, and supportive services from one of two social service agencies that help 
clients maintain their health and continuity of care.  Originally begun to address the 
perinatal transmission of HIV, the program has evolved to serve more adolescents and 
adults than infants and young children.   
  FAN includes pediatric clinical services for HIV-infected persons up to the age 
of 24, and provides these services to the majority of children and adolescents at two 
University of South Florida Department of Pediatrics clinics in Hillsborough and Pinellas 
counties.  The FAN pediatric clinics have a policy to disclose HIV status to children by 
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age 13 regardless of parental preferences.  Clinical staff work with parents, caregivers, 
social workers, and mental health personnel to develop a plan for disclosure of HIV 
status to children, and generally they begin the process and discussion well in advance of 
the actual disclosure. They also counsel children and adolescents on medication 
adherence and safer sexual behavior. 
 There are currently 163 perinatally infected persons enrolled in FAN, of whom 
130 are between the ages of 13 and 24, and their demographic characteristics, age, 
gender, and race/ethnicity, are shown in Table 3.1.  Figure 3.1 shows the current ages of 
the perinatal FAN clients and their HIV disease status.  The numbers of perinatally 
infected persons in FAN mirrors the perinatal population living in Florida (Figure 1.3).  
The FAN perinatal population, as well as the study sample, is comprised of a higher 
percentage of girls than boys.  Evidence suggests that mother-to-child transmission of 
HIV at birth is significantly higher in girls, though the precise mechanisms targeting 
females in utero are not known (Biggar et al. 2006; Taha et al. 2005; Thorne and Newell 
2004). 
Table 3.1 FAN Perinatal Clients    †Asian, More than one race, Other, or Not Specified 
 FAN Program (N=163) Number Percent  
   Gender   
        Female 94 58 
        Male 69 42 
   Race/Ethnicity   
        Black 97 60 
        Hispanic 28 17 
        White 29 18 
        Other† 9 5 
   Age   
        <2 1 <1 
        2-12 29 18 
        13-24 130 80 
        >24 3 2 
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 The vast majority of FAN clients are living near the federal poverty level and are 
receiving Medicaid benefits.  Among the perinatal clients, about 80% live below, at, or 
slightly above the poverty level, and about 74% are on Medicaid.  Among the participants 
in this research study, 88% receive Medicaid benefits, and about 82% are at 120% of the 
poverty level or below.  There are 14 perinatal FAN clients with private insurance, and 
only one of them is in the research study.  
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      Figure 3.1 Current FAN Perinatal HIV and AIDS Clients (N=163) 
 
Study Participants 
 Seventeen adolescents participated in the study, sitting for an interview lasting 
from thirty minutes to just under two hours, with most lasting for one hour.  Participants 
were interviewed in their homes, at their case management agencies or other community-
based organization, or at the researcher’s university-based office or other campus 
location.  Table 3.2 shows the demographics of the adolescents in the research study. 
 80
 
 
 
 
 
 
 
 
 
 
 
 
 These young people lived in households with a variety of primary caregivers and 
other relatives.  None of the adolescents were living in a household with both biological 
parents.  Eight of the seventeen adolescents were living with their biological mothers at 
the time of the study, and three were living with their biological fathers.  One was living 
with an aunt and one was currently living with a cousin but had lived for most of her life 
with her grandmother.  The four remaining participants were living with adoptive or 
foster non-relative mothers.  The six participants who were not living with a biological 
parent had been with their caregivers since they were young children.  Three participants 
had a biological parent with whom they were not living, but they knew and had contact 
with them.  At least ten of the seventeen participants had lost one or both parents. 
Table 3.2  Adolescent Participants      *Numbers rounded to equal 100 
Research Participants Number Percent* 
   Gender   
      Female 13 76 
      Male 4 24 
   Race/Ethnicity   
      Black 12 70 
      Hispanic 2 12 
      White 3 18 
   Age   
      13-17 10 59 
      18-24 7 41 
   Primary Caregiver   
      Biological Mother 8 47 
      Biological Father 3 18 
      Other Relative 2 12 
      Non-Relative/Adoptive 4 23 
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Recruitment of Participants 
 The study sample of adolescents was drawn from clients of FAN who were 
between the ages of thirteen and twenty-four at the time of the study and who were 
perinatally infected with HIV.  Prior to recruitment, the support and permission to 
conduct this research were obtained from the principal investigators of the FAN grant and 
from the FAN administrator.  Subsequently, the research proposal was presented for 
approval to the medical director at the USF pediatric clinic, and to the director or 
supervisor at the case management agencies that are part of the FAN network, and it was 
submitted to and approved by the USF Institutional Review Board.   
 The FAN program’s perinatally-infected adolescents include 73 females and 57 
males ranging in age from 13 to 24.  Close to 60% of the youth are Black, 18% are 
Hispanic, 17% are White, and 6% are more than one race or ‘other.’  The research study 
was presented and discussed with the clinical staff at the University of South Florida’s 
Pediatric Services in Tampa, and the FAN social worker at the clinic assisted in 
informing the adolescents about this research when they attended the clinics for their 
routine appointments. Additional collaboration was sought for recruitment of youth from 
the Tampa Hillsborough Action Plan (THAP) and the AIDS Service Association of 
Pinellas (ASAP), the two case management agencies where many of these adolescents 
receive support services. 
 The clinical care providers were asked to participate in the study, because they are 
a key source of information and guidance for these young people, in terms of their sexual, 
reproductive, and general health, adherence to medications, and the complexities of HIV 
status disclosure.  A trusting relationship between the clinician and the patient can affect 
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the patient’s success at assuming responsibility for his or her disease management.  The 
five clinicians who cared for adolescent patients at the USF pediatric clinic were each 
asked to sit for a semi-structured interview.   
 One focus group of biological mothers was included in the study in order to 
explore the unique dynamic between biological mothers and infected children.  These 
mothers are likely to be taking antiretroviral medications, will have had their own 
experiences, good or bad, with those medicines, and may harbor guilt about transmitting 
the virus to their children.  How they view and approach medical treatment for their 
children may be dictated by these experiences, and could well be a factor in the 
knowledge and attitudes that their children will bring to their HIV management and 
adherence to medication regimens. The perspectives and experience of the parent, 
especially the biological mother, regarding medications, health care providers, social 
support and influence, and cultural beliefs can shed light on the child or adolescent’s 
potential to accept and abide by the directives of the medical care providers (Wrubel et al. 
2005). 
 Biological mothers of infected children were recruited from among those women 
who were FAN clients and whose records indicated that they had an infected child.  From 
this group, recruitment was carried out through the case management agencies where 
they were receiving services.   
Sampling 
 The purposive sample was made up of those adolescents who were informed of 
the study at the clinic or by case managers, and agreed to participate.  The procedure for 
recruiting participants at the clinic involved informing each perinatal patient aged 13 to 
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24 about the study when they came to their clinic appointment.  In addition, the social 
worker examined the clinic’s appointment calendar and telephoned patients who were 
scheduled to attend upcoming clinics.  When a patient agreed to participate, the social 
worker provided me with a telephone number and I attempted to establish contact with 
the patient or, if the patient was under eighteen, with the patient’s parent.  Of the eighteen 
patients approached at the clinic or telephoned by the social worker, two declined to be 
part of the study and one was hesitant and was not contacted again.  Of the remaining 
fifteen, contact information was given to me for fourteen adolescents, and ten were 
enrolled and interviewed.   The remaining four teens agreed to participate, but contact 
with the teen or the teen’s parent was unsuccessful after several attempts. The mother of 
one of these four teens subsequently participated in the biological mothers’ focus group, 
and at that time, she agreed to let her daughter be interviewed.  Recruitment and 
enrollment in the study continued according to a schedule that allowed for four months of 
recruitment and data collection.  When data collection was terminated, eleven adolescents 
recruited through the USF clinic had been interviewed. 
 In order to expand the possibilities of engaging more adolescents within the study 
population, the FAN case managers at THAP and ASAP were also approached and asked 
to call any of their clients who fit the study’s eligibility parameters.  In an effort to 
connect with adolescents within the time allotted for the data collection, THAP case 
managers were asked to call residents of Tampa, and ASAP case managers were asked to 
call St. Petersburg residents, before calling residents of outlying counties.  In all, there 
were eleven active perinatal clients seen by three case managers at THAP, and four seen 
at ASAP by two case managers.  Contact information for five THAP clients was 
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obtained, and four were contacted and agreed to participate.  One was contacted several 
times, and messages were left for the caregiver, but contact with the caregiver was never 
established.  At ASAP, contact information for two perinatal clients was obtained. Thus, 
from the two case management agencies, six clients were enrolled and interviewed.  Data 
collection was terminated before any other recruitment efforts were made with the 
remaining clients at the two case management agencies.  
 All five clinicians who regularly cared for adolescent patients at the USF pediatric 
clinic were interviewed. 
 A list of thirteen biological mothers who had been actively case managed within 
six months of the focus group date was given to case managers, who were asked to 
contact their clients.  The case managers notified me when a client agreed to participate. 
When seven women agreed to participate, enrollment was stopped.  One additional 
woman had been contacted, but was unable to attend the focus group on the scheduled 
date.  Six clients attended the group, and one was sick on the day of the focus group and 
could not attend.  Four of the mothers who participated in the focus group had children 
who were interviewed for this study; two did not.  
 The participant groups and methods used are summarized in Table 3.3. 
Table 3.3.  Summary of Study Participants 
Participant  
Group 
Number of 
Participants Methods Used 
Adolescents 17 
Semi-structured interviews 
Medication & adherence questionnaire 
Viral load & CD4 measures 
Clinicians 5 Semi-structured interviews 
Biological mothers 
of infected children 6 Focus Group 
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Limitation of Recruitment Process 
 An important limitation of the recruitment process is that the adolescents who 
were approached and asked to participate were those who were attending clinic 
appointments or had recent and regular contact with their case managers.  Those who 
were not attending clinic or had been lost to clinic and social service care were not 
approached, and it is those who were hard to reach who were likely to have had very 
different management styles when it came to their HIV disease.  Thus, the study 
participants represented a bias in that they were more likely to be more conscientious 
about their care and treatment.   
Research Techniques and Data Collection 
 Upon agreement and consent to participate (parental consent and child assent 
were obtained for participants under 18, in accordance with IRB guidelines), the 
adolescents filled out surveys (Appendix A) before sitting for an in-depth, semi-
structured interview.  The interviews took place at the participant’s home, at one of the 
case management agencies, or in a private room on the USF campus.  Focus groups with 
adolescents were originally included in the methodology, but attendance at the first two 
scheduled groups was too low and the focus groups were removed from the methodology.  
However, the three adolescents who attended the first focus group sat for a group 
interview (due to time constraints, individual interviews were not possible).  Each 
participant responded individually to the questions and probes.  The three adolescents 
who showed up for the second focus group were interviewed separately.    
 Mothers (biological and adoptive) were present at four of the adolescent 
interviews.  Three were present either intermittently or at the end of the interview, as the 
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interviews took place in the home.  The fourth mother was present to aid her daughter, 
who had physical disabilities that made understanding her responses difficult.  Her 
mother repeated answers when necessary, and when she added her own comments, 
concurrence was sought from the adolescent.  While the presence of the mother altered 
the setting of the interview, each of the adolescents answered all questions posed and 
none indicated any unwillingness or inability to address any of the topics.  Some of the 
mothers’ comments were used, along with the data from the biological mothers’ focus 
group, to provide family context in which adolescents experienced and coped with their 
HIV disease. 
 More than half of the participants were under 18 years of age, so as children, they 
were considered to be in the category of a ‘vulnerable population,’ and thus, in 
accordance with Federal Research Guidelines, special efforts were made to protect them.  
Every effort was made to assure the participants that they could withdraw from the study 
at any time without penalty, and could freely refuse to answer any questions of their 
choosing.  In addition, and importantly, they were informed that the content of their 
interviews would not be shared with parents or health care providers.  All data collected 
from the participants has been protected by storage in a locked file cabinet, which is 
secured in a locked office.  All identities have been protected by changing participants’ 
names, and any data shared publicly would be aggregate data or data using pseudonyms.  
Thus, respect for the adolescents, demonstrated by both maintaining their privacy and 
safeguarding the confidentiality of their information, was assured (Whiteford and Trotter 
2008). 
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The FAN project utilizes CAREWare, a software program which connects all of the 
FAN agencies to a central database housed on a secure server at the University of South 
Florida.  CAREWare contains client-level clinical and supportive service data, as well as 
demographic information, and is equipped to generate customized reports on 
demographic indicators and clinical performance measures.  Reports of two clinical 
performance measures, the viral load and the CD4 (T cell) count/percentage, were 
generated from CAREWare data for the research participants.  
Consent was also obtained from the women who participated in the focus group, 
and protection of data was assured.  Women were reminded that all information shared in 
the group was confidential and should not be shared outside the group.  
HIV-Positive Adolescents, N=17 
FAN Data and Chart Reviews   
 CAREWare reports were run for all participants on demographic and clinical 
information, including age, ethnicity, HIV/AIDS status, primary caregiver, viral load and 
CD4 counts, and medication history. 
Questionnaires   
 Questionnaires were administered to all participants, which included demographic 
information as well as questions about health care, medications, and adherence recall.  
Adherence recall used the Treatment Interview Protocol, or TIP (Marhefka et al. 2004), 
which was adapted for use with the adolescent participants (Appendix A).   
Semi-Structured Interviews   
 Individual interviews provided the participants with the opportunity to tell their 
stories of living with HIV and managing their disease. It is well known that adolescents, 
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even those who are aware of their HIV-positive status, engage in risky sexual behavior, 
despite their knowledge of HIV and STI transmission and safer sex practices (Murphy et 
al. 2001). Since the transmission risks involved in unprotected sex are increased when 
HIV-positive people have elevated viral loads, the issue of medication adherence must 
also be addressed.  It has been shown that perfect adherence to a medication regimen is 
rare even for adults, and tends to be more problematic for adolescents (Merzel et al. 
2008).  The issues surrounding adherence may be distinct for the perinatally-infected 
teens, since they have lived with HIV since birth and have had family members live with 
and perhaps die from AIDS.  The interviews included questions about their attitudes and 
behavior, as well as external influences, regarding medication adherence. 
 The formulation of the interview questions was guided by the medical ecological 
perspective in which the research was situated (Brown et al. 2000; Williams et al. 2006; 
Steele et al. 2007), and by literature pointing to the main factors impinging upon the 
adolescent’s adherence to medication and management of HIV disease – personal 
meanings and identity, social influences among family and peers, clinical care and 
relationships (Dodds et al. 2003; Pontali 2005), and attitudes and behaviors regarding 
their chronic disease and treatment (Pontali 2005).  
In order to understand if and why they engage in risky medical and social 
behaviors, it was necessary to discover the meanings that these adolescents attach to HIV, 
their attitudes  toward medication and adherence, and their behavior and communication 
within sexual relationships.  The interviews probed for the participants’ perceptions of 
risk, social pressures, and decision-making regarding health, and revealed why and when 
youth choose to take health risks, particularly those related to adherence.  The reduction 
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of risky sexual behaviors in this population, while conferring health advantages on the 
youth themselves, is also aimed at protecting partners and stopping the spread of HIV.  
For individuals already living with HIV, particularly young people and those born with 
HIV, the notion of protecting others in a sexual relationship is perhaps less salient than 
that of procuring certain social benefits for themselves that may involve risky behaviors. 
Living with an incurable, stigmatized disease may color the decisions these adolescents 
make, so it was important to understand whether they experienced stigma, and  how they 
felt about and coped with stigma and with their disease overall.  Therefore, the interviews 
included questions about living with HIV on a daily basis and within their social 
environment. 
Thus, the interview guide  (Appendix B) included open-ended questions related to 
adherence, living with HIV, stigma, outlook and the future, sexuality, and risk, as well as 
questions concerning family, peer relationships and school, health care and relationships 
with providers, and other contextual aspects, such as social support and health care 
access. 
Clinical Care Providers, N=5 
Semi-Structured Interviews 
 Adherence is a topic routinely addressed by clinical providers and medical case 
managers, with whom HIV-positive adolescents have regular contact.  The provider-
patient dyad can be one of the most important relationships for the perinatally-infected 
patient (Dodds et al. 2003:43), and so the communication dynamics and the content and 
presentation of adherence and health risk counseling can be very influential in the 
acceptance of adherence responsibilities by the adolescent. Therefore, semi-structured 
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interviews (Appendix C) covering these topics were conducted with providers in order to 
ascertain the needs and possibilities for future implementation of such services.  
Biological Mothers of Perinatally Infected Adolescents, N=6 
Focus Group 
 Mothers had the opportunity to discuss their concerns, beliefs, and attitudes 
regarding HIV biomedical health care, antiretroviral therapy, and their own lived 
experience of HIV management.  In addition, they discussed HIV disclosure to their 
children and their children’s health care.  The focus group guide is found in Appendix D. 
Data Analysis 
 
 All of the adolescent and clinician interviews, as well as the mothers’ focus 
group, were transcribed and entered into the qualitative analysis software, Atlas.ti, 
Version 6.  Transcripts were read, reviewed, and coded; codes (Appendix E) emerged 
from the study’s research questions and hypotheses, as well as from a review of relevant 
literature. Codes and accompanying quotes were examined in order to compare and 
contrast the experiences of the adolescents.  The adolescents were then divided into 
contrasting groups based on the study’s hypotheses: earlier vs. later disclosure, family 
acceptance vs. family ambivalence, peer support versus peer non-support, and so on.  
Analysis of the adolescent interviews, in keeping with the theoretical perspective of 
medical ecology, was also conducted individually in order to situate each adolescent’s 
distinct lived experience of HIV disease management within his or her personal and 
social spheres of influence.  The comparison analysis and the individual analysis were 
undertaken in order to identify the variables which had an association with the 
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adolescent’s disease management, defined by the two most salient dependent variables, 
medication adherence and disclosure of HIV status to others, especially sexual partners. 
 Concurrent with the qualitative analysis of the interview data was the examination 
of two external biological variables for each adolescent: viral load and CD4 (T cell) count 
over time.  Viral load was an important indicator of medication adherence, and CD4 
count gave a general view of health status. 
 Analysis of the clinicians’ interviews and the biological mothers’ focus group 
transcript were done similarly to the adolescent analysis, with codes used as identifying 
themes.  The information from these data was used as contextual background in the 
discussion of adolescents’ experiences with HIV disease management. 
 Since time and logistics did not allow the inclusion of the participants as partners 
in each phase of the research process, it was especially important to affirm their lived 
experience of HIV disease by highlighting their voices in the analysis and discussion.  By 
using their own words throughout, the particularities of their experiences were 
safeguarded, and acknowledged their social competence as well as the nuances of their 
social spheres of influence.  
Study Limitations 
 
 This study was limited by the fact that the adolescents who were recruited and 
enrolled in this study were among those FAN clients who were scheduling and keeping 
appointments on a regular basis.  They were approached when they came to the clinic or 
were called if their appointment was approaching.  Disease management and its 
facilitators and obstacles might have been very different among adolescents who had not 
been in care for an extended period of time.  Also, the seventeen adolescents who were 
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enrolled were all in good health, and all but one had fair to excellent immune function.  
Adolescents with poorer health indicators may also have revealed very different lived 
experiences managing their HIV disease.  
 The study was also limited by the small study sample and the fact that each 
adolescent was interviewed only once.  In retrospect, particularly for adolescents, 
triangulated data collection, such as interviews supplemented by drawing, free listing, 
and pile sorting, would have produced more nuanced data, and the adolescents might 
have been more uninhibited in the drawing, free listing, and pile sorting exercises than in 
the one-on-one interview.  Also, focus groups had been planned but did not materialize; 
they would have provided a venue for the expression of the culture of adolescence and 
elucidated some of the shared cultural domains of HIV experience, such as disclosure, 
stigma, and adherence.  
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CHAPTER 4:  RESEARCH RESULTS 
 
Adolescent Data 
 The adolescents’ interviews revealed the complexity of their social, personal, and 
cultural environments and the factors that intersect in different ways to make each 
person’s lived experience and management of HIV complex.  While the small study 
sample precluded causal connections between a personal attribute, such as age at 
disclosure, or a medical element, such as understanding of medications and labs, and 
successful adherence, some factors suggested subsequent success at adherence and 
overall management of HIV disease.  The myriad influences on adherence and disease 
management confirmed the need to look more comprehensively at the medical/ecological 
situation of each adolescent in order to discover how best to ensure success for these 
young people. 
 The primary indicator of the participants’ management of their HIV disease was 
the level of adherence to their antiretroviral (ARV) medication regimen.  All of the 
questions posed during the interviews were designed to reveal the factors in the 
individuals’ lived experience which affected their ability to take their medications as 
prescribed.  These factors will be presented in response to each of the study’s hypotheses.  
Below in Table 4.1, the participants’ names and ages, and their adherence level, as 
evidenced by lab measurements of viral load, are listed.  Viral load is measured using an 
HIV RNA assay that generally measures HIV levels as low as 50 copies (or 48 in some 
tests) of HIV-1 RNA per milliliter, though more recently, viral load tests have been 
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developed that can detect even fewer than 50 copies (Pascual-Pareja et al. 2010).  An 
undetectable viral load, which is less than the level of detection of 50 (or 48) copies, 
indicates successful viral suppression, and is achieved by a patient’s practice of optimum 
adherence.  Studies have indicated that at least 95% adherence is necessary for viral 
suppression (Bangsberg 2006), though there is evidence that lower adherence can achieve 
suppression, depending on the class of medications comprising the regimen (Maggiolo et 
al. 2005).  Nevertheless, high adherence to medications is necessary for viral suppression 
and low adherence increases the risk of a detectable viral load, i.e., the failure to suppress 
the virus (Martin et al. 2008; Bangsberg 2006) and the risk of viral resistance (Veinot et 
al. 2006; Quinn et al. 2000).  
 If optimum adherence is being practiced and viral suppression is not achieved, 
then resistance to one or more drugs is suspected.  Among the study participants, 47% 
had undetectable viral loads according to the available data.  Among all of the perinatal 
patients at the USF clinic, 65% were found to be undetectable, according to one of the 
nurse practitioners, who had examined the clinic’s data.  The last two columns in Table 
4.1 are participants’ own recall of skipped medications in the two weeks prior to the 
interview and estimated skipped medications overall.  This recall of skipped medications 
was recorded on the Adolescent Medication Questionnaire (Appendix A), adapted from 
the Treatment Interview Protocol (Marhefka et al. 2004). 
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The measure of adherence was taken from the participants’ records of their viral 
load tests.  Optimum adherence will maintain an undetectable viral load, that is, below 48 
or 50 copies of the virus in the blood, unless viral resistance is ascertained.  When the 
viral load spikes into the detectable range, it is likely that adherence has fallen.  The viral 
load responds quickly to this fall in adherence, as evidenced by Bridget.  Her viral load 
                                                 
2
 Participants’ names have been changed to protect their privacy. 
3
 Undetectable is less than 48 or 50 copies/ml, depending on the commercial test. 
4
 Bridget had 9 consecutive undetectable viral load tests over two years, but her last two were detectable. 
5
 At least 2 consecutive undetectable viral loads and others under 1500 copies/ml. 
6
 Viral loads above 1500 copies/ml 
7
 Skipped medications in the previous two weeks were due to an unplanned 5-day stay at a friend’s house.  
8
 Olivia’s mother recollected having to remind her daughter often to take her medicines.  However, Olivia’s 
medications may have stopped working, as  her CD4 count had decreased continuously to extremely low 
levels, in addition to her failure to achieve viral suppression.  She began a new medication regimen shortly 
after her interview. 
Table 4.1  Study Participants and Adherence  
Participant’s 
Name2 
Age at 
Interview 
Adherence 
(Based on VL) 
Adherence Recall 
Days Skipped 
Medications, 
Last Two Weeks 
Adherence Recall 
Days Skipped 
Medications 
Overall,  
per month 
Paula 13 Undetectable3 1 1 
Lucy 19 Undetectable 0 0 
Rachel 16 Undetectable 0 0 
Valerie 16 Undetectable 0 0 
Nina 17 Undetectable 0 0 
Mark 14 Undetectable 0 1x/3 months 
Bridget 18 Undetectable4 0 1 
Katie 22 Good5 2-3 3 or more 
Jeff 16 Good 0 0 
Vanessa 16 Good 0 0 
Angela 17 Fair6 0 1x/2 months 
Stephanie 20 Fair 2-3 3 or more 
Diana 19 Fair 4 or more7 2 
Zoë 16 Fair 2-3 3 or more 
Olivia 13 Fair 08 0 
Keith 18 Medication  Stopped N/A N/A 
Sean 20 Medication Stopped N/A N/A 
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was consistently undetectable, when suddenly it spiked to about 7000 in one of her recent 
lab tests.  Records show that she admitted to not taking her medicines regularly.  Each of 
the study participant’s viral loads, CD4 (T cell) counts, and medications were examined 
from the data entered into the FAN CAREWare database.  The graphs displaying each 
participant’s viral load and CD4 count/percentage over time are found in Appendices F 
and G. 
Biological Mothers’ Focus Group 
 The four main topics on which the discussion centered were mothers’ disclosure 
to their children, the health care system serving them and their children, mothers’ 
medication adherence, and concerns about institutions that were involved in research on 
HIV and treatments, vaccines, and cures.  The women also alluded to stigma while 
discussing their experiences and difficulties living with HIV.    
 The mothers’ responses and insights are integrated into the results of the 
adolescent interviews, as they relate to the perceptions and experiences proffered by the 
adolescents.  Before the summary of findings in each section, additional results may be 
included from the mothers’ focus group. 
Clinician Interviews 
 The clinician interviews were conducted with two physicians, Dr. Flynn and Dr. 
Lane, and three nurse practitioners, Carol, Ann, and Ed.9  One of the nurse practitioners 
had a background in adult medicine, so his adolescent patients were all aged sixteen to 
twenty-four.  The interviews elucidated the substance of the adolescent clinic visit, the 
clinicians’ perspectives regarding the HIV management issues of adolescent patients, and 
                                                 
9
 The names of the doctors and nurse practitioners are pseudonyms. 
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the relationship style of the clinician vis-à-vis adolescent patient.  Aside from the 
physical examination, the clinic consultation included a discussion with the patient (and 
often the caregiver) of medication and adherence, lab tests, psychosocial issues, including 
sexual activity and risky behavior, and other issues specific to the patient.  The 
encounters, according to the clinicians’ descriptions, were comprehensive and typically 
longer than what might be expected in an adult clinic.  Responses referring to how the 
clinicians communicated with their adolescents patients were examined to determine the 
extent to which the patient appeared personally engaged in his or her care and treatment, 
and the level of power and control that the patient assumed or was given. 
Results 
Adolescent Engagement, Provider-Patient Relationship, and Adherence  
(Hypothesis 1) 
 
 The level of engagement by the adolescents in their health care and the level of 
trust and interaction between them and the clinicians who regularly cared for them were 
hypothesized to have a positive influence on their adherence behavior.  It was posited that 
the greater the youths actively participated in their care and treatment, the better their 
adherence would be.  Likewise, greater trust and interaction between participants and 
their clinicians during their medical appointments would have a positive impact on their 
adherence.  Hypothesis 1 reads: 
The active participation of the adolescent in his or her health care and 
treatment plan, and the level of trust in his or her health care 
providers have a direct relationship on the adolescent’s 
understanding of the importance of adherence and his or her 
acceptance of adherence responsibility.   
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 The active participation of the adolescents in their own health care and treatment 
plan was measured by the level and type of responsibility they had in taking their 
medicines.  More basically, an active rather than passive disease management style was 
reflected in their knowing the names and doses of the medicines they were taking, 
understanding what their lab tests meant, and being able to discuss viral load, CD4 count, 
and viral resistance.  Provider trust was expanded during the interviews to cover the 
overall relationship that patients had with their HIV clinical providers, including the 
adolescents’ rating of their providers’ understanding of their HIV-related issues and 
challenges, the providers’ efforts to discuss and understand the patients’ lives outside of 
the clinic, patients’ complaints about their provider or medical visit, and the patients’ 
comfort and desire to ask questions.   
Adolescent Medical Knowledge 
 Table 4.2 provides an overview of the participants’ medical knowledge, which is 
discussed in the following sections.  
Medications   
 The assumption that perinatally infected adolescents would know the names and 
dosages of their medications because they have been accustomed to taking medications 
throughout their lives was not supported by the participants’ responses in the written 
questionnaire and in the interviews.  Only about 30% of the participants could name their 
medications without looking at their medication bottles or a chart that listed and pictured  
all of the currently available antiretroviral medications.  Thus, in and of itself, naming the 
medications was not associated with good adherence.  Angela, a 17-year old, after 
consulting the chart and not being able to pick out her medications, finally said that her 
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mother knew the names and left the room to consult her.  Most did know how many pills 
they took each day, though there was some hesitation by a few of the participants as they 
gave their answers.   
 
 This finding is somewhat surprising, since all of  the clinicians who provide care 
to these adolescents and were interviewed for this study said that, during most visits, they 
asked their patients to name their medications and reviewed the importance of adherence 
with them.  In fact, some of the adolescents referred to the repetitiveness of the providers’ 
questions about medications.  One of the women in the biological mothers’ focus group 
raised this issue in expressing her exasperation with the pressures of the clinic visit.  
                                                 
 
10
 Adherence based on recall of missed doses: A = Never or less than once a month; B = Misses once a 
month; C = Misses twice a month; D = Misses 3 or more times a month 
11
 Charts of all antiretroviral medications, with names and pictures of pills. 
Table 4.2 Adolescent Engagement and Adherence 
Participant Medical Knowledge Adherence 
Name Age Knows ARV Names 
VL, CD4, and 
Resistance Knowledge VL Recall
10
 
Paula 13 W/Chart11 VL, CD4 U B 
Bridget 18 W/Chart VL, CD4 U B 
Lucy 19 Yes VL, CD4 U A 
Rachel 16 Yes VL, CD4, R U A 
Valerie 16 Used List R U A 
Mark 14 Read Bottles R U A 
Nina 17 W/Chart VL, CD4 U A 
Katie 22 Yes VL, CD4, R Good D 
Vanessa 16 Read Bottles VL, CD4, R Good A 
Jeff 16 Yes VL, CD4, R Good A 
Zoë 16 W/Chart None   Fair D 
Angela 17 No VL, CD4 Fair A 
Stephanie 20 W/Chart VL, CD4 Fair D 
Olivia 13 No None Fair A 
Diana 19 Yes VL, CD4 Fair C 
Keith 18 N/A VL, CD4 N/A N/A 
Sean 20 N/A VL, CD4 N/A N/A 
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While Anita12 described the visit  as “overwhelming” because it included too many 
different professional encounters, she also thought it was a waste of time to ask the 
adolescents about their medications at each visit: 
You got the nutritionist, you got the nurse case manager, you got to see 
the doctor, you got to see him.  It’s just too many people…it’s so much 
pressure.  Name your pills.  You ask them that every time they come.  If 
they don’t know the name of those pills by now, come on.”   
 
The adolescents’ medication knowledge, the clinician’s and patient’s views of the 
necessity of reviewing medications at each clinic visit, and a mother’s perception that 
adolescents already knew the names of their medications indicate a divergence of opinion 
among patient, parent, and practitioner on what adolescents know and the instruction and 
guidance they continue to need. 
Labs and Viral Resistance   
 Also reviewed during clinic visits were the patient’s lab results.  When asked 
about the two main lab tests, the viral load and the CD4 (T cell) count, which indicate 
viral suppression and immune function, there was general familiarity by almost all of the 
participants.  Three of them got confused by which count was supposed to be high and 
which should be low for optimum functioning.  Only five had some idea of the results of 
their last tests, but 75% of the participants were aware of and demonstrated some 
understanding of these two measurements.  Only two participants were unable to talk 
about them at all.  
 Of particular interest was the ability of the participants to discuss the importance 
of taking their medicines faithfully every day, and the connection of adherence to an 
undetectable viral load and to the risk of viral resistance.  Only Katie, who was 22 years 
                                                 
12
 The mothers in the focus group have all been given pseudonyms. 
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old at the time of her interview, mentioned the term resistance without prompting, and 
two participants had a general, if somewhat inaccurate, idea of what resistance meant 
when prompted.  When asked why it was important to take the antiretrovirals every day 
as instructed, none of the participants mentioned the threat of resistance, though Mark 
and Valerie did say that the medicines would stop working.  All of the participants did 
say that their clinicians reiterated the importance of remembering to take the medicines 
every day.  When I asked them if the doctor or nurse explained why, they could all give 
an answer, though their responses ranged from “it keeps the bad guys away” [Zoë, 16] to 
an attempt to explain resistance, “…the medicine will stop working…They say that my 
body won’t get immune to not taking them, and then it’ll stop accepting, it will reject 
them” [Vanessa, 16].    
 When I asked Diana, 19, if she had any idea of what would happen if she didn’t 
take her medicines every day, she replied with a chuckle, “Death.”  She did, however, 
add that taking the medicines every day would “get your viral load up and my T cells 
back up or something like that.”  This response showed an awareness of the viral load 
and T cells, though she confused the effect on the viral load, which would be lowered 
with good medication adherence.  Lucy, 19, also was aware of the effect of the 
medications, saying they “keep my viral load high and I think my T cells down.  I think 
that’s right.  Is that right?”  Again we see a slight stumble as she attempts to explain the 
effect on viral load.  Paula, on the other hand, mentioned correctly that taking the 
medications keeps the viral load down and the T cells up, and Jeff understood the effects 
as well, with some probing.  Rachel was able to explain resistance with some probing, 
and explained it this way, “I know they’ve told me that my body could start getting used 
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to my medication like too used to it and that it will reject my medication again and it will 
stop working because it’s been working so well for so long, like that could happen.”  Two 
girls, Angela and Olivia, simply mentioned that they would get sick if they didn’t take 
their medicines every day. 
Provider Explanations of Medical Concepts 
 The confusion and incomplete explanations with regard to viral load, CD4 (T cell) 
count, and resistance are somewhat surprising, given the clinicians’ descriptions of how 
they explain these concepts to their patients.  Each of the clinicians was asked if and to 
what extent they addressed lab tests and viral resistance in their encounters with 
adolescent patients.  All of them said that they review the patient’s viral load and CD4 
count, providing more detailed information as the child ages.  Two of the nurse 
practitioners gave interested patients health record cards with the patients’ viral load and 
CD4 count so that patients could see their progress over time.   
 The explanations of these two measures ranged from a very basic description of 
target numbers to metaphorical or graphic representations.  The detail of each clinician’s 
explanation was somewhat varied, but generally basic, and seemed to depend on the 
interest and perceived ability of the patient to understand what these measures meant.  
Carol considered it very important for her patients to understand their viral load and CD4 
count, and probed her patients for knowledge on which should ideally be low and which 
should be high, and then introduced specific numbers.  She admitted that sometimes 
patients would still not be able to tell her their numbers, but she tried to get them to 
understand that they want an undetectable viral load and high CD4 count: 
I kind of go a little bit into, like, “Well, tell me what your, what do I want 
your blood work looking like?” because I find that a lot of times it’s very 
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characteristic of adolescents,…“if I don’t feel sick well I must not be 
sick,” so I try to really get them to buy into their numbers, like their T 
cells and their viral load…so I’m trying to make sure they understand, 
like, you want more than five hundred [T cells] and undetectable [viral 
load] and kind of make sure that they know where they are in that range of 
T cells, and then sometimes I’ll say, “Do you know what yours 
are?”...Because I pretty much go over them every time they’re in.  I’ll be 
like, “Well, do you think they’re above five hundred or under five 
hundred?” And they’ll be like, “Oh no, I know they’re above five hundred 
because you say my labs look good every time,” so they kind of, they may 
not remember that they were 780, but they know that they’re in this really 
good range. 
 
Ann described her discussion of viral load and CD4 count in a similar way, trying to 
involve the patients in the discussion of their numbers:  
As they get older I definitely would go over their CD4 and their viral load, 
teach them about that…I explain what it is and definitely that’s going to 
be different levels for different people, for different kids and adolescents, 
but I pretty much, or sometimes most of mine explain it to me.  I also will 
ask, “Now your CD4 what is that again?”  And I try to have them give it 
back to me then, ’cause I can help correct it if it’s wrong.  Or I’ll say, 
“Now is it supposed to be high or is it supposed to be low?”...So teaching 
about it, asking questions so that they can tell me what it is, and then 
going over their numbers. I’ll get a little tracker thing for kids or families 
who are interested.  Some are, some aren’t, some don’t want to be carrying 
that around, some are really interested. 
 
When asked if all of her adolescent patients knew what a viral load was, she responded, 
“They should definitely know what it is.”  When asked if they knew what a CD4 count 
was and if they knew what their own CD4 count was, she said, “Yeah, and ideally, at the 
very least, they should know theirs [viral load] is undetectable and their CD4 is good.  
That would be great.  If they could have a closer like, oh, 500 is their CD4, that would be 
great.”  However, when I probed further for whether she thought her adolescent patients 
would know their count, she then replied, “I would say, I bet, know for sure the exact 
number or very close to the exact number, probably 40 to 50%, maybe 40%.  Would 
know like, could say if they’re 560, could say five hundreds, I’m going to go with 40%.”  
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She did add the caveat that sometimes the patients who are doing extremely well, with 
numbers to reflect good adherence and good health, will not know their numbers, and this 
was indeed the case among several of the study’s adolescents.  This is because    
when they’re doing well…they seem less, they don’t worry about it, so 
like I have some who are, they’re just doing great but like if I asked her 
what her exact number is she would say I know it’s very good, I’m 
undetectable, but she might not be able to tell me what her number is 
because at some point I think she’s kind of said, well it’s good and I’m 
not going to worry about that. [Ann]    
                 
 Carol and Ann were not asked specifically if they discussed viral resistance with 
their adolescent patients.  However, when Ann was asked whether her patients ever 
voiced any concerns or fears about taking their medicines, she did not point out any 
mention by her patients of resistance or the medicines not working.   
 Ed described viral load and resistance together in a boxing metaphor, which he 
said was very well received and understood by his patients.  His description of resistance 
is particularly vivid, and was more detailed than the other clinicians’ explanations.  He 
also presented the concept in a way that his patients could relate to, and it bears quoting 
at some length in order to follow the thread to its conclusion, especially his inclusion of 
the somewhat difficult concept of resistance: 
In the simplest terms I’ll say, “Well, what happens when you take your 
meds?” and this is where I get into resistance, because I build all that into 
the same conversation.  You know, “You’re taking your meds and if you 
take them the right way, you’re beating the virus down, beating the virus 
down, beating it down, beating it down, beating it down.  When you have 
the virus way up to here, it’s doing, it can do a lot of damage in your body, 
so the goal is to take your meds,…beat it down until the virus isn’t even 
hardly thinking so well you’re beating it down so good… down to such a 
low level that it’s really not doing much.  It’s there, it’s in your body, if 
you don’t take your meds it’s going to start growing again and getting 
really big but you’re taking your meds, you’re beating it down so it’s not 
hurting you.  You know, you’re just keeping it smashed down as far as 
you can keep it smashed down.”  And I’ll say undetectable…“we just say 
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undetectable, that means it’s less than… thirty-eight…That means it’s at 
such a low level that we just, we don’t keep looking for it anymore 
because we don’t really need to know the number, but you’ve done great, 
you’ve gotten it smashed down to such a low level, it’s really just there, 
it’s not doing the damage that it can do”…and so [I] get them to the point 
where they can finally do all that and explain it all to me. 
… 
“[B]ut if you are beating it down really good and you kinda stop taking 
your meds or start skipping doses, you’re letting the virus come up a little 
bit so you want to just keep on beating it down…but when you don’t do 
that, say you go hang out for the weekend, you go to a few parties, you 
don’t take your meds, the virus is like ah, it’s coming up again.  So the 
virus starts coming up again but then you throw the meds on it again, you 
beat it down with the meds…and the virus is like,…oh shit, you know he’s 
giving me the meds again.  So then when it comes up again, when you 
stop taking your meds because you’re partying for a weekend or you 
forget your meds…the virus is like, okay,…I know you just want to hit me 
with those meds again, so before he hits me with those meds I’m gonna 
change myself so when he hits me with those meds those meds aren’t 
gonna work anymore, you know and then I’ll say to people that’s what 
resistance is.  It’s when you’re not beating the meds down much 
anymore and you’ve given the virus the opportunity to think, 
because…when you’re beating it down every single day, you’re not 
missing any meds, the virus can’t even think, but when you give the virus 
a chance to think, because it’s smart, it’s going to mutate and change 
itself so the meds don’t work.” [Emphasis added to specific excerpts on 
resistance] 
 
 Both physicians said that they discussed the viral load and CD4 count with their 
patients at each visit.  They also said that they explained the concept of resistance.  Dr. 
Flynn said,  
I show them what’s happening, try to explain in a simple way, like what 
resistance is, how does it develop and why it’s bad for them to have a  
resistant virus.  So we try to explain in simple terms of why does it 
happen, and yeah, we discuss about resistance. We don’t go into the 
details, like the mutations or the numbers, but just what happens if the 
virus becomes resistant and what are the problems from that. 
 
Dr. Lane said she discussed resistance with her patients in particular when a medication 
change was demanded (presumably because of resistance to one or more drugs in the old 
regimen) or there were problems with adherence.  She went into greater detail in her 
 106
explanation, used imagery to present the concept of resistance to her patients, and 
sometimes showed them the resistance test results.  She likened the virus and the 
medicine to geometric shapes that must be alike in order for the medicine to work against 
the virus: 
What I try to do, you know, sometimes I kind of draw a picture of why a 
virus changed from a triangle, let’s say, in the surface to like a square in 
the surface, so the medication that was targeting the triangle doesn’t work 
and now we have to switch to this square…[O]r I show them …the 
resistant test and because it’s very graphic…I think that for some patients 
it’s kind of an open eye of why, you know, I’m having issues, because 
when you see [it]… they give you different arrows and bars and stuff, but 
then on the right side usually has an interpretation… sensitive, resistant or 
partial susceptibility, and the resistance is…kind of highlighted so when 
you see your page, and you see that you are really not sensitive to most of 
the medications, I think that kind of puts the emphasis, yes, this is bad, 
you know, I’ve really blown most of my possibility for treatment. 
 
Dr. Lane also said that she explains the level of adherence that is necessary for the 
medicines to continue to work and for the virus not to become resistant to them.   
 Despite all of the clinical details that the clinicians said they reviewed with their 
patients, including certain details at every visit, the clinicians’ interviews nonetheless 
indicated that many adolescent patients do not have a committed interest in their clinical 
indicators and outcome measures, nor have they made the connection between these 
measures and their present and future health status. The clinicians also mentioned that 
there may be other priorities in a patient’s life, issues that dwarf the importance even of 
their HIV, and prevent them from taking a keen interest in their health care.  Several 
remarks illustrate this incomplete understanding: 
It [a rising viral load] seems to make a difference maybe for a few 
patients, but for others, it’s just like a number and a piece of paper…and 
they always go back to that argument, I’m still feeling okay, I don’t feel 
bad, so maybe it’s not so bad having a viral load, that the number looks 
very pretty on paper and you’re [the doctor] really happy about it, but for 
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me [the patient], it really doesn’t make a difference. I mean having a little 
viral load or having 50,000, I’m feeling the same way so why take it?  
Why bother. [Dr. Flynn] 
 
Sometimes you want to…make them remember that a undetectable viral 
load doesn’t mean that the virus went away, but it’s just that we really 
suppressed the virus so we can [no] longer detect it by the regular, you 
know, routine methods in the lab. Sometimes that kind of, you know, they 
say, well maybe it actually went away. [Dr. Lane] 
  
There definitely is an issue of the ones who are deteriorating, who’ve 
never really felt bad anyway, and probably haven’t taken their meds much, 
like you know, they’re not very adherent, but fortunately for a long time 
they’ve done really well.  I’m sitting here telling you your T cells are 
going down, okay they’re going down, this is a problem, you’re below 
200, and they don’t feel a difference between when they were 600 or 500 
or when they’re 150, no difference.  And they didn’t take their meds when 
they were 500 and they are not going to take them when they’re 150. 
[Ann]  
 
Summary of Adolescent Medical Knowledge 
 In summary, despite the providers’ emphasis on the medical aspects of HIV 
during the adolescents’ clinic visits, most of the participants in this study did not display 
a detailed understanding of these concepts.  During the discussion of why it was 
important to take their medicines every day, thirteen of the seventeen participants 
mentioned the terms ‘T cells’ and ‘viral load,’ and generally knew that the former should 
be high and the latter low.  Two adolescents mentioned that if they did not take their 
medicines, they would stop working, and two simply said that they would get sick. In 
addition to the two adolescents who said that the medicines would stop working if they 
were not adherent, three participants had a good or fair understanding of viral resistance.  
Thus, the association between active participation in one’s care and treatment and good 
adherence (as measured by viral load tests) was generally a positive one, where those 
more actively engaged had excellent or good adherence.  However, it is worth noting that 
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that none of the participants displayed a confident knowledge of the medical aspects of 
HIV and the implications of adherence for future health outcomes and HIV 
transmissibility. 
Adolescent Responsibility  
 The responsibility for taking antiretroviral medicines every day has been fully 
assumed by about half of the fifteen participants currently taking them, meaning that they 
do not depend on anyone to give them their medications or remind them to take them.  
All but one of these youth had undetectable or nearly undetectable viral loads, which 
strongly suggests very good adherence.  Valerie, Jeff, and Diana, on the contrary, took 
their medicines with significant participation of the biological parent.  Valerie lives with 
her biological mother, and together they regularly organize their pills.  Valerie, however, 
is responsible for taking them, and said that she needs to be reminded only once in a 
while.  The fact that Valerie’s mother also takes antiretrovirals, appears to be diligent in 
taking her own medications, and is involved in her daughter’s life, seems to be a factor in 
Valerie’s success at adherence.  Jeff’s father sets out the pills for his son, and watches 
him take them, and this level of involvement again seems to ensure good adherence.  Of 
all the participants who either have full responsibility or full involvement by a parent, 
only Diana, whose mother also sets out her pills, did not have perfect or very good 
adherence.  Her situation and her mother’s attitudes toward biomedical health care and 
antiretroviral therapy will be discussed further in the section on provider-patient 
relationships. 
 The young people who had problems with adherence were those for whom the 
locus of responsibility was less clear or those who were ambivalent about taking their 
 109
medicines.  Olivia needed constant reminding and Angela said that her mother would 
“remind me if I like forget, like if I walk out of the house, she’ll be like, did you take 
your medicine.  I’ll be like, oh yeah.”  Zoë, Diana, and Angela mentioned that they had in 
the past stopped taking their medicines.  Zoë said she was “going through something at 
the time.  So I just stopped.”  Angela said she stopped when she learned that her father 
had died (from AIDS) and felt depressed.  Diana stopped only for several days, saying 
that she “just didn’t feel like taking them.”  While all three resumed taking their 
medicines, emotional difficulties or indifference may still have an effect on their current, 
less than optimum, adherence.   
Timing of Responsibility 
 The assumption of responsibility may also have been premature or overdue.  Zoë, 
16, has had full responsibility for her medications since she was thirteen, when her 
mother “gave me a choice to take it and not take it, so…she don’t remind me no more.  
It’s just me, it’s all on me.”  However, her motivation for resuming her medications, after 
her decision to stop for a month, was not directed at her own health, but rather “just to 
keep my mom happy, and keep her from stressing… Just to make life easier for her.”  
Full responsibility for taking her medicines appears to be difficult for Zoë.  
 Diana is nineteen, and has not yet taken full responsibility for her medications: 
“I’m not sure about the dosage, ‘cause my mom, she does it for me.”  She said that she 
wanted to perform this task herself, but “I try to tell her, let me do it myself, but she 
wants to do it…But I can’t learn if she doesn’t let me do it.” 
 It was conjectured that among adolescents living with their biological mothers, 
the disease management style and adherence behavior of the mothers might have an 
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impact on how the children assume responsibility for their own care and treatment.  From 
the mothers in the focus group, there did not appear to be a relationship between a 
mother’s adherence and her child’s.  Teresa, Joyce, and Nancy all spoke about the 
difficulties they had taking their own medications, whether because of side effects or 
forgetfulness, yet their children all had undetectable viral loads.  Nancy was not vigilant 
about her own adherence, but she was about her daughter’s.  Anita confessed to being 
tired occasionally and not taking a dose, but overall, she was adherent and appreciated the 
importance of good adherence.  However, she had  two children, one of whom had 
perfect adherence and the other only fair adherence.   
 What seems to be more vital is the mother’s attitude toward antiretroviral therapy 
and her involvement in the child’s treatment and adherence.  Donna was not convinced of 
the safety and necessity of the antiretroviral medications, and her daughter displayed 
laxity in her own adherence.  Teresa was ambivalent about her own adherence, but said 
that her six-year-old son is accustomed to taking his medicine and understands that “it’s 
his duty to take his medicine morning and night.” However, one wonders how she will 
monitor her son’s adherence as he gets older, because she also insisted that “you can’t 
force somebody to take medicine.  I don’t care how old they are.”   
 These examples, as well as comments from the clinicians, point to the difficulties 
that both caregivers and clinicians have in determining the amount of responsibility that 
an adolescent can handle and amount of involvement that they should have in their 
children’s disease management.  They find themselves trying to shelter these adolescents 
from the challenges of HIV, but at the same time, expecting or demanding that they 
assume responsibility for their medications.  Among the clinicians, Ed, who sees older 
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adolescents, believed strongly that these young people would be more responsible for 
managing their disease if they were treated more like adults than like children by the 
health care providers.  He emphasized his role in helping the patients to develop power 
and control in their disease management.  He described the success he had with one 
patient:   
He was a young man who was developing a disease identity, felt pretty 
hopeless, helpless because that’s what happens with kids with chronic 
disease, they grow up feeling like this, you know, that they’re, you know, 
dependent upon the health care system, their providers and everything.  
Their parents are worriers so they kind of overprotect and not let them 
kind of start developing but this one particular patient I was working with, 
when I first got him he had zero T cells and in a year and a half I just got 
three hundred and something T cells on him but for him it was changing 
the pediatric focus.  He needed an adult focus; the pediatric providers, he 
wouldn’t even come for their appointments because they couldn’t shift 
from talking to him like a baby or a child or lecturing him like a parent 
would as opposed to giving him some adult skills, working some adult 
skills in, saying its up to you, dude, you know, and then he flew with that. 
 
Both Ann and Dr. Flynn, however, cautioned that sometimes parents prematurely think 
that their adolescent children should be responsible for their medications, but the children 
are not yet ready to take on this responsibility without some continued guidance from the 
caregiver: 
…what I find is sometimes, you know, the parents are like, they’re 
fifteen, they’re an adult, they need to know how to do that and I’m 
like, I understand, they’re working to be an adult but as much as we 
want them to be able to do that, they’re still learning, so then I do try 
to get the parent involved in still supervising it. [Ann] 
 
…parents try to give away some of that responsibility and…they 
[adolescents] come to the clinic and they’ve always been undetectable  
and all of a sudden we see a big spike in the viral load and like, what’s 
changed?  Well I try to give up the responsibility and we say like, 
they’re not ready.  You’re going to have to go back and watch every 
single dose; obviously they’re not doing what they’re supposed to be 
doing. [Dr. Flynn] 
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 Some of the adolescents accepted the responsibility with aplomb.  Thirteen-year-
old Paula acknowledged that it was her responsibility to take her medicines, saying, “it’s 
not really his [father’s] job to remind me, so if he doesn’t remind me, I remember 
myself.”  Lucy, 19, nicknamed her medications “my three special friends” and 
recognized their importance in keeping her alive and healthy when she described how she 
felt on the rare occasion that she forgot to take her pills, “I got scared ’cause I thought 
something was going to happen…That my count would go down really low.  And fast.”  
Lucy was the only participant who expressed this kind of concern about being adherent. 
 Olivia’s case was complicated by the fact that her health care providers had 
decided that her medications were no longer effective.  It is difficult at this point to know 
whether she was non-adherent or whether the virus had become resistant to the 
medications, though resistance itself could indicate prior non-adherence.  Since her 
doctors had decided soon after her interview to change her regimen, it is probable that 
resistance was causing the lack of viral suppression.  Nonetheless, during her interview, 
Olivia, 13, displayed little motivation toward managing her illness.  Her adoptive mother, 
who joined the interview for the last several minutes, made it clear that Olivia needed 
constant reminding to take her medicines, and remembered on her own only when she 
wanted to demonstrate her sense of responsibility in exchange for getting something she 
wanted from her mother.  Her mother also insinuated that Olivia was not at ease with the 
virus as part of her life.  Her mother’s words are revealing and helpful, since Olivia was 
not very forthcoming during her interview.  In addition to mentioning Olivia’s needing to 
be reminded to take her medicines, her mother also revealed that Olivia felt like she was 
the only child with HIV: 
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Why should I remind her when she knows she got to take her medicine?  
All the time.  Not sometimes, all the time…She takes it every day, twice  
a day, but it’s like, I shouldn’t have to remind her, she knows she got to 
take her medicine.  It’s like, she don’t want to take it.  If I don’t say 
nothing, then it’s be done.  She won’t…[But] [i]f it’s something she want, 
if she wants to go somewhere or whatever, then she’ll bring the medicine.  
Like last night, you brought the medicine, right? Because she want to get 
her hair fixed today…  
I tell her, she’s not the only one.  It’s people out there that’s sick and  
she feels that she’s the only one and she’s not.  It’s kids younger than  
her has it, but she just don’t know who they is…I think...that she should 
like have, meet other people, let her know that she’s not the only child  
of the age of thirteen, there’s other kids, younger than her and older than 
her that has it, but they’re not going to come out and say it, you know, 
open that that’s what they have.  Because they don’t want anyone picking 
on them.  But you’re not the only one, that’s what I keep letting her know. 
 
Barriers to Responsibility 
    The clinicians mentioned additional barriers that hinder the adolescent’s taking 
responsibility for adherence.  Though they were not the focus of this study, it is important 
to note that psychosocial issues, substance use, and the physical side effects of the 
medications were mentioned as factors that could interfere with adherence among 
adolescents.  For the perinatally infected adolescents, the sense of unfairness is a theme 
that clinicians hear in their practices.  Even when they are healthy, the patients are 
reminded of their disease on a daily basis when they have to stop and take their medicine, 
and this can lead to rebellion and depression.  Ann acknowledged the frustration of the 
psychosocial issues, because “it’s the hardest stuff to fix.”  She also alluded to the 
complex lived experience of the adolescents and its effects on when and why they decide 
to become adherent: 
And I’ll tell you I have some who, they never take [their medicines] 
for years and like one day it clicks and they do it, and I can tell you,  
I mean it wasn’t anything, I mean I’ve been doing the same thing for 
five years so it wasn’t something I did.  It was something, somehow, 
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between them and their life, and maybe something, somewhere, I 
maybe taught them along the way and it maybe clicked. 
 
 Ed focused more on the psychological issues that are a part of adolescence, 
including identity development and a period of rebellion.  He believed that many 
adolescents, particularly the perinatally infected, wanted to “separate themselves from the 
disease, separate from the meds.”  When asked at what age he saw this behavior, he said 
it was around the age of sixteen, but “usually by…late adolescence I can kind of get them 
over that hump.”   
 All of the clinicians agreed that mental health is a serious issue that needs to be 
addressed among the perinatal adolescent population.  Asked to give a rough percentage 
of the adolescents that they think were currently in need of some mental health attention, 
they reached the same conclusion that half could use some help.  Carol first cited 30 to 
35% who have been diagnosed with a mental health issue, but then added that another 
15% may be in need but not yet diagnosed.  Dr. Flynn was at the high end, estimating 
that 60-70% of the adolescents had mental health needs requiring attention.  Carol 
believed there was a “a huge need for more, kind of, high quality support groups and 
mental health…[that] their mental health needs are far bigger than their issues related to 
HIV.”   
 Problematic substance use was less prevalent, according to the clinicians, with 
most putting the level at around 10%, though Ann thought it might be around 20%.  Dr. 
Lane added that of the older adolescents, she thought perhaps about 30% had tried drugs 
or alcohol.  She added that in addressing adherence issues, 
I don’t like to generalize, but I would say that a greater part of the patients  
that may have an issue with compliance, do have some substance abuse  
going on, even if they’re not necessarily, you know, getting in trouble with  
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it, you know with the police or stuff like that, but it’s kind of a common  
practice and  in percentage I would say I mean 30% at the minimum. 
 
Summary of Adolescent Responsibility 
 In sum, taking responsibility for their health care and treatment meant good 
adherence for most of the adolescents, but only if the individual had the tools with which 
to be successful.  One of these tools was comprehension of HIV and lab tests, as well as 
an appreciation of the importance of taking the medications every day.  However, for 
some adolescents, active participation in their treatment may need to be tempered by 
active monitoring by the caregiver, and gradually increased as the adolescent matures.  
For others, mental health care and substance abuse counseling need to be provided.    
Non-Adherence, Treatment Fatigue, and Treatment Interruption  
 Keith, 18, and Sean, 20, were two unusual cases among the study participants.  
They had stopped taking antiretroviral medications at the instruction of their health care 
providers, because they were not adherent to their medications.  Sean’s explanation was 
inaccurate: “I was doing good and they wanted to see if I could keep doing good off, so 
they just gave me the chance to stop and they said I was doing good without it.”  Keith 
complained to his health care provider that the medicines “make me feel like I’m going to 
throw up all the time, and they take away my energy.  They make me weary, I had to lay, 
sleep all day, go to sleep so I could wake up and feel better.”  Since inadequate adherence 
can lead to viral resistance, the health care provider decided, in both of these cases, to 
interrupt antiretroviral therapy in order to avoid viral resistance and, therefore, safeguard 
their future medication options.  When the clinicians who were interviewed for this study 
were asked whether they would ever stop antiretroviral therapy if a patient was doing 
well, they said they would rarely consider doing so, and pointed out that guidelines do 
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not recommend discontinuing treatment.  They added that, during treatment interruption, 
there is increased morbidity and mortality, as well as “progressive immune 
deterioration.”  One of the providers said that one might consider discontinuing treatment 
if a patient was clearly non-adherent but had relatively stable CD4 counts and low viral 
load.    
 Keith’s medications were stopped in January 2009.  He was experiencing 
difficulties with his current regimen, and discussed this with his provider.  He explained 
that he was directed to take his pills until his viral load reached very low levels, at which 
point the clinician stopped the medications and monitored his levels.  However, from the 
available records of his viral load, it is not possible to ascertain viral suppression in 
January 2009.   As of April 2008, Sean was not taking his medications and his medical 
chart indicated that he was not prescribed further treatment at that time due to his non-
adherence.   
 As the graphs below indicate, their viral loads, though not suppressed, were 
somewhat steady at relatively low levels.  Their CD4 percentages were at the low end of 
normal or below normal, the normal range being from about 30% to 60%.  Thus, they 
were maintaining a relatively healthy status without their antiretroviral therapy, though 
Sean had been out care for about a year at the time of his interview, so it is unknown how 
his viral load and CD4 count had changed since his last medical visit in 2009.  Keith, 
however, continues to show relatively low viremia without his medicines. 
 Studies on planned treatment interruption (PTI) demonstrate a rise in viral load in 
the weeks after PTI began and subsequent viremia stabilization, along with rapid 
decreases in the CD4 count and percentage and subsequent stabilization (Noguera et al. 
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2010; Castro et al. 2010).  Thus, Keith and Sean appeared to be somewhat stabilized 
during their PTI, as of their most recent lab tests. 
Keith
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         Figure 4.1 Keith’s Viral Load, 2008-2010 
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         Figure 4.2 Keith’s CD4 Count and Percentage, 2008-2010 
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         Figure 4.3 Sean’s Viral Load, 2008-2009 
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          Figure 4.4 Sean’s CD4 Count and Percentage, 2008-2009 
 
 These two adolescents, Keith and Sean, evoke the issue of treatment fatigue.  
Keith was especially frustrated with his regimen and its effects on his wellbeing.  The 
lives of these adolescents have been defined by their medical experiences, especially 
frequent clinic appointments and daily medications.  Parents, as we have seen, may be 
able to obviate this fatigue by continued involvement in and support of their children’s 
adherence.  However, clinicians play an important role, too, through their medical 
instruction, facilitation of a sense of responsibility in their patients, and their help in 
resolving some of the problems (e.g., side effects, pill burden) that may lead to treatment 
fatigue. 
 The clinicians who were interviewed for this study had very different attitudes 
toward the issue of patient responsibility and continued adherence.  Carol, taking the 
more pediatric focus, saw her role and message directed at the caregivers: 
…the role of the caregiver at home is ultimately what makes you or breaks 
you….I think you have to kind of empower them [parents] and say, your 
message to them is that not taking them [the medicines] is not an option.  
It’s like, do you want to take them with dinner or after dinner or with 
apple juice or milk?  There are certain things and absolutely, there can be 
lots of choices that are reasonable, but not taking them is not an option, 
and I think some of our caregivers, they get that, like you don’t have to 
have that conversation and it’s just clear and that’s probably how they 
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parent….I just think that message [is] that not taking them is not an 
option. [Emphasis added] 
 
Ed also spoke to treatment fatigue and observed that, because of it, the perinatally 
infected were not as adherent as the behaviorally infected adolescents.  He noted that 
rebellion tends to occur when adolescents reach about sixteen and are given or must take 
responsibility for their medications.  In addition, he referred to the adolescent’s identity 
development at this time, and the danger for an adolescent “to develop a disease-based 
identity because that can lead to dependent personality issues and a lot of helplessness.”  
For this reason, Ed took a totally different approach, and since he sees older adolescents, 
he directed his actions and message to the adolescents: 
I’m happier when they rebel a little bit than not rebel a little bit because 
when they rebel a little bit and stop taking medications for a while, I’ll 
even give them a break sometimes, because at that point in their develop-
ment they’re saying, you know, I know I’ve had HIV, I’ve had it for my 
whole life, I don’t want it to be part of my self-identity….I kind of expect 
that the adherence is going to be an issue with, not all kids.  Some kids just 
continue on and take them, a lot of them in the teen years stop taking them 
and I think it creates a lot of anxiety in some providers when they do that, 
and if they’re not particularly doing well it creates a little bit of anxiety in 
me too, if they’re not doing well, but I know that once they get through 
some of these milestones, you know, more than likely they’re going to 
start taking the medications again and I’ve actually seen that with a few  
of the patients here.  You know, I think that’s a very common issue, you 
know. 
 
             Dr. Flynn also brought up the realization by some adolescents of the lifelong 
nature of medications, which could lead to fatigue and the thought, “I want to see what 
happens if I don’t take it.”  The problem with this treatment rejection is that sometimes 
the patients continue to feel well or to feel better, and it is then incumbent on the 
physician to explain that “yeah, you’re gonna in the future, in the long term, it’s gonna 
hurt you more than the short term benefit, if there’s any to it.”            
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 The concern with the adolescent’s decision to stop treatment or the physician’s 
prescription of treatment interruption is that the adolescent’s viral load may rise to levels 
that make him or her more infectious to sexual partners.  This is discussed in Chapter 5.  
Summary of Adolescent Engagement  
 The active participation of these adolescents in their health care and treatment was 
measured by their knowledge of medication names and dosages, lab tests and results, and 
viral resistance.  What the interviews reveal to be even more important in terms of 
successful adherence is an internalized appreciation for what taking these medicines 
means.  All of the participants admitted that the disruptions of daily living sometimes 
interfered with their medication schedules.  What differentiates those with successful 
adherence from those who have problems is that the successful adolescents knew that 
they had to take the medicines regardless of the distractions, and found a way to do so.  
Whereas Vanessa, 16, took her pills everywhere and went into the bathroom to take them 
privately, Stephanie, 20, did not take her pills when she went to a friend’s house.  Olivia, 
13, had to be reminded constantly to take her pills, whereas Paula, also 13, said it was her 
responsibility, not her father’s, to remember to take her pills.   Whereas Nina, 17, 
discussed her stomachaches and sleeping problems with her nurse practitioner, Keith, 18, 
stopped taking his medicines.   
 Overall, if the adolescents were actively involved and interested – took full 
responsibility, understood and accepted the importance of medication adherence – and 
had good support, they had better adherence.  They are the ones who accepted the 
responsibility for managing their disease more completely, remembered to take their 
medicines, understood the importance of taking them, and were engaged in and 
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knowledgeable about their health care.  The participants for whom responsibility was not 
accompanied by understanding and appreciation for what adherence meant had more 
trouble adhering to their medications.      
Provider-Patient Relationship 
 The relationship between the adolescents and their health care providers had a 
weaker impact on how well these young people adhered to their medication regimens.  
Overall, the participants reported a good and trusting relationship with their health care 
team, and generally thought that their clinicians understood their particular issues 
regarding HIV medicines and adherence.  Yet, among the adolescents who had a good 
relationship with their providers, some were considerably more successful at adherence 
than others were.  Table 4.3 shows the participants’ ratings of their health care provider’s 
understanding of their personal experience with medications in response to the question: 
 On a scale of 1 to 10, how well does your doctor or nurse understand 
 your issues, challenges, problems, and experience with taking HIV 
 medications? 
 
  Table 4.3  Adolescent Rating of Provider’s Understanding 
 
 
 
 
 
 
 
 
 
 
                       
     
 The two teens who did not give a high rating to their providers’ understanding of 
their medication issues, Zoë and Diana, are the participants who were less successful at 
medication adherence than the others.  In her interview, Zoë expressed disinterest in her 
           1      2     3     4     5     6      7     8     9     10 
             /___/___/___/___/___/___/___/___/___/ 
          1—Doesn’t understand at all----10 Understands everything 
 
Paula 9 Bridget 10 Diana 5 
Lucy 9 Katie 10 Zoë 4 
Rachel 8 Jeff 8 Olivia 10 
Valerie 8 Vanessa 7 Keith 10 
Nina 6 Angela 8 Sean 10 
Mark 8 Stephanie 10 
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medical care, and in answer to a question about her lab results, she said, “it’s kind of 
confusing, so I just let my mom deal with it.”  She also expressed annoyance with the 
repetitiveness of the clinician’s information and admonitions, saying, “she [the clinician] 
come in like every time I visit, it’s just complain about what’s happening to me.  And she 
goes on and on for like ever…I know the stuff she telling me and she just go on and on.” 
The repetitiveness of the providers’ questions and explanations was also mentioned by 
Vanessa, Lucy, and Paula, though this did not interfere with their commitment to 
adherence.  Bridget explained her take on this when she said,  
…like when you’re young, they ask you, they’ll like constantly remind 
you that you have HIV, but as you like get older, like when you start to 
become more independent, they’ll start talking to you about protection and 
birth control and everything.  ‘Cause they just put me on birth control…So 
it’ll change, once you get older.   
 
 Adherence counseling and discussion about medication regimens and problems 
are part of the clinical visit protocol, and the clinicians bring up adherence, lab results, 
and medications at most every visit in order to advance the knowledge of the patient 
according to his or her age and level of understanding.  From the perspective of some of 
the adolescents, the process is not seen as educative, but redundant.  This results in 
irritation and, sometimes, disinterestedness.  Vanessa and Lucy, for example, knew the 
terms viral load and CD4 or T cell count, but were unable to state their latest numbers.  
This may reflect a lack of attention to what happens each time they visit the clinic. 
 Diana’s situation is complicated by the fact that her biological mother, with whom 
she lives, voiced ambivalent feelings about taking antiretroviral medication.  Diana said 
that she is taking her antiretroviral medicines as well as alternative herbal medicines.  She 
had changed health care providers recently, having seen her current doctor only twice.  
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She does not appear to have established a rapport with her doctor; when asked whether 
she talked to the doctor and asked the doctor questions, she replied, “Nope…I just listen.”  
While Diana knew the names of her medicines and had a basic understanding of her lab 
tests, she seemed to be less engaged with her health care than some of the other 
participants who displayed a similar knowledge.  Her mother’s attitudes toward the health 
care she and her daughter received, and toward the antiretroviral medications, are likely 
to have exerted an influence on Diana’s commitment to her own health care.  Diana’s 
mother was a participant in the biological mothers’ focus group, and her input will be 
discussed further in the section on family influences.   
 The influence of the biological mother on a child’s disease management is one of 
many aspects of a child’s environment that shape the child’s approach to his or her HIV 
disease.  Some of the mothers in the focus group voiced dissatisfaction with the structure 
of the clinic visit (discussed below) and said that their children did not like going to their 
clinic appointments.  It is noteworthy, though, that mothers who voiced dissatisfaction 
with certain aspects of their children’s health care had children who were extremely 
diligent with their medication regimens as well as children who were less engaged.   The 
mother’s attitude toward her child’s health care seemed to affect the child’s attitude 
toward the clinic visit, but did not directly affect the child’s adherence. 
 The availability of different staff and services at the clinic, which some regarded 
as excessive, raises the issue of perinatal adolescents’ “care fatigue” and their changing 
needs.  The clinicians mentioned that many of their patients’ needs could be addressed at 
the clinic, a convenience and advantage for many who otherwise would not have access 
to these services.  However, the adolescents themselves, as well as some parents, referred 
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to the structure and content of a typical clinic visit as overwhelming, and this affected 
their satisfaction with the services and their willingness to keep their appointments.  One 
of the nurse practitioners brought up this problem in his interview: 
I think that has shown up on our patient surveys too, where they say, no, 
they don’t like coming here, because they spend one, two, some patients  
are here three hours.  By the time the provider is done obsessing, by the 
time they’re shoved in to see the nutritionist and then they’re shoved in  
to see a nurse and then the social worker comes in, that’s, I think, that is 
cruel and brutal to do to some patients, to have them here for that long. [Ed] 
 
 Even though some patients think that the services are excessive, their dependence 
on the comprehensive attention to their needs becomes evident when they transition to 
adult care services.  Many of them are not prepared to take the initiative that is required 
of adults if they want to have all of their needs met and questions answered.  Four of the 
five clinicians underscored the problem and their role in it: 
…a negative to that, though, is it’s kind of like culture shock when they go 
to adult care, because there’s not a half an hour long visit…and you know, 
my patients just call me directly…I think there’s a huge need for them to 
really gain the skills that they’re going to need in adult care, because, I 
mean, they don’t know anything different than our little world and it’s 
going to be a little bit of a shocker… And we normally just…let people 
reschedule, we don’t ever turn people away.  I think in adult care they’re 
like, you no-show three times and you’re done.  We couldn’t do that 
because there’s nowhere else for them to go. [Carol] 
 
By the time they see me they’re getting quite a bit older, so they need to 
transition to adult care soon…It’s kind of typical in this program, it’s an 
acute problem.  The youth don’t transition well to adult care.  When they 
get to adult care they have no skills to transition. They don’t even know 
how to make their own appointments usually,…so I spend a lot of time in 
preparedness with them to get them ready to move into adult care, which I 
think, it takes a while for a pediatric provider to…shift gears…I kind of 
want to get the kids used to what it’s going to be like when they get to 
adult care.  It’s not going to be coming to clinic and sitting in clinic and, 
you know, the provider taking an hour with them.  That’s just not gonna 
happen in adult care so …I get them used to choosing two or so 
complaints and not a full list of issues that I’ve already talked to them 
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before about and kind of worked to empower them to take care of some of 
these things on their own. [Ed] 
  
We over-shelter and protect our perinatal patients a lot…like here if they 
miss an appointment we call them, hey what’s going on, what’s 
happening? Or if they show up late we still see them and we’re kind of 
more flexible and nurturing, but then once they move into the real world a 
lot of things are not gonna be there…[S]ome others have become too 
attached to the program and they go to the adult care clinics and they don’t 
like them and they don’t want to go back there.  They want to stay with us, 
which is impossible, so yeah it creates an issue. [Dr. Flynn]  
  
Usually we call, we send letters, we are very persistent with our younger 
patients, but they’re [adult care providers] not going to call more than two 
times…[S]ometimes in pediatrics, we kind of are more like the mother and 
father of the patient, and then they are not going to have this in other 
settings. [Dr. Lane] 
 
 The clinicians’ responses about the trust and understanding they had with their 
patients were generally comparable to the adolescents’ assessment of clinicians’ 
understanding of their adherence challenges.  The questions were different, but the 
answers of both groups acknowledge that the providers understood at least some of the 
adolescent’s experiences.  However, the clinicians attributed some of this trust and 
understanding to the adequate length and the comprehensiveness of the clinic visits, 
aspects that some adolescents, as well as some of the mothers in the focus group, did not 
consider a positive aspect of their health care.  In addition, while some adolescents found 
the clinicians to be repetitive, the clinicians considered it necessary, and were glad that 
they had the time to explain, review, discuss, and ask and answer questions, and could 
instruct their patients about medications and lab results at every visit, if necessary.   
       The latitude that the clinicians enjoyed in their clinic visits means that their 
acquaintance and their medical encounters with the patients were comprehensive.  They 
indicated that many of their adolescent patients became very comfortable in discussing 
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their lives and their experiences with them.  In this way, the clinicians had greater 
opportunity to look beyond patients’ charts and attempt to see and understand the non-
medical circumstances that can impinge upon individuals’ ability, willingness, and means 
to undertake the necessary actions to manage and maintain their health.  As Ed, one of the 
nurse practitioners pointed out, “for an adolescent, most of the issues are non-medical.”  
This level of interaction and knowledge allowed for a far more in-depth encounter than 
patients normally have at adult clinics.  Because the perinatally infected patients had 
generally been going to the clinic for years, the clinicians believed that they had a good 
rapport with patients and knew their patients intimately.  
 However, the clinicians had different views on how understanding they could be 
and how trusting their patients were toward them.  They also had very different 
interaction styles. Regarding trust, understanding, and communication, one of the 
doctors, Dr. Flynn, rated his level of understanding of patients’ experiences and 
challenges a seven (on a scale of one to ten, ten being a high level of understanding).  
Carol, a nurse practitioners said,  
They trust us a lot.  I mean, I think I’m normally fairly aware if it pertains 
to, I guess, the part of their life which would affect their medical care, 
which is a lot of it.  So yeah, I mean I think most of our patients are very 
open, and again we have more time…I can tell you where they work, 
where they live, their last partner’s name, whether they use a condom, you 
know, fifty, eighty, a hundred percent.  I mean, I think we get to know 
them pretty intimately.  
 
Another nurse practitioner, Ed, answered, “I think I’m able to form a really good 
relationship with my patients.  I would, I’d put me on a nine.”  On the other hand, the 
third nurse practitioner, Ann, described the level of trust among her patients as “the 
standard deviation curve” and rated her level of understanding of patients a five.  She also 
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acknowledged, “You know, I understand some of it but you know, I’ve never walked in 
their shoes.  I don’t really understand. Maybe I know a little, yeah.” 
 The stark contrast in interaction styles among the practitioners was apparent in 
two responses, one by a nurse practitioner and the other by a physician.  The nurse 
practitioner, Ed, tried to shed some of the adult role in order to relate to the patients’ 
adolescent experience.  He put it this way:  
You know, I’m funkier, I use humor a tremendous amount in my 
healthcare approach to things, you know.  So yeah, I think I’m  
pretty well trusted.  The older they get the more they trust me,  
I think. 
  
He also indicated his attempt to treat the adolescents more like adults:      
What I do for you is this much, what you do for you is this much.  
You can come in, you can see me, we can shoot the shit, we can 
bullshit, but if you don’t do what you need to do to be healthy, you 
know, then that’s [referring to viral resistance] gonna happen to you, 
because I can do this much.  Everything’s up to you and in your 
control now.  Adolescents love that, you know, because that’s part  
of adolescence, that’s where they want to move into.  They want to  
be adults, they want to have power over their lives. 
 
Later, he added: 
sometimes I’m provider, sometimes I’m life coach, sometimes 
I’m…perceived as almost a big brother, sometimes I get perceived, 
particularly from the kids who are looking for that, I almost get 
perceived as a parent sometimes. 
 
 The physician, Dr. Lane, took what appeared to be a more no-nonsense approach, 
emphasizing her role as the medical provider, who had to make the best possible 
decisions for her patients, while admitting that she could not understand her patients’ 
experiences completely: 
…we try to understand, I try to be open, but unless you live the situations, 
I don’t think that you can really understand…. I hope I am in the higher 
end [of the rating scale] so that my patients believe that I am caring and 
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understanding their problems…I think that, you know, there are some 
patients that may be reluctant or some patients that really kind of connect 
more with their peers or someone from like a group or social worker… As 
a medical provider, you want to be able to understand your patient but you 
also, you’re not necessarily the friend so sometimes, and that’s what we 
try to build in our clinic is that there are these different layers [of services] 
so you know, I cannot be your friend because I want to be, I want to 
understand what happens to you, but I also want to make the best 
decision…[be] impartial…in what I’m actually going to do or going to tell 
you or make the best medical decision. You know, if you are emotional all 
the time involving the situation of the patient, sometimes that may not be 
of benefit to them.  So you need to set up boundaries of where you are and 
how you provide help.  But I’ll say that the majority of the patients, 
because they have been coming…for the longest time and I think that they 
do have a good rapport with the majority of the staff. 
  
  Perhaps not surprisingly, the adolescents and clinicians had somewhat different 
perceptions of the level of trust and understanding in the patient-provider relationship, as 
well as different descriptions of and opinions about the comprehensiveness of the health 
care visit.  The comments of the adolescents and the clinicians show that there is a 
conflict between, on the one hand, providing comprehensive services that patients need 
and addressing all of their issues as they arise, and on the other hand, treating the 
adolescents as responsible individuals, expecting them to understand and integrate 
medical information into their lives, and addressing them in a way that the adolescents 
receive as respectful of their age and maturity. 
Summary of Findings for Hypothesis 1  
 Disease management requires a level of knowledge and acceptance as children 
enter adolescence and are expected to participate more in their HIV care and treatment.  
Whether or not their caregivers still had more responsibility for their children’s 
adherence, the successful adolescents were those who had accepted that they had to take 
these medicines every day.  If this acceptance was combined with knowledge of the 
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medical aspects of HIV and adherence, then they might be more likely to practice 
successful adherence.  Those who were more ambivalent or who did not accept the 
responsibility for daily medication were less successful. 
 The provider-patient relationship among these adolescents and these clinicians 
was generally good, and the effect of this relationship on adherence was mixed.  
However, those who were less engaged with their providers were indeed the participants 
who had more problems being steadily adherent. 
Family Dynamics and Peer Relationships (Hypothesis 2)  
 Family interactions and peer relationships provide the key backdrops for the 
adolescents’ daily experience of HIV disease management.  For the participants in this 
study, the activity of taking medications is, or is not, performed in the presence of family 
or friends.  Thus, my second hypothesis was: 
The lack of family stability (e.g., loss of parents or siblings to HIV) 
and peer support adversely influences adolescents’ adherence. 
 
Family Dynamics and Involvement 
Support and Openness: Valerie, Jeff, Katie, and Mark   
 Greater family involvement, openness, and support led to greater success at 
adherence.  Family structure and stability, however, did not correlate with the 
participants’ success at adherence.  Among those with excellent adherence and 
consistently undetectable viral loads, as well as among those who were struggling with 
their adherence, were adolescents who were in a stable household.  In addition, fifteen of 
the adolescents, both adherent and less so, had lost one or both parents, never known one 
or both parents, or had been taken from a mother who had substance abuse problems.  
More than the stability and structure of the household, it appears that the caregiver’s 
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involvement and openness about HIV led these families, and the adolescents themselves, 
to adapt to HIV in their lives and to incorporate the demands of the disease into their 
daily routines. 
 The clinicians also agreed that families who had adjusted emotionally to HIV and 
had made HIV disease management a part of the family’s routine had adolescents who 
were more adherent to their medications.  Ann’s perception was that   
our kids that were born with it who do well are generally, generally have 
been…in a family where they talk about it, it’s part of what you do, you 
just take the meds whether you feel bad or good and so they’ve always felt 
good and they take their meds….I have some who live in very caring 
homes but the issues around the HIV are still very difficult for them.  So 
they’re safe, they’re loved, but the family, there’s still a lot of feelings 
about the HIV, whether it’s mom or dad also has it or, you know, that they 
have trouble dealing with it and maybe mom hasn’t always been great at 
taking her meds and she has trouble telling her child to or there’s just 
general chaos.  I have some who, there are very loving, safe, great 
homes…[b]ut the environment around their HIV is still not great as far as, 
like, taking care of that.    
 
Dr. Flynn admitted that there is no “magic solution” to adherence for all adolescents, but 
he did note that patients who were successful at adherence were those who  
told me it’s to make it a routine like…when I go brush my teeth that’s 
where I do it or when I have dinner.  It’s when they’ve been able to 
incorporate it as part of a routine in daily life.  Or I think it’s the most 
successful thing is like when they are able to incorporate it…that they 
don’t have to think too much about it, when it becomes kind of an 
automatic thing. 
 
Dr. Lane also pointed to routine and openness as characterizing the environment most 
conducive to successful adherence: 
I would say that I think one is the family support so I think that if they 
learn from their parents or they have a supportive environment, you know, 
sometimes also there is a lot of secrecy, it’s really hard, you know, if like 
there are ten people in the home and nobody knows about it, and they have 
the meds in a cabinet somewhere and need to hide to take them and have 
two minutes to try to do that and get a glass of water.  And so if you have 
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family support – “I understand that it’s just normal, I take an aspirin, I take 
whatever, and I take these meds”….So in those patients that kind of get 
these medications as part of their routine, as I brush my teeth, I take the 
meds.  So I think that family support is very, very important…if you have 
a happy boy or happy girl, they stay in a stable environment, most of the 
time the patient will adhere. 
 
 Valerie and Jeff’s parents are examples of involvement and support.  Valerie and 
her (biological) mother organize their medications together, and Jeff’s father readies his 
son’s medications and watches him take them.  Since Valerie has some physical 
disabilities, her mother is closely involved in providing for her daughter’s needs, 
including monitoring her medications.  Both Valerie and her mother seem to have made 
room for HIV and its daily demands in their normal routines.  Jeff has other adults in his 
life who also make sure he takes his medicines.  When he is at his aunt’s house or his 
close friend’s house (whose parents know about his HIV), the adults make sure that he 
takes his medicines.  He has both support and supervision that help him adhere to his 
medications. 
 Katie and Mark exemplify the adaptation to and acceptance of their HIV disease 
that comes from having mothers who have always been open and unashamed about this 
disease.  Katie does not ever remember having to be secretive about her disease.  Her 
description of her (adoptive) mother illustrates the no-nonsense and shame-free approach 
to HIV that is reflected in Katie’s good nature and acceptance of who she is: 
My mom, she always was open about it.  She never sugarcoated, she never 
hid it from us, and it was never, like, not a discussion or topic.  We could 
actually be sitting at the dining room table, and ask her a question, and she 
never hesitated to answer, so she would tell us, you know… My mother is 
the free type of person, she’s like,…you be who you are, you are who you 
are, and you know what I’m saying, if it is that no one don’t like you for 
who you are, then screw them.   
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Mark’s (biological) mother, who was present for part of Mark’s interview, expressed the 
same sentiments about living with and accepting HIV, and being open with her son and 
not caring too much about what other people think: 
I don’t keep any kind of secrets from him… and I try to explain it to 
him…[M]ost kids don’t understand and children fear something if they 
don’t understand it…I don’t live my life any different than you would live 
yours, my brother lives his, they all have to breathe the same. They’re not 
Martians or anything like that, but for his sake [and] the children, you 
know, like if he cuts himself or hurts himself, he knows [what to do]…  
I’m not ashamed of what I have.  It’s a mistake I made when I was a child 
and the first thing I will tell anybody, this is why, I was straight, I knew 
for years …yes, you can get it, yes you do need to use protection, this and 
this and this, and don’t hide it.  That’s the first thing that comes out of my 
mouth. 
 
Ambivalence and Silence: Zoë, Diana, and Stephanie   
 Many of the families displayed ambivalence and less involvement in their 
children’s disease management.  Others either did not talk about the disease or were 
careful to keep the subject within the bounds of the household.  Zoe and Diana had 
problems with adherence, and both were in families where the mother had either 
relinquished responsibility or felt some uncertainty about how best to exercise 
responsibility.  Stephanie and her family appeared to try to normalize life by not talking 
about her disease. 
 Zoë said that “until I was thirteen, it was my mom who had to tell me when to 
take it [the medications] and how to take it.  But after that it was like, she like gave me a 
choice to take it and not take it.”  When asked if she was now taking her medicines 
herself, and whether her mother reminded her, she responded, “she don’t remind me no 
more.  It’s just me, it’s all on me.” Yet Zoë, now 16, deferred completely to her mother in 
matters concerning her health care.  When asked if she knew what her viral load and T 
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cells were, she responded that she did not, but when probed about whether the doctor told 
her what those numbers were, she said, “They tell me, but it’s kind of confusing, so I just 
let my mom deal with it.”  Later, she explained what made her resume taking her 
medications after stopping for a month, she said, “I started realizing what I was doing, 
‘cause she [her mother] was, she said, she said, I’m not going to deal with you no more, 
let God deal with you.  So that made me feel kind of bad, ‘cause I was hurting her.  I 
wasn’t really thinking about her at the time.  So I started taking it.”  Zoë’s disease 
management reflects a keen dissonance in her understanding of, engagement in, and 
responsibility for her health.  She has assumed responsibility for taking her medications, 
but not for engaging in her health care and treatment during her clinic visits. Her 
engagement in the management of her HIV disease seems not to be so much for her own 
benefit as it is for her mother’s benefit and mollification. 
 Diana’s adherence seems to have been influenced by the ambivalence her mother, 
Donna, expressed about the merits and safety of antiretroviral therapy.  Diana’s 
knowledge of her medications and familiarity with viral load and CD4 counts, coupled 
with her mother’s support and stable family life, might have helped her to maintain good 
adherence.  However, her mother’s decision to stop taking her own antiretroviral 
medications in favor of herbal remedies, may have influenced her daughter’s attitude 
toward the medicines she was prescribed.  In the mothers’ focus group, Donna voiced 
serious reservations about the health care system, though she did not say that her 
daughter had stopped her HIV medications.  She only said that she used herbal therapies 
to treat some of the side effects of the medications.  Nevertheless, Donna was dissatisfied 
with the care provided by the health care providers, and was extremely critical of their 
 134
treatment towards her.  She was also very doubtful about the veracity of public 
information about AIDS, AIDS vaccines, and an AIDS cure, and voiced her belief about 
political and economic motives underlying the cause, potential cure, and treatments of 
AIDS.  Her distrust of the system, as well as her belief in the toxicity of HAART, may be 
having an effect on how Diana approaches her own HIV disease management.  
 Stephanie seemed both engaged in and knowledgeable about her health, lab tests, 
and medications, but still seemed to be having difficulty maintaining good adherence.  Of 
interest in Stephanie’s case is her family history.  She mentioned several times that she 
knew nothing about her biological mother and she lived with relatives in her home 
country until she was fourteen.  Her biological father was in the United States and 
Stephanie relates her coming to join him here in this way: “…[M]y dad was in America.  
I was the type of children my dad never wanted.  So the only reason I came to America is 
because of my stepmother.  The first time she saw me she knew I was my dad daughter.  
But my dad didn’t want to believe that I was his daughter.”  In addition to her father’s 
initial ambivalence, and her early family instability, Stephanie said that there was little 
talk of her HIV in the home.  While she maintained that her family treated her “just like I 
was a regular person, just like every, they don’t treat anybody any different,” the fact that 
“My dad just, we just live in the house just regular, none of the family never mention it” 
seems to indicate some reticence to confront and accept Stephanie’s HIV.  When asked if 
her family ever mentioned her disease, she said, “Yes, they ask me how my low level is 
[presumably meaning, how low my viral load level is], and I tell them….[m]y blood, how 
my like my blood thing is.  How my labs, how the virus is doing.”  Beyond that, 
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Stephanie insisted that she was doing well because she didn’t think about her HIV that 
much, and no one reminded her of it. 
Effects of Stigma on Family Dynamics 
 The women who participated in the mothers’ focus group did not bring up the 
subject of stigma, but they shared anecdotes that intimated both felt and enacted stigma 
(Scambler 2009; Lekas et al. 2006) in interactions with their families.  The women were 
asked to describe the circumstances of their own diagnosis, how they reacted, and whom 
they involved initially.  Rita was married and had a four-year-old daughter when her 
husband was diagnosed.  She and her daughter were tested subsequently.  She described 
her reaction and those of her family and in-laws: 
My initial reaction was complete and utter disbelief….My family  
reacted, I think, well during the circumstance.  My husband’s family  
reacted terribly and we don’t speak to this day. [Emphasis added.] 
 
Teresa exhibited the secrecy that continues to mark this disease, even within families:  
I was actually diagnosed when I was having my son.  I have five kids  
and he’s the baby…[A]t the time my son was born, I had my father, my 
mother, and my sister, ’cause those are the only ones that I have down 
here.  I had told my older sister and my youngest aunt and that was it.  So 
basically nobody else know.  My other four children, they don’t know.  
They know we take, me and the baby takes medicine, but they don’t know 
what it’s for. [Emphasis added.] 
 
Anita’s reaction of denial and anger certainly characterizes other diseases, but is 
especially prevalent among those who have HIV: 
I didn’t tell them [her family] right away.  For a while I ran away from it, 
and was in denial.  And I started using drugs and staying on the streets a 
lot.  I didn’t want to deal with it, and I was in a very abusive relationship 
at the time, so it was just a lot going on.  He was in denial, he didn’t want 
to admit it, and he didn’t until he died.  I was very angry about it.  I was 
very angry at him. [Emphasis added.] 
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Peer Relationships and Support 
 
Culture and Stigma in Peer Relationships   
 Peer support for the participants in this study is suggested by the number of 
friends or other individuals in their social network with whom they have shared their HIV 
diagnosis.  The data show that those who have less peer support, as evidenced by their 
confiding in very few or no friends about their HIV status, generally had more difficulty 
with their medication adherence.  This should not be interpreted as a causal factor in 
adherence, but rather may be a reflection of the fact that those who are less adjusted to 
and accepting of their own disease status are both less adherent and less likely to share 
their status with others.  Only these tentative correlations, and not causality, could be 
suggested in this study with its small sample size.  That said, two of the young women 
who had undetectable viral loads and were thus very adherent to their medications also 
had not disclosed their status to anyone, so the correlation between peer support and 
medication adherence represents but one of many possible facilitators in an adolescent’s 
efforts to assume responsibility for his or her disease management. 
 The adolescents’ discussion of disclosure to others revealed the social world of 
adolescence as well as cultural mores surrounding family privacy and AIDS as a 
stigmatized condition.  The decision to disclose or not to disclose centered around the 
issues of trust and normalcy, as many decisions about sharing do in adolescence.  The 
participants who shared their diagnosis with a friend all talked about trusting that friend 
to keep the information secret.  Those who did not disclose to any friends mentioned the 
risk of having their information publicized if they told anyone.  The following examples 
demonstrate this: 
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Because kids are immature and like, they’ll spread it around. [Angela, 17]   
 
Because then they’ll tell the whole school…They would pick on me. 
[Olivia, 13]  
 
Because I don’t want everybody to know, ’cause everybody might talk, 
send it around…I don’t like, I don’t want everybody in my business.  
[Jeff, 16]   
 
You tell somebody, they’ll go run back there, run back to that person and 
now the whole world knows. [Sean, 20] 
 
 In addition to just wanting to keep their business private, these young people 
feared the stigmatization that accompanies an AIDS diagnosis.  The participants were 
asked about the knowledge and attitudes of their school mates, and several mentioned 
their peers’ scorn were they to learn of a friend’s AIDS, as well as the use of AIDS as an 
insult toward those who were different or those who demonstrated an understanding of 
AIDS.  Paula, who was knowledgeable about and comfortable with her diagnosis, 
especially at her age of 13, nonetheless denied her status:  “just ’cause you know 
something about it, just ’cause you know a lot about it doesn’t mean you have it, but I do 
have it, but I don’t want the whole school knowing.”  Zoë discussed her experience with 
a boyfriend and other peers:  
Well, I had a boyfriend, but it’s like, if I asked him like certain questions, 
like what if, and he was like, if that was so, I couldn’t be with a girl like 
that, so like, three months later I broke up with him.  And then I asked my 
friends, what would they do, and they was like, I couldn’t hang around no 
one who had it, so I just left it alone, and just kept it to myself.  
 
Keith echoes this idea of people’s wanting to keep their distance from people with HIV.  
He said, 
And the type of people that I hang around and I have friends with?  Some 
of them is not the type that I tell, because of their mind frame and the way 
they think.  Because once a black person like, the ones I hang around, hear 
about a disease or something, it’s like oh, well, I can’t be around you, I 
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can’t, I don’t know, I just got to be my distance.  'Cause they fear that if I 
cough in their face, something going to go wrong. 
 
 The stigma and secrecy surrounding a subject like AIDS was experienced very 
differently among the adolescents in this study.  Rachel, sixteen at the time of her 
interview, and Mark, who was fourteen, were the only participants who construed the 
secrecy about their HIV status as a lie.  More than once Rachel voiced her unease with 
keeping her status a secret from people:  “I was just like, I don’t need to lie to him 
anymore.  Like I’ve lied to so many people it bothers me.”  And at another point: “it was 
like I just felt like I was hiding a large part of my life from him so I decided that I was 
going to tell him.”  When asked what the worst thing about having HIV was, Rachel 
replied,  
I don’t know, I mean one thing that’s always bothered me is having to lie 
to people that I know.  It’s so secretive that it’s like, and it doesn’t even 
need to be, just the fact that it has been in my case, I guess.  I wouldn’t say 
that would be the worst thing, I would say that’s the thing that bothers me 
the most. 
 
When Mark was asked what the worst thing about taking HIV medicines was, he replied, 
“Whenever you just met a friend that they want you to spend the night you have to take 
your meds over there and they ask, why you gotta take that for?  Then you don’t want to 
lie to them.” 
 Katie was very open and comfortable about her diagnosis.  This seemed to be a 
consequence of her adoptive mother’s openness and conviction.  Even though Katie 
admitted to keeping her diagnosis from one boyfriend, overall she characterized 
disclosure thus:  
I told other people if they asked me.  She never told me that I didn’t 
have to tell, you know what I’m saying…If they can’t accept me for 
me, then oh well, if you don’t like me.  That’s why I don’t, I’m an 
 139
open, free person about my illness.  That’s just it.  It’s like I’m not 
going to sugarcoat who I am or what I am.  Nothing in this world can 
stop what’s going on in my body, besides me taking my medicine and 
doing what I have to do for myself, but someone else’s opinion about 
it doesn’t even matter, because if you don’t like me because of that, 
obviously it’s not a good thing, right? 
 
 Lucy, on the other hand, had no desire to share her HIV status with any of her 
friends.  When asked to give a reason for not telling a friend or friends about her HIV, 
she gave an answer that reflected the nature of cultural beliefs: she pointed out the way 
things are rather than giving a specific reason for her silence.  At first, she responded, “I 
don’t tell people.”  When probed for a reason, she said, “’Cause I choose to keep it to 
myself.  As I think of it as a secret that only I can share it with my mom and my sister.”  
Stephanie echoed the secrecy surrounding her diagnosis when she said, “I would not let 
my friend know I’m on medicine.  Because my parents, even at the house, my parents 
doesn’t even mention it, why would I even try to let my friends know that I’m taking 
medicine.”  Vanessa said she did not think she would ever tell anybody, even as an adult, 
because it was “none of their business.”  She conceded that she would make an exception 
in the case of a sexual partner: “Yeah.  That’s the only way I’m going to tell.” 
  Of the ten adolescents who talked about what is was like to share their status with 
someone, six made a point of including how the virus was transmitted to them.  They all 
mentioned being born with it or having gotten it from a parent.  Nina said, “I told him I 
was born with it and that it wasn’t my fault” (emphasis added), when she disclosed her 
status to a romantic partner.  Keith’s girlfriend, upon learning his diagnosis, told him it 
was not his fault.  While this may infer a feeling of blamelessness, nonetheless, most of 
the adolescents still refused to share their status with others.  They already perceived the 
general stigma of AIDS and presumably did not think that they would be accepted even if 
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they made it clear that they were not responsible for contracting the disease.  Thus, for 
both those who disclosed with the disclaimer that they were born with it and those who 
did not disclose, the perception of stigma was salient. 
 The secrecy surrounding the adolescents’ HIV status has had a logistical effect on 
adherence, in addition to its psychosocial sequelae.  Diana, Angela, and Stephanie 
mentioned choosing not to or forgetting to take their medicines when they stayed over at 
a friend’s house.  Vanessa, on the other hand, maintained that, “I take them with me 
everywhere because I never know if I’m going to be back in time to take them.  So when 
I take, I always get a little bag, and I put it in there.  Then I get water, bottled water, and I 
take it.”  When asked what she did if people were around, she said simply, “I go in the 
bathroom [to take the medicine].” 
 Thus, while it would seem that support from friends would facilitate adherence, 
the attitudes toward sharing personal information about a stigmatized condition seemed 
to take precedence over this support, so that some of the adolescents seemed more 
comfortable with people not knowing and could still be adherent, while others felt more 
at ease sharing their status.  Even among those who shared their diagnosis with friends, 
however, there did not seem to be an accompanying supportive interaction that came 
from discussing the participant’s illness.  Diana was the only participant who said that 
having friends who knew her status “makes me feel like there are people that care.  Like 
they’re not going to discriminate.”  Yet even she said that she and these friends did not 
discuss it, and she did not feel the need to do so. 
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Sexual Relationships and Disclosure   
 Peer support is perhaps most important in sexual relationships, because both 
disclosure of HIV status and medication adherence are key strategies associated with 
reducing HIV transmission.  All of the study participants, both the sexually active and 
those who were not yet sexually active, knew that the practice of safer sex meant using a 
condom during sexual activity.  Table 4.4 shows the participants who have ever been 
sexually active, current relationship status, and disclosure of HIV status to partners.  
Paula and Bridget were included, because they had discussed disclosure to boyfriends but 
had not explicitly stated whether they were, in fact, sexually active.  Of the six 
participants who were or had been sexually active at the time of their interviews, five had 
disclosed their status to at least one partner.  Katie and Diana said that they disclosed to 
their most recent partners, but not to past partners. 
 
 Katie described the discomfort she felt because she had not disclosed her status at 
the outset of her first relationship.  She compared her feelings for this person to her 
feeling for her subsequent partner, whom she told about her illness right away: 
Table 4.4  Sexual Activity 
Name 
Ever 
Sexually 
Active 
Sexually 
Active not 
confirmed 
Current 
Boy/Girlfriend, 
Sexually Active 
 Past  
Boy/Girlfriend,  
Sexually Active 
Disclosed  
HIV Status 
Paula  √ ?  ? Yes 
Bridget  √ No Boyfriend ? Yes, after  
one year 
Nina √  Yes ? Yes 
Katie √  No Boyfriend Y No (first) Yes (second) 
Vanessa √  Boyfriend, not 
sexually active Y 
No(Current) 
Yes (Past) 
Diana √  No Boyfriend Y No (at age 15)  Yes (recent) 
Keith √  Yes ? Yes 
Sean √  Yes ? No 
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“I could not tell him [first boyfriend] why I liked, I really liked him 
[second boyfriend], because he understood about my illness.  He [second 
boyfriend] was not afraid of me, he accepted me for all of me, you know 
what I’m saying, which he [first boyfriend] did not know, but that was my 
fault, because I should’ve told him in the beginning, which made it so 
much easier with Matt13 [second boyfriend].  If I would’ve told him in the 
very beginning, it kind of would’ve made it a lot easier with us… I can’t 
believe I did not tell him, I can’t believe I’m in this situation, I can’t 
believe this, ’cause I’ve always been a person that just really was free and 
open…. But when it came down to this guy, I was like, why, why, why, 
why.  Everybody I could always tell, why, what was so different about 
him.  I don’t know, I really did care for him so much, and I think, I think 
was the fact that I let my emotions get the best of my brain, you know 
what I’m saying.” 
 
We see that even Katie, who was very comfortable with her status, had a difficult time 
disclosing to a romantic partner.   
 Diana disclosed her status to her most recent sexual partner before they had sex, 
and they used a condom.  When asked how often she used condoms, she replied, “All the 
time,” but when asked if she ever did not use a condom, she conceded that she had not 
used a condom when she was fifteen.  She learned her diagnosis at fifteen, and said that 
she had unprotected sex after learning her diagnosis, at the time that she lost her virginity.  
Interestingly, Diana’s mother, Donna, had not been ready to tell her daughter that she had 
HIV even at Diana’s relatively advanced age of fifteen, insisting that her daughter 
understood, without knowing her diagnosis, the universal precautions that she must take 
in order to prevent HIV exposure through blood and sex.  She said,  
I always emphasized to her, “Diana, you know when you’re playing in the 
playground, don’t ever touch anybody’s blood,” and she learned that when 
she was like three years old.  “And don’t let anybody touch your blood,” 
and she says, “I know, Mom,” you know, so she knew and she told me one 
time, she says, “You know, my friend is so stupid.  She had sex with 
somebody and she didn’t even use a condom.”  Now she didn’t know she 
was HIV-positive, so when they used to come to me and say, well, she has 
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 Pseudonym. 
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to know because she can spread this now, I said she is very well educated.  
She knows not to have sex without a condom, ’cause she doesn’t know she 
can pass it on, but she’s, but she know, and they asked her all types of 
questions and they knew she was up to date on things. 
 
 Nina was in a long-term relationship (at least two years) with a young man who 
knew her status early in the relationship.  Within a few weeks of beginning to see each 
other, Nina felt that she had to tell him her status.  She described it this way: 
…the first day, well, not the first day but like a couple of weeks before 
that I had the feeling I had to tell him, I had to tell him, I had to tell him.  I 
had that thing stuck in my head, I’m like, no I gotta tell him so I told my 
mom and my mom was like, “Don’t tell him, don’t tell him yet.  You’re 
gonna lose him.”  I was like, no it’s not that so and I told how I was like, 
I’m just gonna tell him, if he leave me, he leave me, I don’t care.  So I sat 
down with him, I told him and he was shocked.  He was shocked but 
we’ve been through thick and thin. 
 
Nina was just shy of eighteen at the time of her interview, so disclosure to her boyfriend 
occurred when she was no more than sixteen.  With regard to protected sex, Nina 
admitted that her boyfriend did not always use a condom, but he understood the 
implications of his actions, and was tested for HIV regularly. The fact that she decided to 
disclose her status to a boyfriend when she was only about sixteen, despite her mother’s 
admonishments, indicates Nina’s fortitude and willingness to accept her HIV as a part of 
who she is.  As we shall see in the next section, she was also one of the adolescents who 
learned her HIV diagnosis at a young age.  This may have allowed her the time to adapt 
to her disease, and thus be more comfortable in disclosing to a potential boyfriend.   
 The cases of Keith and Sean were more problematic because they were not taking 
antiretroviral medications, were sexually active, and male-to-female transmission of HIV 
is more efficient than female-to-male transmission is (Stine 2003:212).  Keith told his 
girlfriend of his HIV status at the beginning, and he said that he knew about using 
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protection.  Yet, he admitted that condoms were not used every time they had sex, and his 
girlfriend had became pregnant, lost the pregnancy, and was, at the time of the interview, 
pregnant again.  Sean had a girlfriend for about two months at the time of his interview, 
and said that it probably would not be a long-term relationship.   For this reason, he did 
not disclose his HIV status to her, though he said that they used condoms during sex. He 
also was one of the participants who had told no one outside his family.  When pressed 
about whether he could foresee disclosing his status to anyone in the future, he 
responded: 
 If I been with a girl for about two or three years, then I tell her. It’s been 
so long why not?...If our relationship really good and she really like me 
and I really like her and we planning on being together for a long time, 
then I sit down and say hey. 
 
Sean did, however, see a problem, including possible legal ramifications, with having a 
sexual relationship with a woman and not disclosing his status to her, but he could not see 
himself telling a woman at the beginning of the relationship:   
Interviewer (I):  What’s the problem? 
Sean (S):  I’m having sex with her but not telling her what I got. 
I:  So why don’t you tell her? 
S:  I can’t do it. 
I:  You just can’t do it.  You would have to wait awhile.  Why, what if you 
 told her? Are you afraid to tell her?  Would you be afraid to tell her?  
 Would you feel embarrassed or like…? 
S:  I’d be afraid and be embarrassed at the same time. 
I:  Why, what would you be afraid of? 
S:  If I tell her that’s gonna stop our relationship. 
I:  You think she would leave you? 
S:  Yeah, stop our relationship.  Then she go back, probably tell her mom 
and dad, I was with him for such this long and he didn’t told me. 
I:  And now he’s telling you. 
S:  Now he’s telling, the police get involved and I’ve been messing with 
her daughter. 
I:  So why don’t you think it’s a good thing just to tell her right at the 
beginning, then there’s no problem? 
S:  She wouldn’t want to be with me because I’m sick, I’ve got a disease. 
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  In summary, the adolescents who were sexually active knew how to protect 
themselves and their partners during sexual activity, but they did not all practice safer 
sex, nor did they declare that they did or would disclose their status before engaging in 
sexual activity.  These results point to the difficulty and fear of discussing a sensitive and 
stigmatized issue with sexual partners that all of the adolescents may face.   
Clinicians’ Discussions of Sexual Behavior   
 Adolescents are, however, prepared for the eventuality of disclosure and 
negotiation of safer sex through discussions with their health care providers.  All of the 
interviewed clinicians reported that they addressed sexuality and sexual activity during 
their clinical encounters with adolescents.  These issues included sexual preference, 
condom use, sexually transmitted infections (STIs), contraception, disclosure to sexual 
partners, and the legal ramifications of HIV transmission and non-disclosure.  
 The three nurse practitioners tried to approached the subject of sexual behavior 
within the context of the adolescent culture.  Carol and Ann often introduced the subject 
of sex by first asking about the patient’s life at school and with friends.  Carol recognized 
that for these young people, especially those who may appear a little uneasy, 
…somehow it’s easier to talk about friends than yourself and I think that’s 
done for a lot of different things as well, but I think if you can get a gauge 
of what’s going on with their friends, and then they get a little bit comfort-
able talking about that.  Like it’s somebody else, then it’s kind of an ease 
into what’s going on with them. 
 
Ann also recognized the importance of understanding the patient’s social environment, 
and might begin the discussion by asking the patient if any of his or her friends had 
girlfriends or boyfriends.  She explained, “That’s something I lead in [with] because a lot 
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of times what their friends are doing is very reflective of what they’re potentially doing, 
so those are my early lead-in questions.” 
 The adult nurse practitioner, Ed, also recognized that the patient’s friends, and 
especially romantic partners, may influence their behavior.  Because of the importance of 
safer sexual practices among the infected youth, not only to prevent transmission of HIV 
but also to avoid exposure to and possible infection with other STIs, the disclosure of 
one’s HIV status and the use of condoms become primary considerations in a sexual 
relationship.  Yet, these are difficult actions to execute, and may be fraught with anxiety, 
fear, and even danger.  For this reason, Ed encouraged his patients to bring their partners 
to the clinic so that he could facilitate the discussion and provide information and 
explanations relevant to the couple’s relationship. 
 Four of the clinicians said that they brought up the legal implications of not 
disclosing one’s status or using condoms, and the fifth alluded to them by speaking of the 
“repercussions” of not using condoms.  Florida statute 384.24 states that it is unlawful for 
any person with HIV, who is aware of his or her status, to engage in sexual intercourse 
with another person unless that person has been informed of the HIV and has consented 
to the sexual intercourse (Florida Legislature 2010).  This complicates the sexual 
relationship, because it not only requires disclosure of one’s HIV status, but ostensibly 
also requires that the infected individual obtain and retain proof of the partner’s 
awareness and consent. 
While all of the clinicians addressed the importance of disclosing one’s status and 
using condoms, for both legal and health reasons, their responses to patients’ fear, 
ambivalence, refusal, or just human error regarding condom use and disclosure within 
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their sexual relationships were markedly different.  The two physicians took a more 
clinical approach, while two of the nurse practitioners were more instructional and 
disciplinary, and the third NP was realistic and direct.  Though the interviews did not 
contain actual conversations that the clinicians had with patients, I think that they do 
reflect how they communicated the information to their patients. Examples of each 
clinician’s style follow, and they raise the issue of how the clinician’s style may affect 
how and what the adolescent shares with the clinician, and how and which messages are 
received by the adolescents.  This will be discussed in Chapter 5.   
I also try to do some sex education like how it can be transmitted, about 
protecting themselves or using condoms, both for females and males, 
addressing the issues about the law in Florida, like what happens…how  
you need to disclose…how to address talking to a partner…and all the 
different aspects, so that if they have questions about like sexual 
practices…a lot of kids have a lot of questions…We also provide condoms 
in our clinic. We give them free condoms and we also tell them the other 
places they can go…. [Dr. Flynn] 
 
…“do you have a partner…or have you been sexually active?” and…I also 
try to relate that with disclosure, so I tend to be actually very up front with 
that.  You know, “You really need to disclose your partner, because you 
can get in trouble, and your partner can make charges against you and all 
that.”  But then we try to relate that to the protection that they need to use, 
so…“Because you have HIV, you are at a higher risk of getting other 
things that may be harmful for you, and in the same way that you don’t 
want to transmit  HIV, you also don’t want to get other things that you 
don’t want.”…You know, we kind of go over…“When do you think that 
you’re going to be ready to be sexually active and…if you are in a long-
term relationship and you think that you will be sexually active in 
particular with this person, you know that the disclosure should come.”  
So I kind of try to say, “You need to feel comfortable with the person that 
you’re going to disclose your HIV status.” [Dr. Lane] 
 
So what my message about that is, “This is what you should do and this is 
why.  The person you’re having sex with has a right to know that it’s 
possible they transmit HIV.  They need to realize why condoms are so 
important, but if you choose not to tell them you cannot have unprotected 
sex, you can’t.”  And I think some of the guys, and I just had a pretty in-
depth kind of guy visit the other week…It’s like I can almost see that he’s 
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toying, he’s never had sex before, but he’s like right there…and he’s 
undetectable, he’s toying with having sex but having it not be protected.  
And it’s like, “No, no, no, that’s not an option,” and not  telling, and I’m 
like, “No, no, no, you can’t do that.” [Carol]    
 
I try to do things like, well, what might be some reasons to choose not to 
have sex? And I try to get them to give me some ideas, and…then I try to 
then give something back.  So… we’ll talk about pregnancy risk…[w]e’ll 
talk about sexually transmitted infections, of them getting another 
infection.  We talk about it in terms of them exposing somebody 
else…[W]e get into disclosure… just emotional, definitely with some of 
the younger patients I’ll talk about, you know, not just the risk of STIs and 
pregnancy but also, “When you go to have sex with somebody, that’s a big 
choice, and is that the first thing you want, are you ready to do that?”...As 
far as disclosing to partners, I try to let them say what their concerns are 
about it and we try to talk about that.  I do have a good little [information] 
packet and…sometimes I’ll use the packet with them to try to talk about 
maybe getting ready for the process. [Ann] 
 
…we get into the conversations too that are harder…because sometimes if 
they’re sexually active…they’ll say “Well, no, I’m having sex now and 
I’m not telling my partners …because I’m just kind of fooling around with 
people, but I make sure that condoms are used, so I don’t tell them.” And I 
think the pediatric response to that may be, you have to do that, you have 
to do that, ’cause it’s that parenting thing that they like to do…I’m totally 
different.  I’m like…in the perfect world, people would tell each other 
that…that you have something that can be transmitted…. This isn’t the 
perfect world and do people do that?  No. It’s great if you can, if you can’t 
but you’re having sex and people aren’t going to stop having sex, just 
make sure that you use condoms, make sure that you’re protecting 
yourself, protecting who you’re with.  Is disclosure as important if you’re 
undetectable and you’re using condoms, or you’re using condoms?  You 
know, that’s a very personal decision that you have to feel comfortable 
with, and you have to see what’s okay for you and what you can live with 
if something happens. [Ed] 
 
Support from Other HIV-Positive Adolescents   
 A final significant detail absent in the interviews with regard to peer support was 
any talk about wanting or obtaining support from other adolescents perinatally infected 
with HIV.  Diana’s mother, when approached about this research study, had hoped that, 
by participating, her daughter might meet other positive adolescents, because until then, 
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she did not know any other infected young people.  Beyond that, however, four 
participants mentioned having gone to a camp for HIV-infected children at one time in 
their lives.  None of the adolescents brought up the issue of support from other HIV-
positive adolescents, though not all of them were directly questioned about it.  In 
response to a question about whether they would like that kind of support, Stephanie and 
Diana specifically said that they do not need it, though Diana toyed with the idea. 
Stephanie: Actually, I’m okay.  It’s because my, I like, I’m really great 
with it, because my family doesn’t make me feel, um, they never mention 
 it, treating me bad.  And I like it because they never mention it, and I  
feel kind of better because I don’t think about it. 
 
Diana:  Might be good, but it’s not going to help, ’cause I don’t have a 
problem with it anymore.  But the lady, I forgot her name, she just told  
me about the YES14 [Program]…I was going to try that out. 
 
Summary of Findings for Hypothesis 2 
  
 The adolescents who were very adherent to their medications were those whose 
parents and caregivers were open and accepting about HIV in the adolescent and in the 
family.  These adolescents also had adults in their lives who were involved in their 
disease management, or they and their caregivers had designated clear roles in the 
process of management and the youths were ready to assume these roles.  The 
adolescents who had difficulty taking their medicines as prescribed were those who had 
less involved and less open caregivers and seemed not to be equipped with the medical 
knowledge and psychosocial resources to be independently responsible.   
 The support of peers was extremely low overall among the participants, because 
most had not disclosed their diagnosis to any friends, or had perhaps told one or two 
persons.  Thus, their peer networks did not provide acceptance and support that comes 
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with sharing personal details with peers and helps adolescents cope (Sherman et al. 
2000).  The ability to disclose this kind of information was also problematic for some of 
the sexually active adolescents.  While adherence among those who had shared their 
diagnosis with peers was generally better than among those who had not, there was not a 
strong correlation, and it seems that the cultural salience of keeping secrets may have 
been more conducive to adherence than any potential help they would have gotten from 
friends.  The problem with keeping the diagnosis a secret, however, was that it sometimes 
interfered with pill taking, as when adolescents were spending time at a friend’s house or 
were involved in a social activity at the time when medications were normally taken. 
Disclosure of HIV Diagnosis to the Child (Hypothesis 3)   
 Carol, one of the nurse practitioners who treats adolescents at the USF pediatric 
clinic and was interviewed for this study, underscored the importance of disclosure in the 
child’s progress toward engaging in and taking responsibility for disease management: 
…until I can use the word HIV or the letters HIV with the patient…I think 
once you can use all the language and all the terms and just speak freely, I 
think there’s a shift…in like your history, you know.  At some point I kind 
of turn this way and I direct the questions to the patient and I think some 
kids just naturally respond to that and answer and do the best they can and 
if they can’t then they look at the parent.  Or I’ll look at the parent 
sometimes [and] the parent or caregiver doesn’t really realize…and so 
they’ll keep answering and you’ll be like no, they can tell me how they’ve 
been feeling. 
 
Children have to learn their diagnosis sometime and have been disclosed to at a wide 
range of ages, but the event is imbued with the fear, anxiety, and guilt that accompanies 
perinatal HIV transmission.  This prompted the third hypothesis: 
The timing and circumstances of disclosure to the adolescents have an 
impact on their subsequent adherence behavior. 
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 The adolescents who learned their diagnosis at an early age could not, for the 
most part, remember exactly when the disclosure was made.  When probed for an 
approximate age, most estimated an age of about five to eight years old.  Only Mark 
remembered his age at disclosure, “because it was a week before my tenth birthday.”  
Thus, in Table 4.6, their age at disclosure is noted as less than or equal to age ten, and 
they were considered “earlier disclosures.”  Since the clinics which are part of the Florida 
Family AIDS Network have instituted a policy of disclosure by age thirteen, but others 
have suggested an age as low as ten (Myer et al. 2006) and the American Society of 
Pediatrics recommends disclosure to “school-age” children, any disclosures occurring at 
age eleven or older were established as “later disclosures” in this study.     
 Table 4.5 shows participants’ age at disclosure and their adherence, based on two 
measures, viral load and recall.  Nine of the seventeen participants (53%) learned their 
diagnosis at the age of 10 or younger, and all of them, with the exception of Keith, were 
practicing good or excellent adherence.  At the time of their interviews, five of the nine 
(56%) had consecutive undetectable viral loads (see Appendix F). 
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 Since this study was limited by the small number of adolescent participants, no 
statistically-based conclusions between age at disclosure and current adherence level can 
be drawn.  However, it is noteworthy that all but one of the adolescents who learned that 
they had HIV at a young age were practicing successful adherence, as indicated by 
consistently undetectable viral loads or periodic undetectable viral loads.  The exception 
was Keith, who had problems with his medications and was prescribed treatment 
interruption.  Conversely, all but one adolescent who learned his or her diagnosis later 
                                                 
15
 Adherence based on recall: A: Never or less than once a month; B: Misses once a month; C: Misses twice 
a month; D: Misses 3 or more times a month 
16
 U: Undetectable Viral Load 
17
 Bridget’s viral load spiked following her interview. 
18
 At least 2 consecutive undetectable viral loads and others under 1500 copies/ml.  
19
 Viral loads above 1500 copies/ml 
20
 Olivia’s case may have been affected by viral resistance.  Her medication regimen was changed soon 
after her interview. 
 
Table 4.5  Age at Disclosure and Adherence 
Name Age at Interview 
Age at 
Disclosure 
Adherence 
Based on 
Viral Load 
Adherence 
Based on 
Recall15   
Paula 13 <10    U16 B 
Bridget 18 <10    U17 B 
Lucy 19 15 U A 
Rachel 16 11 U A 
Valerie 16 <10 U A 
Mark 14 <10 U A 
Nina 17 <10 U A 
Katie 22 <10    Good18 D 
Vanessa 16 <10 Good A 
Jeff 16 <10 Good A 
Zoë 16 13     Fair19 D 
Angela 17 12 Fair A 
Stephanie 20 17 Fair D 
Olivia 13 12     Fair20 A 
Diana 19 15 Fair C 
Keith 18 <10 N/A N/A 
Sean 20 16 N/A N/A 
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were having greater problems maintaining adherence or reaching undetectable viral 
loads.  These exceptions will be addressed at the end of this section.  
 It should be reiterated that sometimes lower adherence to certain regimens can 
still result in viral suppression (undetectable viral load), and optimum adherence does not 
always suppress the virus to undetectable levels.  This is because viral suppression and 
optimum adherence levels also depend on the specifics of the antiretroviral regimen and 
on the presence of resistance to medications (Maggiolo et al. 2005).  As with Keith and 
Sean, some patients whose treatment has been interrupted can sustain low levels of virus 
(Noguera et al. 2010; Castro et al. 2010).  Nevertheless, high adherence to medications is 
necessary for viral suppression and low adherence increases the risk of a detectable viral 
load, that is, the failure to suppress the virus (Martin et al. 2008; Bangsberg 2006) and the 
risk of viral resistance (Veinot et al. 2006; Quinn et al. 2000).  
Profiles: Earlier Disclosure of HIV Diagnosis    
 The disclosure of HIV diagnosis to children at an early age does not cause 
excellent adherence, but seems to result in adaptation to both the medical and social 
challenges of HIV in their lived experience and in a sense of well-being despite these 
challenges.  Adaptation to the disease and a sense of acceptance seemed to foster both an 
internal fortitude and an external routine that made adherence behavior possible and 
relatively easy.  Short profiles of several of the participants will illustrate the effect of 
earlier disclosure on later adaptation and adherence.  They reveal how accustomed the 
adolescents had become to HIV as a part of their lives, since early disclosure had made it 
part of their lives for so long. 
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Jeff, 16   
 Jeff is a quiet, polite, 16-year-old tenth-grader.  He said he learned of his HIV 
disease when he was very young, and when asked how he felt about it now, he said, “I’m 
kind of used to it now.  I’ve been growing into it.”  He also believed that it was good for 
children with perinatally acquired HIV to be told about their disease when they’re very 
young, because then “[t]hey can grow into it as a teenager.”  The early disclosure seemed 
to make the disease much less disruptive in his life now; as he said, “I don’t really think 
about it.  I just live my life as a teenager.” 
Paula, 13   
 Paula is extremely forthcoming and knowledgeable about her HIV disease.  She is 
13 years old, and has known her diagnosis since she was very young.  She described her 
disclosure:  “I’m thirteen right now and I don’t remember when or who told me.  I think I 
grew up knowing it.  I don’t remember, I think it was the doctor, but then again, I think it 
was my father.  I don’t really remember.  But I knew it was for HIV.  I knew it was HIV 
medication I was taking, because my dad left the pill bottle on the counter and when he 
left, I read it, and it was for treating HIV, and I asked him and he said yes and then, I 
knew.” 
Katie, 22   
 Katie is in her early twenties, and in college.  She has lived with her adoptive 
mother since she was a baby.  Her biological mother had problems with drugs, and Katie 
was taken from her after birth. She had some contact with her biological mother when she 
was a young child, but it did not continue. She never knew her father.  Katie was an 
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articulate and outgoing woman who was very comfortable talking about her life and her 
HIV disease, which, as noted above, seemed to be due to the fact that  
My mom, she always was open about it.  She never sugarcoated, she 
never hid it from us, and it was never, like, not a discussion or 
topic...Unfortunately, I know, like, I’d say about four years ago, my 
mom had gotten a little Spanish girl, and she had just found out when 
she came to this house, and she was twelve years old.  She just found 
out that she had the virus. And I’m like, she was born with it, and her 
mother never told her, and I was like, wow, I can’t never really imagine 
that, ‘cause I’ve always known. 
 
Nina, 17   
 Of the participants who learned of their HIV at a young age, Nina was most 
plainspoken about the disruption it caused in her life.  She admitted that living with HIV 
was a nuisance:  
Well, I felt kind of sad and kind of like…mad because I know it wasn’t 
my fault, it was my mom’s fault when she was young, and I understand 
that and sometimes I kind of like argue with my mom about the situation, 
because like I got a life that’s wonderful but it’s still like, I don’t know.  It 
don’t feel right, like I’m not living the life that everybody else is kind of 
living, like taking medicines every day and waking up at night…   
 
Yet, Nina has lived with the knowledge of her HIV, and its everyday ramifications, since 
she was young:  
Well I found out when I was a little girl, I don’t know what age but I really 
didn’t know nothing about it…The only thing that had told me was that 
you got to be careful when you grow up with your partner, you gotta tell 
them your condition and how everything is supposed to be, you have to 
tell him or tell her that if you do become with somebody you gotta use 
condoms and if you have a cut you gotta warn the person about the blood, 
they gotta use gloves or other materials.” 
 
Summary: Earlier Disclosure 
 The adolescents who were disclosed to early all seemed to take their HIV disease 
in stride.  They were a bit more open about their diagnosis with others, though some still 
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did not think disclosure to friends was a good idea.  Most of these adolescents also had a 
caregiver who was either involved in their care or was accepting of and open about the 
disease.  These two elements of the adolescents’ lived experience, awareness of their HIV 
throughout childhood and caregivers who guided their process of adaptation to the 
presence of HIV in their lives, resulted in adolescents who were able and willing to 
adhere well to their antiretroviral therapy.  They were also a little more likely to disclose 
their diagnosis to boyfriends or girlfriends than those who were disclosed to later, though 
as we saw in the section above, other factors, such as stigma and cultural ideas about 
secrecy, also influenced disclosure to others. 
Profiles: Later Disclosure of HIV Diagnosis 
 The participants who were disclosed to later seemed less comfortable with their 
diagnosis and had more difficulty adjusting to or accepting HIV into their lives. They did 
not seem to understand fully and accept the importance of taking their medications every 
day, and their adherence reflected this ambivalence.  They were also more likely to 
engage in risky behaviors, such as stopping their medications and having unsafe sex.  
Finally, there was greater silence surrounding the disease.   
Diana, 19   
 Diana’s difficulty managing her illness, at least from a biomedical perspective, 
has likely been affected by her mother’s grave reservations about the biomedical health 
care that she and daughter have received, as well as her concerns about the efficacy and 
safety of antiretroviral therapy.  However, it is also evident that Diana did not accept and 
adjust well to her HIV diagnosis when she learned of it at age fifteen, saying “it was kind 
of a shocker.”  She had problems with alcohol and drug use after she learned of her HIV, 
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and as mentioned earlier, she also had unprotected sex.  When asked if she thought that 
the disclosure process could have been done differently, her response reveals that her 
adjustment was a difficult and confusing time:   
“First, I wanted to know, like, I was mad at my mom ’cause she didn’t tell 
me earlier, but then she explained, like, I wouldn’t know what to do with 
that information at a young age.  So I was like, whatever.  But now that I 
think about it, like, I wish I would’ve known, like, when I turned eighteen 
or something, you know.  ’Cause I know I would have been more mature 
about it.  ’Cause I don’t know, when I found out that just made my life go 
downhill.” 
 
The delay of disclosure until an individual is an adolescent, such as Diana’s 
disclosure at age fifteen, means that there is increased risk of unprotected sex and 
hence possible exposure of HIV to sexual partners and exposure to other sexually 
transmitted infections for the HIV-infected adolescent before he or she learns of 
the HIV diagnosis.  Though awareness of one’s HIV status does not necessarily 
mean that one will practice safer sex, disclosure to the adolescent allows for the 
discussion of the implications of unsafe sex to take place. 
Stephanie, 20   
 Learning her diagnosis at the age of seventeen, Stephanie has had only 
three years to adjust to this knowledge, years that mark her transition from 
adolescence to adulthood.  Her life before disclosure was marked by secrecy and 
ambiguity.  She lived in her home country until she was fourteen, but she never 
knew her biological mother.  She lived with relatives until her father accepted her 
as his daughter, at the behest of his wife, Stephanie’s stepmother.  She insisted 
that she did not know she was sick until after she arrived in the United States and 
was diagnosed while being treated in the hospital for an unidentified illness.  At 
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that time, however, her parents did not share her diagnosis with her, but 
apparently fabricated an explanation.  Finally, at seventeen or eighteen, her doctor 
disclosed her diagnosis to her.  Her reaction differs markedly from some of the 
participants who learned their diagnosis earlier, before they could be fully aware 
of the implications: 
I didn’t want to believe it because they, in my country, I heard when you 
have that sickness you die.  And how am I going to have it.  It’s none of 
my parents, it’s none of my sister have it, my dad doesn’t have it, so I 
didn’t want to believe it… I’m still doesn’t want to believe if I was born 
with it, because if I had it, one of my, my dad would have it, or my mom.  
Even I, I don’t know, because I never know my mom.  I don’t know if 
she did have it or didn’t have it.  I never know my mother. 
 
 Learning of her HIV disease at seventeen seems to have been especially disturbing to 
Stephanie, because she knows little about her history and her family is generally silent 
about her illness.  For Stephanie, this silence is a sign that she is normal, like everyone 
else in the household.  The silence has extended into her social relationships, in which 
she is unwilling to make her status known to anyone: 
…if I have a lot of people at my house, and I have people sleeping 
over, or if I’m sleeping over at someone house, and that person doesn’t 
know I’m on medicine, and I would not let my friend know I’m on 
medicine.  Because my parents, even at the house, my parents doesn’t 
even mention it.  Why would I even try to let my friends know that I’m 
taking medicine? 
  
She conveyed her fear of stigma, and the extreme caution she would exercise when 
deciding whom to share her status with: 
The person I will spend my life with and I’ll know that person would 
never want to hurt me.  I would definitely tell that person.  And 
sometime I think if I ever told them, they might treat me differently 
because sometime when they talk about people who like, people with 
other sickness, I saw sometime, I wonder in my head, what if they 
know I had that kind of disease, how would they treat me. Would they 
ever be my friend, would they talk to me. 
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Sean, 20   
 Sean, like Stephanie, learned his diagnosis at the age of sixteen or seventeen.  He 
had lived with his adoptive mother since the age of seven, and never knew his biological 
parents.  Like most of the participants in this study, Sean was never curious about the 
medicines he was taking.  He explained that it was perhaps because he is “slow” that he 
did not know why he was going to the doctor and was not told his diagnosis earlier: 
I was young and like, I’m kind of like slow, so I didn’t like really  
catch on till the last minute.  I could not understand what AIDS  
was and all that.  I didn’t understand all that. 
             
At 20, Sean was definitely aware of what AIDS was, and he understood the ramifications 
of sexual activity without disclosure or condoms.  His ambivalence about disclosure, both 
to friends and to sexual partners, was articulated above.  He did not share his disclosure 
with any friends, and said he would not share the disclosure with a romantic partner until 
he had been with her for two or three years and was sure that it was serious. 
Zoë, 16   
 Zoë was one of the least knowledgeable and engaged participants regarding her 
HIV disease management.  Disclosed to at thirteen, she remembers being angry with her 
mother for not telling her sooner.  Yet, in the three years since disclosure, she has not 
made an effort to engage in her health care during her clinic appointments, and she has, 
on at least one occasion, stopped taking her medications for about a month.  When asked 
what made taking the medicines as prescribed a challenge, she gave an answer similar to 
the reason she gave for stopping them for a month: “Sometimes I have problems, like, 
going on in my life, or stuff just on my mind.”  Though she said she had sole 
responsibility for taking her medicines, she did not seem to understand the implications 
 160
of that responsibility and thus did not seem ready to take that responsibility.  Whereas 
other participants found a way to make room for the medicines, even though it was often 
problematic and tiresome, Zoë would sometimes just not take them.  She is a marked 
contrast to Jeff and Valerie, both 16, who each expressed some irritation toward their 
situations.  When I asked Jeff, “How often would you say it comes in your mind, I’m so 
sick of taking these medicines?” he replied, “Like every two days.”  Yet, he rated the 
importance of taking his medicines “really important, like a nine” and said he never 
forgot to take them.  Valerie said that sometimes she still got sad about her situation, both 
her HIV and her disabilities.  When I asked her if, during these times, she ever thought of 
not taking her medicines, of not “doing this anymore,”  she retorted with a laugh, “No, 
I’m not that upset.” 
 For Zoe, the integration of her HIV and its management into the ups and downs of 
her life is still a challenge.  As noted elsewhere, she also did not trust her peers enough to 
reveal her HIV status in those relationships. 
Summary: Later Disclosure 
 The adolescents who learned their HIV diagnosis at sixteen or seventeen were still 
trying to accept the reality of their HIV three or four years later.  Others who were 
disclosed to later, in their early to mid teens seemed to have accepted the reality of the 
diagnosis, but their management of the disease appeared to have been undermined by a 
lack of responsibility, substance use, and other difficulties in their lives. 
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Exceptions to Disclosure Age -Adherence Correlation 
Lucy, 19   
 Lucy is a curious exception among the adolescents who were successfully 
practicing adherence, in that she was disclosed to at the late age of fifteen.  While it 
seems that those disclosed to early in life were more comfortable with their diagnosis, 
more engaged in their health care, and therefore more adherent to their medications, 
Lucy, too, exhibited this comfort and engagement, and registered undetectable viral loads 
over the two years previous to her interview.  She knew the names of her medications, 
was aware of their effects on her viral load and CD4 count, referred to them as “my three 
special friends,” and was the only participant who expressed apprehension about what a 
rare lapse, in what seems otherwise to be optimum adherence, would mean for her health. 
As noted earlier, she took her responsibility very seriously, saying, “I got scared ’cause I 
thought something was going to happen…[t]hat my count would go down really low.  
Really fast.”  She knew that she should never miss even one dose, because “Even if I am 
undetectable, I want to stay undetectable.”  This concern and awareness seems to have 
served her well, and may be due, in part, to her mother’s role in her life and health care.  
Anita21, Lucy’s mother, has been an AIDS activist and advocate for many years, so the 
importance of seeking and maintaining treatment, as well as taking responsibility for 
one’s health, may have been instilled in Lucy even before she knew her own diagnosis.  
Interestingly, Lucy has a sister who was also perinatally infected, and her engagement 
and adherence were markedly lower than her sister’s; she has not had undetectable viral 
loads in a consistent manner.  There may be individual psychological, emotional, and 
                                                 
21
 Pseudonym. 
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developmental differences that affect the sisters’ responses to their HIV and their 
subsequent success at disease management.    
Keith, 18   
 Keith was one of the participants who learned his HIV diagnosis early, yet he was 
not successful at adherence.  He was also the only one who was disclosed to early who 
seemed to struggle with acceptance of his diagnosis.  One possible variable in his 
scenario was that he was the only one of four children who was HIV-infected.  He talked 
about this during his interview and even at eighteen, he seemed bothered by the 
unfairness of it:   
My mom had gave us up for adoption, because she was strung out on 
drugs and she had addiction problem, and she also is infected, and she 
was the main reason that I really start just like, ’cause when I was young, 
I was always mad, ever since I found out about it, I just always woke up 
on the wrong side of the bed and just always taking stuff so hard. 
 
He said that the worst feeling he had about his HIV was, “Well, being the oddball out of 
your family.  That’s what I feel like, like a oddball out of the family.”  
 Most of the other participants who were disclosed to early in their lives did not 
dwell on their HIV when they were young, probably because they did not understand it.  
Keith, however, seems to have been bothered by his HIV from early on.  He talked about 
being lost and being angry at different points in the interview, and he is still working 
through it: 
[My mother] didn’t want me to go through the same thing she went 
through, so it’s kind of like, I didn’t go through all the drugs and stuff, 
but the anger and all, how to release and how to open up to people?  
Some of that I did go through… 
 
But then, 
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when I heard about it, I wasn’t mad, I was lost, I was lost.  So I had to 
make a way to find that lost image in my head, that I had to register all 
this stuff about that. 
 
He credits both of his mothers with helping him to work through some of his confusion 
and anger, and believes that he has made progress.   
 …like right now today I wouldn’t even be talking to you if it wasn’t for 
her [biological mother], because she the one that, her and Debra 
[adoptive mother] were the ones that opened up to me that I had to let 
things out to certain, to people, not just certain people, just to people, and 
let them know how I feel, just so I won’t have a lot of stuff build up 
inside you and all of that stuff. ‘Cause it do, it cause you to where you be 
wanting to do things… 
 
Keith continues to struggle with the unfairness of his HIV disease. 
 The challenges of acceptance, coupled with medication side effects of nausea and 
fatigue, led to Keith’s discussion with his clinician about continuing to take the 
medications.  The last straw, it seems, was  
the new pills they put me on, these horse pills.  They’d be so big and  
my throat, I don’t guess my throat got bigger… It’s like you got a  
little knot in your throat somewhere right up in here.  And I hate that 
feeling… Every time I took these pills, I had to get some bread or 
something thick, to take down, right on top of it… I had to eat a little 
right then and then I take, and like fill the bottom of my stomach, and 
then put some more on top of the pills to smother them, just to make 
sure they was like gone. 
 
Keith said that the clinician directed him to continue taking his medicine until his viral 
load reached a very low level, and then he stopped the medications.  Keith’s difficulties 
with adherence were evident in the months preceding his treatment interruption (see his 
viral load measures on page 117), so the clinician apparently saw the merit in trying 
interruption in order to delay the onset of resistance. 
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Rachel, 16   
 Rachel is considered a “later disclosure” at age eleven, based on the study’s 
parameters, but this age is still generally one where sexual activity has not yet begun and 
is two years earlier than the age for disclosure set by the USF clinic.  Thus, this age is 
difficult to categorize and could be argued to be an earlier disclosure.  Rachel learned her 
diagnosis at age eleven, because her best friend’s father told his daughter not to share 
drinks and straws with Rachel, because she had HIV.  Once her friend knew, Rachel’s 
mother knew that she had to tell her daughter the truth.  It was not allergies, as she had 
been told for years, it was HIV.  Rachel said that she must have known something was 
not right about the allergy explanation, because she was taking around twenty pills a day 
at the time.  As with the others who were disclosed to earlier, Rachel did not really 
understand HIV so it did not occupy her thinking.  She, like the others, grew up with it, 
and added to her understanding and acceptance as she matured.  The evolution of her 
thinking is evident in the following, and shows how her situation at 16 is very different 
from, say, Zoe, who is 16, or Stephanie, who did not learn her diagnosis until she was 17: 
Well, I would have to say that when I first found out and throughout 
middle school, I just kind of put it out of my mind.  It wasn’t a problem 
for me and I just kind of forgot about it.  I still knew that I had HIV but I 
just kind of let go of it, like, whatever.  But as I’ve gotten older, I guess I 
have thought about it more, and just like I’ve gotten more opinionated 
about life, and I guess it’s kind of like now that I’ve matured and gotten 
older, I’ve gotten a better sense of how I look at life, and I don’t look at 
my HIV as a bad thing.  I look at it that I was put here for a purpose and 
I’m going to help out the world with what I know, and that’s been a pretty 
recent thing for me, because I would have to say like last year, tenth grade, 
I really started to get into like being HIV positive…I was like, you know 
what, this is a part of me and I need to take advantage of that, so I have, I 
guess.  It hasn’t really happened until this year but that’s what I decided 
the last year, if that makes sense. 
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Of particular significance and, it seems, benefit was Rachel’s recent attendance at 
national AIDS conferences, where she learned about others’ experiences of living with 
HIV openly and without shame or fear, and about being an HIV advocate and activist.  
Her profile reflects the conflation of her own dislike of lying to others in order to hide her 
HIV and becoming a person who does not have to. 
Challenges of Disclosure: Biological Mothers  
 Disclosure of HIV status to a perinatally infected child is a highly charged issue, 
and the pain, guilt, and shame that accompany the disclosure can be particularly acute for 
the biological mother.  Studies show that disclosure tends to be later or is desired to be 
later among biological mothers (Wiener et al. 2007; Ledlie 1999).  In this study, a focus 
group was conducted with a group of biological mothers of infected children to explore 
the issues of adherence, health care, and disclosure from the mothers’ perspective.  It was 
hypothesized that the mothers’ attitudes and behavior regarding their own and their 
children’s disease management would influence how the children adapted to and 
experienced HIV in their lives.  Included in their attitudes toward disease management 
were their ideas about the best time to disclose the HIV diagnosis to their children. 
 Six mothers assembled for the focus group.  Four of the mothers in the group had 
children in the study.  Five women were the mothers of infected adolescents, and one was 
the mother of an infected six-year-old child.  Table 4.6 shows their children’s ages at 
disclosure, along with the mothers’ demographic characteristics.  Most of these mothers 
disclosed the HIV diagnosis to their children at a later age. 
 166
 
Table 4.6  Biological Mothers in Focus Group 
Mother’s 
Name Age 
Race/ 
Ethnicity Age of Child  
at Disclosure 
Number of  
Infected 
Children 
Uninfected 
Children 
Rita 41 White 11 1 No 
Donna 53 Black 15 1 No 
Anita 47 Black 12 & 15 >1 Yes 
Joyce 48 Black 9 >1 Yes 
Teresa 44 Black Not disclosed22 1 Yes 
Nancy 43 Hispanic 11 1 No 
 
 The women were mostly in agreement that young children should not be told they 
had HIV, because they would not understand what HIV was or its implications.  They 
also mentioned trying to preserve their children’s childhood and a sense of normalcy by 
not disclosing their diagnosis to them.  There was concern about the children telling 
others indiscriminately and also worry about what the children would think of their 
mothers.  Because most perinatally infected children take antiretroviral medications from 
an early age, the mothers kept the truth from their children by giving vague explanations 
or lying about why they had to take the medications.  Rita voiced her reservations about 
disclosing to very young children this way: 
…when we found out, it was, we had “allergies” and we took “allergy” 
medicine and we kind of have to give it to the kids as they understand it, 
because I’m sorry, a five-year-old is not going to understand, I’m sorry, 
they’re not going to understand what it means, and I’m sorry, an eight-
year-old is not going to understand.  Maybe a ten-year-old, I doubt it, so 
you know, you just have to, you have to go slow. 
  
Anita told her children when they were 12 and 15, but wished that she had told them 
earlier, before adolescence: 
                                                 
22
 Teresa’s infected child was six years old. 
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With my kids, I wish that I would have told them, started talking to them 
about it at younger ages, so that they can understand and because it was 
like I dropped a bomb on them when I told them, and being a adolescent,  
I really feel bad about that, and I wish I, if I could go back and do it 
differently I would, because it interrupted their whole life.  “I’m a 
teenager, I have friends, I’m looking at dating, you know, and now you 
just told me that everything has to be different,” and if I would’ve went 
ahead and just told them, and just started educating them at a young age, 
so that as they grow, they can grow into understanding the virus, it 
wouldn’t have disrupted their life as much. 
 
Anita also admitted that her delay in telling her children was a reflection of her own 
fears:  
But my own fear stopped me from doing what I needed to do as a mom 
and as a parent, ’cause I was so scared that, oh, they’re going to think I’m 
a horrible person, oh, they’re not going to love me anymore, those were 
the things that was going through my head. 
 
 Donna talked at length about being pushed to disclose to her daughter when her 
daughter was very young and also when she was a teenager, the age at which Donna 
finally told her.  She expressed the feeling of not being allowed to control her and her 
daughter’s lives, especially by health care providers, and conveyed a great deal of 
resentment at the attempts by the health care system to ignore her own knowledge of HIV 
and ability to take care of her daughter:  
I said, what is she going to do with that information.  She’s four years old 
at the time or three years old, you know…what is she going to do with that 
information.  “Oh, now, mommy, now that I know, I’m going to start 
taking better care of myself?”  Or is she going to go and, or if I tell her, 
don’t tell anybody, you know, she’s going to start having a self-esteem 
[problem], you know, or is she going to tell people and people are going 
to, ’cause at that time, you know, right now it’s not as bad as it was.  And 
you know, they would just [say] I was doing her such an injustice by not 
telling her…So I had a lot of doctors who pushed me into telling her, and I 
says, I have to tell her when I feel that I’m ready.  I’m the one that’s going 
to have to deal with this, and when I feel that she’s ready…But…they kind 
of forced my hand a little bit, and it’s rough how they play these games, 
but, so, you know, I was forced to tell her when I was unprepared.  I knew 
she wasn’t, the therapist said that she wasn’t prepared… 
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Teresa, whose infected child is six, also had reservations about disclosure.  She 
believed her son was too young, and if told at this age, he would “go to school and say, 
hey, guess what I have, and I know how he is, I know how he’s so energetic.  He is so 
energetic, and he’s like, everything you basically tell him, he’ll just go and run it, run 
with it.”   However, she did not feel comfortable with the idea of disclosure when he 
reached the age of thirteen, the age by which the clinic had determined that all children 
be told.  She worries about the effect it will have on a young  adolescent, because “it’s 
like, you tell him at the age of thirteen, that’s knocking them down, at the age of thirteen, 
‘cause that just getting to know who, trying to get to know who they are, and then they 
got friends.” 
 Anita brought up difficulties that perinatally infected children and adolescents 
may have with adherence upon learning their HIV diagnosis.  Since most of the children 
will have been taking antiretroviral medicines before they learn their diagnosis, the 
reaction to the disclosure may have a negative impact on how the child manages his or 
her disease henceforth.  Anita said that this was why she thought disclosing to her 
children at a younger age would have been beneficial:  
I felt like I should have told them when they were maybe, start talking  
to them about it, when they were seven or eight, nine years old, so that 
they can get an understanding and grow into it…My daughter was doing 
great in school.  She had no problem with taking her meds.  Every day she 
took them.  But as soon as I told her that, “I don’t want to take them.  I 
don’t like it, it makes me sick, it’s nasty, I can’t swallow it,” hiding pills, 
you know, I mean, the dog eating the pills, getting sick.  It was just a 
whole process that, and it was worse than what it could’ve been if I just 
would’ve opened up.” 
 
 The same reservations are implied among the group of adolescents in this study. 
Nine were disclosed to by their biological mothers, and eight by other caregivers.  
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Though this is a small sample, it is interesting that the biological mothers were more 
likely to disclose later than the other caregivers were, which is in line with the literature.  
Table 4.7 shows the study adolescents by age at disclosure and caregiver making the 
disclosure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Of  the biological mothers who disclosed to the adolescents in this study, four out 
of nine disclosed earlier, that is, to children under the age of ten, while five mothers 
disclosed later to their children.  Conversely, of the eight other caregivers, including 
biological fathers (ostensibly all HIV-negative in these cases), five disclosed earlier and 
three disclosed later (or not at all, in the case of Stephanie).  Table 4.8 summarizes these 
numbers. 
Table 4.7  Study Participants’ Disclosure by Caregiver 
Name Age at Disclosure Disclosed to by 
Paula <10 Biological Father 
Valerie <10 Biological Mother 
Mark <10 Biological Mother 
Nina <10 Biological Mother 
Katie <10 Adoptive Mother 
Vanessa <10 Does Not Remember 
Jeff <10 Biological Father 
Bridget <10 Adoptive Mother 
Keith <10 Biological Mother 
Rachel 11 Biological Mother 
Olivia 12 Adoptive Mother 
Angela 12 Biological Mother 
Zoë 13 Biological Mother 
Lucy 15 Biological Mother 
Diana 15 Biological Mother 
Sean 16 Adoptive Mother 
Stephanie 17 Doctor 
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The focus group discussion, as well as the age at which the study participants 
were disclosed to by biological mothers, illustrates the serious reservations and anxiety 
that biological mothers have about naming their child’s disease early in the child‘s life.  
Not only were they concerned about their children’s capacity to cope with the diagnosis 
at a young age, but they might also be plagued by their own fears about how their 
children would regard them.  After all, the child’s disclosure in this case is also the 
disclosure of the mother’s HIV status.  
Summary of Findings for Hypothesis 3 
 
 The results demonstrate the merits of early disclosure of their diagnosis to 
children perinatally infected with HIV.  Though there are many other factors affecting the 
adherence success of these adolescents, early disclosure seems to be a powerful factor in 
promoting the adaptation of the children to their disease, the consequent understanding 
that occurs early in their lives, and the ability to integrate the medications into their daily 
routines.  However, the difficulties of disclosing the HIV diagnosis to a young child, 
especially by biological mothers, cannot be overlooked.     
Health Status and Adherence: The Illness Role in Chronic Disease (Hypothesis 4) 
 For an adolescent dealing with HIV disease since birth, the management of the 
disease can become tiresome.  Adolescents trying to be more independent may decide 
Table 4.8  Early and Late Disclosure by Caregiver 
 Disclosed Early Disclosed Late 
Biological Mothers 44% 56% 
Other Caregivers 62.5% 37.5% 
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that they do not want to continue taking their medicines, or at least desire a temporary 
reprieve.  If long periods of good health are experienced, adolescents may become 
complacent and this could lead to poorer adherence.  The fourth hypothesis addressed 
these issues: 
Health status has an influence on an adolescent’s adherence. Very 
healthy or very ill individuals are more likely to stop taking their 
medicine, or to take it sporadically. 
  
 The participants in the study were all healthy at the time of their interviews, and 
none had had any serious illness episodes or hospitalizations in the recent past.  When 
asked if they were ever sick or in the hospital, most said that they remembered such 
incidents, some quite serious, when they were young children, but as adolescents none 
had any serious illnesses in the last several years.  All were healthy, yet some were 
optimally adherent, while others had trouble with adherence.  None voiced the idea that it 
seemed unnecessary to take medicines because they were healthy; all knew that taking 
their medicines every day was necessary to maintain their health.  As we have seen 
above, other factors, such as psychosocial problems, lack of support, and inconvenience, 
led to problems with adherence. While there were no adolescents who were currently 
seriously ill, those that did describe past illness episodes did not say they stopped taking 
their medicines.  In fact, the illness was more the result of having stopped taking the 
medicines, and spurred them to resume taking them. 
 Sean was the only participant who may not have fully understood the necessity of 
taking the medications even when one was healthy.  His explanation of why he had 
stopped his medications contained no mention of difficulties with taking them or 
maintaining adherence, which was the reason his clinical provider advised the 
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interruption.  Sean saw it this way:  “I was doing good and they wanted to see if I could 
keep doing good off so they just gave me the chance to stop and they said I was doing 
good without it.”  His problems with adherence may have been due to his thinking that he 
was healthy and didn’t need the medicines, but Sean had other problems, including 
serving time in jail, not knowing his biological family, and not understanding and 
accepting his HIV since his late disclosure at about the age of sixteen.  These 
psychosocial issues may have thwarted his efforts to adhere to his medications. 
 While this hypothesis could not be tested in this sample of adolescents, it does 
raise a related issue, that of understanding the medical implications of HIV and its 
management now that the disease is experienced as a chronic condition.  Some of the 
participants iterated the importance of the medications to maintain their health and keep 
their viral loads undetectable, and this indicated an understanding of treatment even 
during long periods of good health.  However, most of the adolescents did not have a 
thorough comprehension of the implications of sporadic adherence on their future health 
outcomes and medication options, nor did they express the importance of low viral loads 
in reducing the risk of transmission to sexual partners.  There may have been some level 
of carelessness or lack of vigilance as the medications have become more effective, less 
cumbersome and harsh, and therefore, more routine.  The exact blend of routine behavior 
and serious vigilance, and its effect on successful disease management, is an issue for 
further study and implementation in HIV education and counseling.   
Summary of Results 
 The data show that the active engagement of adolescents in their HIV disease 
management (Hypothesis 1), the openness about and involvement in HIV disease 
 173
management of the caregiver (Hypothesis 2), and earlier disclosure to the infected child 
of his or her HIV diagnosis (Hypothesis 3) seemed to be associated with the adolescents’ 
better adjustment to the vicissitudes of disease management, especially adherence to 
medications.  Secrecy, shame, and stigma were underlying negative factors in the 
adolescents’ ability and willingness to share their diagnosis with peers and sexual 
partners, and to practice optimum adherence.  
 Biological mothers, other caregivers, and health care providers had an influence 
on how the adolescents accepted and integrated information about their disease into their 
lives.  Biological mothers were more reticent about disclosing the HIV diagnosis to 
young children, but their faith in the importance and effectiveness of antiretroviral 
therapy seemed to have a greater impact on their children’s adherence than their own 
adherence to medications did.  Other caregivers were a bit more likely to disclose the 
HIV diagnosis to children at a younger age than biological mothers were.  The current 
stability of the family and their adaptation to HIV appeared to have a greater influence on 
the children’s disease management than did past instability and loss of parents to HIV. 
 The rating of the patient-provider relationship did not differ considerably between 
adolescents with optimum adherence and those with only fair adherence, though the 
adolescents with the most adherence problems did rate this relationship lower than the 
other adolescents did.  The interviews with adolescents and clinicians did reveal, 
however, that adolescents construed the communication and interaction styles of 
providers differently from the way that providers described them.  Among the providers 
themselves, the styles were quite variable, though the impact of any individual style on a 
patient’s disease management and health outcomes was not explored in this study. 
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 Overall, the adolescents had only a basic understanding of the medical aspects of 
HIV, including the effects of adherence, the ramifications of non-adherence, the meaning 
of HIV-related lab measures, such as viral load and CD4 count, and the meaning and 
implications of viral resistance to antiretroviral drugs.  The less they knew and were 
invested in the importance of their disease management behaviors, the less consistent 
they seemed to be in their medication adherence.   
 Most of the adolescents were extremely reticent about sharing their HIV status 
with peers, and of those who were sexually active, disclosure and use of condoms was 
not practiced every time.   
 The implications of these results, for perinatally infected adolescents and their 
families, as well as for the clinical and social service providers who are part of the 
Florida Family AIDS Network, will be discussed in the next two chapters. 
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CHAPTER 5: DISCUSSION 
  
 Successful management of human immunodeficiency virus (HIV) disease is 
directly linked to optimum adherence to one’s antiretroviral drug regimen.  The 
development and availability of different classes of antiretroviral drugs, as well as 
prescribed therapy that usually involves several different drugs taken in combination, 
have transformed this disease into a chronic, manageable condition.  The possibility of 
long-term survival and improved, stable health outcomes, however, depends on rigorous 
adherence practice.  The level of adherence to therapy also affects the continued 
sensitivity of the virus to the drugs, that is, the likelihood of viral resistance to the drugs. 
 HIV disease management also has public health implications insofar as it involves 
the prevention of virus transmission to others, most often through sexual activity. The 
risk of sexual transmission of HIV is particularly affected by sexual practices, and also by 
the viral load, or the number of copies of HIV per milliliter of blood (Quinn et al. 2000).  
Sexual behavior and viral loads represent the many social and medical aspects of HIV 
disease management, aspects which interact with each other and demand a 
comprehensive examination.  At the same time, disease management is an individual 
endeavor, with individual variations, so a focused, qualitative analysis holds promise of 
addressing and elucidating the personal, social, cultural, and medical constituents of this 
particular group’s HIV disease management (Sankar et al. 2006; Collingridge and Gantt 
2008). 
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 HIV disease management owes its complexity not just to its individual and public 
health effects, but also to the indirect or more distal factors that complicate its execution.  
These factors are numerous, diverse, and complex.  The preceding chapters have been an 
attempt to present some of these factors from the perspective of adolescents with 
perinatally acquired HIV disease. In this chapter, I will discuss perinatally infected 
adolescents’ experience with adherence to antiretroviral therapy, the mainstay of HIV 
disease management, and the significance of the disclosure process in sustaining 
successful management of HIV from childhood into adolescence and young adulthood.  
The discussion will be embedded in the medical ecological framework, in which “health 
and disease…are informed by the perceptions and social relations of patient, healer, 
family, and community…[and] [i]nsults can originate from organic, inorganic, and all 
aspects of the cultural environment” (Armelagos et al. 1990:358). 
 The major themes to emerge from the findings of this research provide support for 
the medical ecological perspective on the chronic disease experience, and for the saliency 
of spheres of social, cultural, and medical influence which make up the adolescent’s 
lifeworld.  These themes include the factors that most significantly associated with the 
adolescents’ adherence to therapy and overall HIV disease management. They are:  
1) early disclosure of HIV diagnosis and caregiver attitudes and support  
2) the dominance of HIV disease as a socially-felt affliction over a medically-
experienced condition 
3) the chronic illness identity and experience  
4) the process and meaning of disclosure to friends  
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5) biomedical knowledge and understanding of HIV and its personal and public 
health implications 
6) stigma as the underlying theme 
Each of these themes will be discussed, followed by sections on additional issues related 
to adherence that were not addressed in this study and unexpected findings among the 
adolescents that did not support the hypotheses. 
Themes 
Disclosure of the HIV Diagnosis to the Child and Caregiver Attitudes 
 A child with perinatally acquired HIV cannot really begin “growing up” with and 
managing HIV until he or she knows the name of the “bug in your blood” or “the bad 
guys in the blood,” as the clinicians described HIV to their younger patients.  Naming the 
bug begins the process of owning their disease and gaining control over it.  Eight of the 
nine participants in this study who were told they had HIV when they were young 
children, age 10 or younger, were either optimally adherent to their medications, as 
evidenced by consistently undetectable viral loads, or were practicing good adherence, 
with alternating undetectable and low viral loads.  Only one adolescent who was 
disclosed to early had problems taking his medicines and was taken off the medications 
in order to prevent the development of resistance.  Conversely, among the eight 
adolescents who were disclosed to later, at age 11 or older, all but two had detectable and 
markedly fluctuating viral loads, indicating some problems with adherence. 
 Findings from studies that looked at psychological and emotional issues following 
disclosure have been inconsistent, though some positive effects of disclosure have been 
found (Butler et al. 2009).  Among my study participants, the most positive effect, that is, 
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successful adaptation to HIV in their lives, seems to be affected not just by disclosure, 
but by early disclosure.  While no tools to measure quality of life indicators were used in 
this study, the interviews reflected more acceptance of their status among those disclosed 
to earlier and excellent or very good adherence behavior.  These adolescents grew up 
knowing about their HIV even before they fully understood it, whereas those who learned 
the diagnosis later, already knew about HIV (and likely were aware of its negative 
connotations) and experienced distress and dismay.  As with adults who are diagnosed 
with a chronic illness, adolescents who learn their HIV diagnosis later in adolescence 
seem to experience the diagnosis as a “biographical disruption” (Bury 1982), whereas 
those disclosed to earlier adapted early to the knowledge and to the disease with little 
disruption.   
 Diana, disclosed to at age 15, said it was “a shocker” and was angry with her 
mother, and then she said her life went “downhill.”  Sean, who learned his diagnosis at 
about 16, was “really, really sad” and still, after a few years, says, “it still get to me, I still 
be hurt.  I still be hurt that I got it.”  Stephanie said, “I didn’t want to believe it” when the 
doctor told her, at age 17, that she had HIV.  Valerie, on the other hand, “wasn’t really 
sad or anything,” when she learned about her HIV at age seven or eight.  Jeff, age 16, 
said, “I’m kind of used to it now.  I’ve been growing into it,” having known his diagnosis 
since he was five or six.  Mark expressed the advantage of early disclosure: “I didn’t 
really know what it was at the time so I didn’t really get all dramatic about it.”  All of the 
adolescents who learned their diagnosis earlier seem to have accepted it into their lives.  
Only Nina expressed some wistfulness when she said, “I got a life that’s wonderful but… 
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I’m not living the life that everybody else is kind of living, like taking medicines every 
day.” 
 The adaptation of the participants who were disclosed to earlier also seems to 
have been influenced by their caregivers’ attitude to HIV.  As one of the clinicians had 
argued, the patients who had the fewest problems with adherence were those who had not 
just loving, stable families, but open families.  The caregivers or parents (three of whom 
were in the mothers’ focus group and two of whom had some input at the time of their 
child’s interview) of half of the study participants who were disclosed to earlier and 
managed their disease better generally did not treat HIV as a secret, nor were they 
ashamed of it.  The caregivers of the other participants who were disclosed to earlier did 
not have input in the study, but all except Keith were adjusted to HIV in their lives and 
did not convey any discomfort in their discourse.  Lucy’s mother was involved in HIV 
advocacy and very open about her HIV, and this may have had an impact on Lucy, who, 
despite being disclosed to quite late, was nonetheless very adherent and made room for 
her medicines in the routine of her everyday life.  Parents who delay disclosure, on the 
other hand, may have their own problems coping with their diagnosis (Wilfert et al. 
1999), and so are not ready to face the inevitable explanations that will come with 
disclosure to their children (Lester et al. 2002; Ledlie 1999).  The openness of the family 
about HIV means that there is greater acceptance and less shame about HIV, and this may 
be a key factor in preventing the child’s developing and harboring a sense of shame about 
his or her own HIV.  
 Conducting the research from the perspective of medical ecology situated the 
adolescents in the social and medical contexts in which they experience their HIV, and 
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highlighted the family context as the setting for health practice (Novilla et al. 2006).  It 
was clear that the families and primary caregivers of the adolescent participants had an 
influence on the social and medical aspects of HIV – the meanings of HIV adopted by the 
adolescents, their adjustment to and engagement in HIV disease management, and their 
adherence to medications and other health-related behaviors.  The parents or other 
caregivers who approach HIV without fear or shame, and discuss it openly with their 
children, afford these children with the opportunity to learn, accept, and engage in their 
HIV care.  These caregivers are also apt to disclose the diagnosis earlier in the child’s 
life.  Studies have shown that good adherence is highly correlated to complete disclosure 
to the child by his or her caregiver (Shet and Kumarasamy 2008; Bikaako-Kajura et al. 
2006).  
 The accommodation of HIV into the family dynamic is often a complicated 
process.  In particular, families with an HIV-infected child who are headed by the 
biological mother or parents necessarily have two or more HIV-infected members, and 
often also uninfected members.  The disclosure process itself can be wrought with 
anxiety, raising questions about how and when to disclose each person’s status.  In this 
research study, two participants in the mothers’ focus group were known to have both 
infected and uninfected children.  One mother revealed the difficulty she had in accepting 
her own HIV, her fear of disclosure to her children, and her conclusion in retrospect that 
earlier disclosure to her children would have been better for them.  The other mother in 
the group admitted that she had not disclosed her and her youngest child’s HIV status to 
her four older children.   
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 The attitudes of biological mothers toward their own HIV disease, their adherence 
to medications, and their health care also may have effects on how their children face 
their own disease and its management (Cunningham et al. 2006).  We have seen that 
Donna, one of the mothers in the focus group, opposed much about the biomedical 
system of care and was extremely dissatisfied with the interactions she experienced with 
biomedical practitioners.  There is some evidence that beliefs about biomedical health 
care and the quality of the patient-provider relationship have an impact on patients’ 
health outcomes, adherence to medications, and retention in health care (Beer et al. 2009; 
Beach et al. 2006).  Indeed, Donna did not take antiretroviral drugs, and used herbal 
medicine instead.  She did intimate that her daughter was continuing her antiretroviral 
therapy, but was not happy about the prospect of her daughter’s continuing these 
medications indefinitely (Shah 2007).  Another mother, Teresa, was not very adherent to 
her own medication regimen, but was very attentive to her child’s adherence.  If the 
mother embraced the efficacy of antiretroviral medications, she was more apt to assist her 
child in adherence behavior, though she herself might not be very adherent. 
 Caregivers and parents need support, both in their own adjustment and in guiding 
their child’s HIV management (Steele et al. 2007).  Disclosure to children sometimes 
requires a team effort of the caregiver and clinical network (Waugh 2003; Gerson et al. 
2001), as the clinicians in this study explained, and biological and unrelated caregivers 
alike need to be instructed on and understand the clinical implications of adherence and 
non-adherence to medications.  In addition, the responsibility for children’s medications 
must be well delineated (Marhefka et al. 2008; Martin et al. 2007), so that there is no 
confusion about who in the household needs to remember each dose.  Assistance from 
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another adult may also help caregivers in ensuring optimum adherence in the child 
(Reddington  2000). 
 The findings from this study also showed that the openness of the family or 
caregivers about HIV and their serious involvement in their children’s HIV treatment are 
key elements in the successful adherence of the adolescents.  It did not matter whether the 
caregiver was a biological mother or adoptive mother, whether the adolescents had lost 
parents to HIV, or if they were born into unstable situations.  What mattered was the 
active involvement of the caregiver and the acceptance of HIV as a part of their lives. 
 Approaching HIV disclosure early in the child’s life allows the caregivers to 
begin a gradual process of increasingly detailed, age-appropriate explanations (Lipson 
93), so that by the age of 10 or 11, the child has been adequately prepared to understand 
and accept the HIV diagnosis.  This process, followed by early disclosure, allows for a 
longer period of living with the knowledge, so that by the time the children reach 
puberty, are developing their identity, and are exploring their sexuality, HIV has become 
more habit than hang-up in their lived experience.  
 In one study, health care providers favored six years of age for the commence-
ment of health discussions, because children can understand basic concepts of health and 
disease, and age ten for introducing HIV into the discussions, an age when more 
complicated explanations are possible (Myer et al. 2006).  The reticence of parents and 
other caregivers, however, to disclose to the child early has been shown in my study and 
in others to be due to their belief that children cannot understand and handle the 
information, but also because the disclosure of a child’s HIV necessarily exposes the 
family’s HIV history and the sometimes difficult circumstances surrounding its 
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contraction (Lesch et al. 2007; Wiener et al. 2007).  The child’s vulnerability to difficult 
truths, as well as the experience of health and illness, are socially constructed notions 
(Christensen 2000) that, in some families, relegate the child to a silent and dependent 
status, rather than acknowledge the competency and awareness that children demonstrate 
as social actors in their own right (Prout 2000). 
 It is this legacy of shame, guilt, and secrecy that differentiates perinatal HIV from 
other childhood illnesses (Wiener et al. 2007; Lester et al. 2002; Lipson 1994), and 
makes disclosure of HIV to a child an experience wrought with psychosocial challenges.  
However, the capacity of the child to accept and understand his illness has been studied 
and recognized in the cases of other childhood illnesses (Lester et al. 2002; Bibace and 
Walsh 1980), and there is no reason, barring individual social and developmental 
contingencies, to think that children with HIV cannot do the same, as my study has 
shown.  In fact, this research study was approached from the perspective of the 
adolescent (and the young child) as a capable social actor experiencing HIV in a culture 
of adolescence that is separate from the culture of adults.  Because many perinatally 
infected individuals are now living with HIV well into their twenties, the necessity of 
learning about, accepting, and preparing to manage their HIV must be considered not 
only an individual and public health need, but also a right (Corbin 2008; Lesch et al. 
2007; Pfaff 2004) that it is incumbent upon the adult culture – parents, teachers, health 
care providers – to respect and grant.  
 Equipping children and adolescents with knowledge is a key ingredient in their 
development of power over their disease and thus over their disease management (Fisher 
et al. 2006). Especially for the perinatally infected, this feeling of power is crucial, 
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because they have had no control over getting the disease and they also may have lost a 
parent or sibling to HIV, which may leave them feeling powerless and hopeless about 
their own futures (Steele et al. 2007). One of the ways to begin this process of 
empowerment is instructing young children about how to take their pills and clearly 
delineating the roles and responsibilities of child and caregiver (Marhefka et al. 2008).  
Katie, who was disclosed to very early in her life, nonetheless, did not take full 
responsibility for her medicines until she was eighteen.  She believed that beginning the 
process at about the age of eight, and teaching children about dosage and showing them 
how to read labels, would make remembering to take the medicines and assuming full 
responsibility much easier as they grew into adolescence and adulthood.  She said,  
…if I would have started when I was maybe like eight years old, when I 
really grasped the understanding about it, it would have been a lot easier…  
[L]ittle kids aren’t going to understand everything, but you teach them or 
tell them what they’re capable of understanding and then they get kind of 
used to it. 
 
 Now that children have a very good chance at an extended future, this cultivation 
of power, which seems to have been taken from them right at birth, is an even more 
urgent need for maintaining their health and protecting their sexual partners.  It is also 
important for these children to begin the process of accepting and gaining power over 
their HIV, because the sting of social stigma that they will inevitably face, even if it is 
just listening to others talk about AIDS, as the study participants shared, may be lessened 
if they have been cultivating a sense of strength and acceptance about their HIV from 
early in their lives. 
  We have seen that HIV management is sometimes an annoyance, and adolescents 
especially want to be independent, in control, and perceived as normal.  All of the 
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participants expressed negative aspects of having HIV, whether disclosed to early or late. 
Vanessa mentioned the hassle of medication and Lucy said she wondered about the 
possible progression of her disease.  However, about two-thirds of the adolescents 
remarked on the difficulties that HIV could cause in social interactions, and this makes it 
all the more critical that they begin to deal with these issues before they become involved 
in social relationships.  It is for this reason that the American Academy of Pediatrics 
(Wilfert et al. 1999) suggests disclosing to school-age children.  Social interaction at 
young ages, for example, requires that HIV-positive children be aware of the danger of 
blood should they get hurt.  However, for adolescents, including this study’s participants, 
social interaction at older ages involves establishing trust with peers and becoming 
sexually active, and HIV can complicate these developments.  
Dominance of HIV as Social Phenomenon 
 The disclosure of the HIV diagnosis to children or adolescents transforms the 
“unknown secret” of their HIV status into HIV as reality (Mellins et al. 2002:112).  How 
they make sense of this information, that is, the meanings they construct for their disease, 
depend on the dynamic social and cultural contexts of their lived experience (Fife 1994: 
315; Thorne 1999:400).  For HIV and AIDS, these contexts include stigma, shame, and 
secrecy, which become more or less salient as the child ages and his or her social world 
changes.  His or her cultural values and interactions will also dictate whether and to what 
degree these aspects become a part of the child or adolescent’s HIV experience.  As Zoë 
and Sean made clear, sharing their status with romantic partners was not an option at 
present, and even Paula, who was quite comfortable with her status, categorically denied 
it when confronted by school mates because she was knowledgeable about HIV/AIDS. 
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 The participants in this research study embraced both social and medical 
meanings of their HIV, though the interviews revealed that they highlighted the “social 
course” of the disease and the “social experience” of HIV in their lives (Kleinman et al. 
1995:1323, 1325).  All but one of the adolescents in this study spoke much more about 
the social ramifications of HIV than the medical effects.  Lucy was the only participant 
who brought up the medical aspects more than the social effects.  She brought up the 
issues of taking or forgetting her medicine, of wanting to remain undetectable, and of 
thinking, “do I want to live to see another day.  So I stop and I drop everything I’m doing 
and take it.”  Virtually all of the others pointed out the difficulties of telling other people, 
including romantic partners, the reactions of others who learn about their diagnosis, the 
ignorance of others about HIV, and the stigmatizing reactions of people who learned their 
diagnosis. 
 Even though Lucy was disclosed to late and had constructed the most salient 
medical meaning of HIV disease, in general, it was the adolescents who were disclosed to 
early in their lives who saw the disease in somewhat more medical terms (in addition to 
social terms) than did their late-disclosed counterparts.  They knew a little more about 
their medicines, about their lab tests, and were more adherent to their medicines.  Those 
disclosed to later experienced their HIV and defined it in more emotional terms and by its 
effects on their social interactions.  For some, like Zoe, Diana, Angela, and Stephanie, 
there was a sense of denial or separation from the disease, as evidenced by stopping their 
medications and preferring to ignore the disease in family and peer interactions. Whereas 
the adolescents disclosed to early experienced control of their disease through acceptance 
and adherence, the others took control by opposite tactics, denial and refusal.  
 187
 The medical versus social meaning of HIV has implications for whether and how 
much these adolescents exercise agency in their experience and management of HIV.  
Those who adopted a medical, in addition to a social, meaning of HIV understood, to a 
greater degree than those who did not, the clinical aspects of the disease, the effects of 
medication and medication adherence, and the importance of assuming responsibility for 
beneficial health-related behaviors.  It appears that the participants who were disclosed to 
early adopted this more medical perspective of HIV before the experiences of 
adolescence – social and developmental complexities, such as the formation of the adult 
self and identity, exploration of one’s sexuality, and the onset of romantic and sexual 
relationships – began.  While social meanings of HIV were constructed by all of the 
adolescents, if HIV as medical construct anteceded or coincided with the social meaning, 
it seemed to provide the adolescents with a foundation to support their ongoing 
involvement and engagement in their health care and treatment (Gerson et al. 2001).  It 
may also affect how these adolescents approach the social and cultural attitudes and 
meanings that they face and develop later in life, since they have approached the disease 
first as a medical reality and subsequently or coincidentally as a social one. 
 Attaching a medical meaning to HIV and engaging early in HIV care and 
treatment may aid in the child’s development of an adolescent and adult identity that 
affords rather than denies a space for HIV.  These adolescents are then likely to exhibit 
problem-centered coping (LeBlanc et al 2003), having reached an acceptance of their 
HIV as a part of their developing selves (Hosek et al. 2002).  Those who learn of their 
HIV as older children or as adolescents appear to use a more emotion-based strategy 
(LeBlanc et al 2003), which has been shown among the study participants to result in 
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denial or avoidance, reactions that can have negative consequences on both physical and 
mental health (Dahlbeck and Lightsey 2008).  
 It is notable that one of this study’s clinician interviewees emphasized the danger 
in an adolescent’s adopting a disease identity: 
So with an adolescent you don’t want them to develop a disease identity 
but you want to empower them to learn to fight it. So sometimes you’ve 
got to let them go to the rocky times as you’re working towards, you 
know, let them separate themselves from the disease and that’s what 
they’re doing when these perinatal kids stop taking the medication. [Ed]  
 
In the next sentence, however, he acknowledged the detriment involved in this kind of 
behavior:  “They’re trying to separate themselves from the disease and you don’t want 
that, because then they become really awful adult patients.”  The psychological 
underpinnings of adolescent identity formation are beyond the purview of this analysis, 
but from an anthropological perspective, there is room for the child and, later, the 
adolescent to engage in positive symbolic interactions with the immediate actors in his or 
her medical ecological niche – peers, family, community, and health care providers.  
These interactions, especially when initiated early in the child’s life, can produce new 
meanings of HIV that contest the “flawed identity” (Hosek et al. 2002:356) engendered 
by social stigma.  Among the study participants, those who learned their diagnosis early 
and had caregivers who normalized the child’s condition succeeded in incorporating their 
HIV and its treatment into their developing selves and “reframing…the ontology of 
suffering” (Kleinman et al. 1995:1321). 
 The meanings construed and identities realized gradually throughout these 
children’s lives work in tandem to influence the agency they exercise in the management 
of their HIV.  I have argued that a precedent medical meaning, developed early in the 
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child’s life, accompanied by the development of a normalized illness identity, produce a 
more engaged individual, whose agency, the  “socioculturally mediated capacity to act”   
(Ahearn 2001:112), results in consistent behavior, feelings of power, and responsibility.  
The age at disclosure, parental attitudes and beliefs, the role given to stigma in “creating 
sickness stories” (Kleinman et al. 1995:1321), the medical efforts to engage children, to 
name the  most important factors, have an impact on whether an adolescent has the 
capacity to take control of his or her disease and be an active collaborator in his or her 
treatment and care.  
HIV as Chronic Disease:  Meaning, Identity, and Agency 
 Adolescence is a stage during which individuals want to fit in, feel normal, and 
exert a measure of independence.  The presence of HIV threatens all three of these 
objectives.  Accommodation to the rigors of health care and medication adherence does 
not mean that these young people do not grow weary of the constant reminders and 
inconvenience of their illness (Belzer et al. 1999).  Health care and medication fatigue are 
a danger among these adolescents, and as we have seen, they sometimes decide to stop 
taking their medications (Pontali 2005).  The early disclosure of HIV holds the promise 
of the child’s gaining a sense of normalcy about HIV early on, and certainly by the time 
they reach adolescence.  The earlier the explanation of HIV and its treatment begins, the 
sooner the child can begin to take control of the condition and its ongoing exigencies, 
thereby facilitating habituation.  The more habitual the HIV care and treatment become, 
the less it will interfere with the normal adolescent culture that he or she shares with 
peers.  HIV must remain an important part of the child or adolescent’s experience, but at 
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the same time, the familiarity with and proficiency at the daily health-related behaviors 
make it less prominent in that lived experience. 
 Disease management, especially adherence, is a challenging endeavor for all 
perinatally infected adolescents, even those who learned their diagnosis early.  It 
presupposes a measure of control and skill. The adolescent’s opportunities to gain control 
and skill, and then to apply that control and skill to addressing the medical needs of his or 
her HIV disease, are limited by the medical, social, and cultural resources, that is, the 
medical ecology in which his or her lived experience is situated (Armelagos et al. 1990).  
These resources are embedded in concentric circles of socioecological influence (Steele 
et al. 2007:59).  The perinatally infected child is surrounded first by family, some of 
whom may also be living with HIV or may have died as a result of it.  Beyond the family, 
he or she has interaction with friends, school mates, teachers, neighbors, and others in the 
immediate community.  The next influential niche is the health care system and the 
practitioners who care for the child or adolescent (Steele et al. 2007).   
 The capacity to act is a phenomenon that the above social actors around them 
have been ambivalent about facilitating or accepting in the perinatally infected 
adolescents, and they have at times had a negative influence on whether or how these 
young people act in the face of HIV (Pontali 2005).  Diana’s mother, for example, 
insisted on preparing her daughter’s medications, even though Diana was 19, but at the 
same time harbored negative feelings about the safety and efficacy of the medications.  
Others in the adolescent’s environment may either promote agency based on secrecy, 
shame, and difficulty in accepting the disease as normal, or they fail to allow them 
agency at all.  Their peers have been shown to be especially influential in this regard.  
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More than one of the participants pointed out the ignorant or mocking comments from 
school mates.  The medical ecological environment is not always a sympathetic one, from 
the family members who demand secrecy, to the peer network that mocks and excludes, 
to the social community that stigmatizes, to the health care practitioners who are both 
reproachful and overprotective.  Among the adolescents in this study, we have evidence 
of each of these pitfalls or lack of support to successful disease management. 
 The interpretation of perinatal adolescents’ HIV disease as a social experience 
more than a medical one may seem at first glance to be counterintuitive, since they have 
been ensconced in the health care system since they were very young, and have been 
taking medicines throughout their lives.  However, as Hunt and Arar have found, 
“patients, out of necessity, modify and adapt long-term illness understandings and self-
care measures when applying them within the constraints of daily life” (Hunt and Arar 
2001:351).  All of the participants in this study knew, to greater and lesser degrees, that 
taking their medications faithfully was essential, that it would keep their viral load and T 
cells at optimum levels, and would keep them healthy, yet several of them had, at one 
time, refused to take them.  Two participants, Keith and Sean, were non-adherent to a 
point that it was considered better to stop their medications altogether.  Others were 
sporadically less than optimally adherent, and even those who were always or almost 
always adherent confessed to feeling sick and tired of taking the medications.  I was 
surprised to hear Jeff, who had integrated his regimen very well into his daily routine, 
admit that he frequently thought about how sick and tired of taking the medicines he was.
 The less dominant medical aspect of HIV owes some of its effect to the fact that 
HIV has become a disease in which people can live for long stretches of time as healthy 
 192
individuals.  The traditional sick role (Crossley 1998) is no longer emphasized, and being 
HIV-positive has now become a kind of liminal state (Little et al. 1998).  For the 
adolescents, being healthy and having none of the visible physical signs of disease gives 
them the chance to be normal, but it also makes them feel the urgency of their medical 
treatment less. 
 The desire for independence combined with medication fatigue, within an 
environment hostile to HIV, can also lead adolescents to rebel against adherence.  The 
chronic nature of the disease can seem like a black hole that, at some point, can drain 
them of their energy and conscientiousness. The lack of control due to HIV in their lives 
is another element that weakens their resolve over time.  The perinatally infected 
adolescents, in contrast to behaviorally infected adolescents and adults, had no control 
over how they got the disease, no control over when and how they were disclosed to, and 
no control over deciding when to begin treatment.  There is evidence that being able to 
take responsibility for contracting HIV (as in those behaviorally infected), even if it is 
tinged with guilt, allows individuals to take control of and responsibility for their disease 
and its treatment (Plattner and Meiring 2006).  Yet, some of the adolescents in this study 
seemed to embrace their blamelessness and accept their status and their management 
responsibility with more equanimity because of it.  In general, the early disclosure to 
children seems to be a key element in this type of acceptance, and the subsequent 
assumption of responsibility for their disease.  Paula, at 13, had already internalized her 
responsibility for taking her medications.  Without hesitation, Jeff rated both the ease and 
the importance of taking his medicines very high.   
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 Some of the adolescents in this study seemed to suffer because of this lack of 
control, feeling a sense of unfairness, which affected them even now as adolescents and 
young adults.  They had a more difficult time accepting the circumstances of the disease, 
including engaging in their ongoing treatment.  Keith thought it was unfair that he was 
the only infected child in his family; he had three uninfected siblings, and he felt like “an 
oddball.”  Olivia did not say it was unfair, but her mother alluded to Olivia’s feeling that 
she was the only child her age who had this disease.  Stephanie found it hard to accept 
her HIV at first because she did not know how she could have gotten it; her father did not 
have HIV, and she never knew her mother. 
Disclosure to Peers  
 All of the participants shied away from sharing their status with friends and 
school mates.  This was not only a personal choice but a socially constructed necessity, as 
the adolescents overwhelmingly agreed that there were social risks involved in sharing 
their status or even demonstrating an understanding of HIV and AIDS.  Specific attitudes 
about keeping one’s business a secret also seemed to come into play.  However, the 
adolescents disclosed to earlier were overall a bit more open about their status with 
friends. 
Peer Relations 
 In this research study, more than half of the adolescents disclosed their HIV status 
to no one or to one friend.  They were generally not inclined to disclose their status, 
because they felt it was not anyone’s business and because they anticipated a negative 
reaction.  Many also described their school mates’ ridiculing or uninformed comments 
about HIV when the subject arose. These results indicate that these adolescents had very 
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few people with whom they could be open about their disease experience (Michaud et al. 
2009)  They also had not had much interaction with other HIV-positive adolescents, and 
some expressed little interest in meeting with other HIV-positive adolescents.  The 
decision to keep their HIV status a secret, in addition to the reasons above, may also be 
made because the disease has no visible effects and the adolescents can pass as normal, 
healthy individuals (Goffman 1963; Michaud et al. 2009).   
 While peer support and openness about HIV status between friends was 
hypothesized to have an impact on adherence, and more of the adherent youth had 
disclosed to more friends than the less adherent individuals, the association was not 
consistent across the adolescent sample in this study.  It is more likely that the 
adolescents who learned their HIV diagnosis at an early age adapted sooner and better to 
the disease in their lives, and thus were both more able to adhere well to their therapy and 
more comfortable disclosing their status to friends (Wiener and Battles 2006).  The 
highly personal and potentially stigmatizing nature of HIV, however, was powerful 
enough that, even among some of the very adherent and adjusted adolescents, there was 
little disclosure.  Lucy is the prime example of this; she was extremely adherent, yet 
insisted that she would disclose to no one outside her family.      
 It has also been theorized that the ability to share the difficult experience of HIV 
disease helps the individual to make cognitive adjustments that allow HIV to occupy a 
place in his or her “existing meaning structures” (Sherman et al. 2000:239), and improves 
their health and behavior (Abel et al. 2004).  In addition, Sherman et al. found that 
disclosure to friends resulted in an increase in the HIV-positive individual’s CD4 level 
(Sherman et al. 2000).   If disclosure to friends does indeed facilitate the acceptance of 
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HIV into the adolescent sense of self, is a part of the culture of childhood and 
adolescence (Sherman et al. 2000:240), and can improve health, then the cultural 
attitudes dictating secrecy, shading the truth, and lying about HIV can prevent significant 
advantages to the adolescent’s physical and psychosocial health. 
Sexual Relationships 
  The lack of peer support and interaction with other HIV-positive adolescents 
indicates that these adolescents are trying to keep their HIV disease in the background of 
their social relationships.  They do not talk about their disease much even to the friends 
who are aware of it.  While this may be part of the adolescent developmental stage that 
includes fitting in and being normal, the silence around their HIV status does raise 
concerns about their ability and willingness to discuss it with romantic and sexual 
partners.  All of the adolescents knew that they should disclose their status to a boyfriend 
or girlfriend, and they were aware of the need for condoms during sexual intercourse, yet 
the study shows that the adolescents’ description of future sexual behavior and what will 
actually occur or has already happened are not always the same.  Of the seven sexually 
active adolescents in this study, two admitted not disclosing their status to at least one 
partner, and one said that he would not disclose to a partner until they had been together 
for a long time.  This suggests the looming challenge of disclosing one’s status to a 
sexual partner.  As a study by Wiener and Battles has shown, adolescents who disclosed 
their status to more people were more likely to disclose to sexual partners, and those who 
scored higher in self-competence in relationships disclosed to more peers (Wiener and 
Battles 2006).  While my study did not measure self-competence, it did show that many 
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of the adolescents were not well prepared, if at all, by their caregivers or clinical 
providers to disclose their status to peers. 
 Over half of the study participants mentioned that one of the worst things about 
having HIV was disclosure to others or the risk of transmission to a partner or children, 
both of which gain salience in the sexual relationship.  Despite their knowledge of the 
importance of disclosure and safer sex, these adolescents have or anticipate having some 
difficulty with these behaviors in their sexual relationships.  It seems that their HIV 
disease is experienced as “biographical disruption” (Bury 1982) at this point, where 
sexual relationships become part of their lives, even for those who were disclosed to early 
in life and appeared not to have felt this disruption previously.  As the literature and the 
clinicians in this study have articulated (D’Angelo et al. 2001), the failure to disclose 
HIV status to casual partners is especially likely.  Sex without condoms is also common 
(Dodds et al. 2003).   
 The most disturbing illustration of unsatisfactory disease management among the 
adolescents in this study was the combination of medication interruption and unsafe 
sexual activity.  Both Keith and Sean had their regimens stopped in order to protect them 
from the viral resistance that their poor adherence was likely to cause.  Their recent viral 
load results showed that they were not suppressing the virus completely during their 
treatment interruption.  This is not surprising, but it does mean that their infectiousness, 
that is, the likelihood of transmitting HIV to a sexual partner, was elevated.  The 
interview with Keith showed that during this time, he had had unprotected sexual 
intercourse with his girlfriend, because she had one past pregnancy and was currently 
pregnant. Sean was also sexually active, and did not disclose his status to his current 
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partner, though he said that he had used condoms.  The decisions of the clinical provider 
to stop therapy and the decisions of the young men to engage in risky sexual activity risk 
result in an increased risk of transmission of HIV to their partners.  Both cases are 
problematic.  In Keith’s case, his girlfriend was aware of his HIV status, but their sexual 
activity had been unprotected.  In Sean’s case, condoms were used, but his partner was 
unaware of his HIV status.  
 The decision to interrupt an adolescent’s antiretroviral therapy should be revisited 
when a clinician is concerned that the adolescent is or will be engaging in sexual activity, 
especially unprotected sex. 
Biomedical Implications and Provider-Patient Relationships 
 
 As argued above, many of the adolescents who participated in this research study 
saw the meaning of their illness in social terms more than in medical terms.  The result is 
that they have not learned and internalized, 1) the effects of the virus if it becomes 
detectable or remains undetectable, 2) the meaning of adherence and how it can affect 
their health and their survival, and 3) the ramifications of their HIV disease management 
for their sexual partners.  They are not approaching HIV disease as a medical 
circumstance that they cope with, but rather as a social problem that they bemoan 
(LeBlanc et al. 2003).  They have not succeeded in making their disease management a 
routine, but rather attend to it when it is convenient.  The fact that many forget, are too 
tired, or are too busy to take their medicines, are in a hurry, or don’t have their medicines 
with them, is evidence of a failure to make taking medicine a habit.  In addition, few in 
this study seemed to use reminder aids, such as pill boxes or alarms.  Furthermore, if they 
did remember their medications, they still might not take them when they were in the 
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presence of friends.  The more successful adolescents seemed to be more habituated to 
taking their pills, and would also, if necessary, find discreet ways to take them when 
among friends. 
 In this study, the adolescents who were able to remember, make time for, and fit 
in their medications, despite busy and changing schedules, social relationships in which 
disclosure had not occurred, and treatment fatigue, also had a somewhat more detailed 
understanding of the medical aspects of HIV and antiretroviral therapy.  Yet all of the 
adolescents had gaps in their understanding of and ability to explain the clinical 
indicators of their health, their medicines’ names, dosages and schedules, the definition 
of resistance, the relationship between adherence and clinical indicators and between 
adherence and resistance, and the effects of adherence, viral load, and resistant virus on 
transmission of HIV to sexual partners.  Though most of them had taken, been given, or 
been expected to assume responsibility for taking their medicines, most had not increased 
their knowledge along with that adherence responsibility (Martin et al. 2007). 
 It is this deficit in a medical conceptualization and understanding of HIV and its 
ramifications that is one of the most important findings of this study.  The adolescents’ 
notions and actions regarding HIV disease, which are based on social, cultural, and 
medical notions and interactions within their environment, have a significant impact on 
the natural history of the human immunodeficiency virus.  The level and consequent 
infectiousness of HIV, as it responds to medications, mutates during their absence, 
multiplies or decreases, depends on the individual’s strict adherence to medications and 
attention to medical details, and has the potential to affect the individual’s sexual partners 
(Wiener et al. 2007). 
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 From both an individual medical perspective and a public health perspective, 
adherence to antiretroviral medications is crucial.  Optimum adherence is necessary to 
suppress and maintain the virus at undetectable levels and to improve immune function.     
Transmission of HIV to sexual partners is rare among infected persons whose viral load 
is at very low (less than 1500 copies per milliliter) or undetectable levels (Quinn et al. 
2000).  Equally important is the effect of optimum adherence on reducing the chances of 
development of resistant virus.  If resistance to medications develops, the infected 
individual will be obligated to change regimens and his or her choices of antiretroviral 
drugs are reduced.  Moreover, if transmission of resistant virus occurs during sexual 
activity (Kourrouski and Lima 2009), then the recipient will enter treatment with a 
reduced range of efficacious antiretroviral drugs. Thus, the consequences of suboptimum 
adherence are felt at the individual level but extend to the epidemiology of HIV and the 
public’s health. 
 The adolescents’ situated construal of and response to their HIV results in a 
model of disease management that is apt to differ significantly from the biomedical 
model to which their clinicians subscribe.  Among the study participants, the biomedical 
details of HIV and its management are understood, but the details are abbreviated.  It is to 
be expected that a patient’s knowledge is limited in comparison to the provider’s, but 
these limitations can become problematic for the adolescent and young adult HIV-
infected individuals when they are assuming responsibility for their therapy and 
becoming sexually active.   
 At the same time, the social and cultural dimensions of an adolescent’s HIV 
experience, which dictate how they define HIV and develop strategies for managing it, 
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seem to be understood only superficially by the practitioner who provides care and 
treatment.  More importantly, the provider may be unable or unwilling to take this 
experience into account when establishing a patient’s plan of care.  All of the providers in 
this study said that they discussed their patients’ lives beyond the clinic, and they tried to 
accommodate specific issues in their prescription of treatment.  For example, regimens 
were changed to twice daily dosages so that patients would not have to take medicine at 
school or risk forgetting them during the day.  However, the primary goal of the medical 
provider was the health of the patient, as evidenced by satisfactory viral load and CD4 
levels, and adherence to antiretroviral therapy to insure that health.   
 The distinction of HIV disease from many other chronic diseases lies in its   
infectiousness during symptom-free periods.  In addition, the antiretroviral drugs are very 
unforgiving (Fisher et al. 2006) if not adhered to strictly.  It is this part of the explanatory 
model of HIV (Kleinman 1978) – “the pathophysiology, course, and treatment” – that are 
approached differently by clinician and patient (Hunt and Arar 2001:349).  In addressing 
these issues, disease management may be better perceived as a process developed by 
means of a provider-patient partnership, rather than as an ideology, “in terms of imposed 
professional expectations” (Trostle 2000:41). 
Stigma: An Underlying Theme 
 The first five themes discussed above all share one construct: the stigma of HIV 
and AIDS.  Disclosure, caregiver behavior, social attitudes, peer relations, and sexual 
activity were shaped by many elements of the adolescent’s medical ecological context, 
but all shared the influence of stigma in making the adolescent’s lived experience of HIV 
challenging.  Only one adolescent mentioned the word stigma during our conversation, 
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and the word was never used during the mothers’ focus group.  A few of the adolescents 
who were asked if they knew what stigma meant said they did not.  Yet, every 
participant’s descriptions of their behaviors and attitudes or their peers’ behaviors or 
attitudes reflected the underlying power of stigma that surrounds HIV and AIDS.   As this 
study has shown, understanding and practicing adherence to therapy is facilitated or 
interrupted by a range of social, cultural, and medical contingencies.  Underlying the 
interactions within these contexts is the continuing menace of HIV/AIDS stigma.  In 
addition to the societal sources of stigma, in the cultural niche of adolescence, the 
presence of any differentiating characteristic can be cause for ridicule, as Olivia insisted 
in her interview.  She said it did not matter whether it was HIV or asthma, the kids would 
pick on an affected child.  Almost every adolescent recounted an instance of stigma – 
comments by school mates, a boyfriend, a relative – which led them to deny their status, 
lie to their friends, or be ostracized by a relative. The majority of the participants had 
decided that their HIV status was no one’s business or best kept a secret, because they 
knew there would be negative reactions.  Thus, the adolescent experience of HIV/AIDS 
evokes particularly harsh responses of “us” versus “them” (Devine et al. 1999; Gilmore 
and Somerville 1994) that plague the AIDS epidemic to this day, and explain the very 
common decision to keep one’s HIV status a secret.   
 The mothers’ focus group discussion also hinted at the presence of stigma, when 
the mothers discussed delaying disclosure of HIV status to their children, not disclosing 
their own status to family members, and receiving negative reactions from family 
members who learned of the diagnosis.  Rita has never spoken to her in-laws since her 
husband’s illness and death, and Teresa has not disclosed to her four older children.  The 
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clinicians, too, described patients and parents who kept their HIV a secret from family, 
friends, and sexual partners.  Carol recounted one poignant example which illustrates the 
impact of the social context and the ramifications of stigma and secrecy.  The adolescent 
patient and her mother lived with the mother’s parents but had not disclosed their status 
to the parents: 
…the child…lives with the mom and the mom’s parents and they’ve 
lived there the whole time I’ve worked here, and the grandparents don’t 
know about their daughter or their granddaughter.  So I’m thinking in 
my mind, how is she [the child] ever going to be disclosed?  I mean, it’s 
like a mega-secret.  I don’t even know how you live, it gives me like 
pain in my chest…I don’t know how you do that every day, I mean, 
with medications and visits and everything, and actually the adolescent 
is, we are seeing the damage of that…she’s going through adolescence 
and she’s, it’s just too much for her.  I mean that’s just too much stress 
and pressure to put on anyone, never mind a twelve-year-old, so I think 
she’s starting to backlash at the mom now….[The mother’s] reason… 
she has a very good reason, is that she is very aware of her 
parents’…thoughts, feelings on HIV, and she will be out like that, so 
she, her impression is that…she and her kids will be disowned, get out 
of the house, they’re so strongly opinionated about it.  I guess…it’s not 
an option…she’s dependent on them financiall, which I’m sure hasn’t 
helped.  I mean it could be totally different if she were more financially 
independent, had her own home, I mean, then it wouldn’t be that much 
of an issue. 
   
While this kind of enacted stigma was not experienced by most of the participants, the 
above instances of felt stigma were widely shared (Scambler 2009; Lekas et al. 2006). 
Additional Factors Complicating Adherence 
 Adolescents’ success at managing their HIV and achieving favorable clinical 
outcomes depends on other clinical factors.  The history of their disease (e.g., higher and 
longer HIV replication following perinatal infection (Mullen et al. 2002)), perinatal 
infection with resistant HIV (Delaugerre et al. 2007), complications from opportunistic 
infections, side effects, changing medication regimens, and disease progression at the 
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initiation of HAART all have an impact on health outcomes (De Beaudrap et al. 2008) 
and successful, ongoing adherence.  In addition, because there is evidence of 
developmental delay in some perinatally-infected individuals (Sherr et al. 2009), it is 
critical that adherence strategies be tailored to accommodate the adolescent’s cognitive 
abilities.  The prevalence of mental health problems also must be addressed, and these 
must be treated before or concurrently with the process of education about the details and 
responsibilities of disease management.  The clinicians interviewed for this research 
agreed that about half of their adolescent patients had mental health issues that required 
attention, and this percentage is supported in the literature on HIV-infected youth (Lam et 
al. 2007). 
Unexpected Findings 
 This study found that adolescents with perinatally acquired HIV were more likely 
to practice good adherence to medications and generally manage their disease well, if 
they were told their diagnosis at an early age (at or before age 10), had caregivers who 
were open about HIV, were themselves relatively open and accepting of their disease, 
and understood the clinical aspects of HIV and medication adherence.  Of all the 
participants in this study, Katie appeared to reflect all of these themes in her life.  
Nonetheless, she was not in the group of adolescents who were extremely adherent and 
had consistently undetectable viral loads.  She herself did not describe her adherence as 
perfect.  So, why was she not able to maintain an undetectable viral load over time?   
 The reasons may stem from the history of Katie’s HIV disease, which was not 
specifically explored in this study.  However, apart from past resistance issues and 
treatment experience, Katie’s inability to maintain an undetectable viral load by 
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achieving optimum adherence seems to be due to her relatively new status as an adult – 
she was 22 at the time of her interview – and the assumption of responsibilities related to 
this status.  She was enrolled in college and talked about her busy school schedule and 
the fatigue that she felt was associated with it.  She also chatted about the difference 
between childhood, when everything was taken of, and adulthood, when “All my money 
has to go on bills.”  Even though she was disclosed to early and her mother was very 
open about the disease, Katie said that she did not take full, independent responsibility for 
taking her medicines until she was about eighteen.  She believed that instruction on 
taking one’s antiretroviral medications should begin early, so that  
when they do get on their own, it’ll be a lot easier for them to remember 
and to take them, and to really understand why they’re taking them and 
not just the fact…you want your viral load low, but also the fact that you 
don’t want to catch resistance to the medicine, because as fast as your 
virus will catch resistance to it, it’s not as fast as the pharmaceutical 
companies are going to be able to make medicine. 
 
When Katie assumed control of her medications and adherence, she found it was 
difficult, especially when she reached adulthood and assumed adult responsibilities. 
 This turning point at which adolescents become adults, not in age but in 
responsibility, seems to reflect a point in the age continuum when adherence may become 
problematic.  Bridget is another example.  She had registered consecutive undetectable 
viral loads for over two years, but her recent lab tests showed a spike in these numbers.  
She admitted to her provider that she had not been taking her medicines like she used to, 
because she was busy with work.  Bridget was eighteen at the time of her interview, and 
about to graduate from high school.  Her viral load spikes appeared after graduation, 
when she was experiencing new, more adult responsibilities. 
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 Conversely, Lucy did not fit completely within the explanatory parameters of 
ideal adherence, yet she was consistently undetectable and said she never forgot to take 
her medicines.  She was not disclosed to at an early age, which was the most important 
variable in the study participants’ adherence success.  She was disclosed to at age fifteen, 
and was also strongly opposed to sharing her diagnosis with anyone.  However, Lucy’s 
mother was a vocal and active AIDS advocate, and very open about her own status.  This 
may have contributed to Lucy’s own personal acceptance that it was her fate to take 
medicines every day.  She was one of the few adolescents who talked about being afraid 
of what would happen if she forgot to take her medicines.  She seemed to have 
internalized the medical aspects of HIV and the concept of adherence as the basis for her 
disease management, even referring to her medicines, somewhat wryly, as her “three 
special friends.”  She knew the names of her medications and took a no-nonsense attitude 
toward them.   
 Interestingly, Lucy had a sibling in this research study, who was disclosed to at an 
earlier age than Lucy.  This sibling was less successful with adherence, did not have 
consistently undetectable viral loads, and could not name the prescribed antiretroviral 
medications.  This sibling had the same mother as Lucy, so there were similarities in the 
social environment of the siblings.  There do not seem to be overt differences in the two 
adolescents based on the findings of this research, yet one had significantly better health 
outcomes and disease management.  This puzzle may require further examination of prior 
disease history, as well as individual factors such as cognitive abilities and mental health 
issues. 
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The Role of the HIV-Positive Researcher Revisited 
 For many people with HIV or AIDS, these two labels – HIV and AIDS – are  
charged with enormous power.  AIDS continues to connote severe deterioration and 
approaching death; HIV is an infection you can live with.  The following exchange 
during the mothers’ focus group, between a mother and me, with the perinatally infected 
daughter serving as translator (Spanish), touches on the distinction between HIV and 
AIDS: 
Researcher:  How’s your mother doing, she forgets [her medicine] 
sometimes? 
Mother:  Yes. 
R:  How often? 
M:  Just two, two or three times. 
R:  Two or three times in how many, in how long? 
M:  In a week. 
R:  Two or three times a week. 
M:  Yes. 
R:  How about you [to daughter]? 
M:  She take it every day. 
Daughter:  I take it every day. 
M:  She undetectable. 
R:  And you’re not? 
M:  No. 
R:  You’re not undetectable. 
M:  No. 
D:  She got AIDS.  
R:  Yeah, but she can still be undetectable.   
 Sometimes I describe myself as having AIDS to try to rob the virus inside me of 
its dark power, to spit it out as I say the word, to show that a healthy, normal-looking 
person can have AIDS.  I am not scary.  I am not dying.  However, in the interviews, I 
hardly ever used the term AIDS.  In 22 interviews and one focus group, I said AIDS 
about ten times; in the first interview alone, I used HIV ten times.  I know that I used the 
term HIV in order to make the discussion less threatening.   
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 The fact of my own HIV infection is what turned my anthropological focus to 
HIV.  Had my HIV test result been negative, I would now almost certainly be deeply 
immersed in the cultural construction of anything but HIV.  This is an admission that I 
find difficult to make, knowing that the fear before my diagnosis, which made me shut 
out any reference to HIV, would probably have turned to relief and made me leave that 
AIDS problem to someone else.  Having HIV has been a peculiar kind of education, 
supplementing my book learning and giving me the opportunity to look at other people’s 
illness experience both emically and etically with a bit more clarity.  I can wade into 
another person’s experience, and then step back.   
 I have been able to take my HIV status and shape it into something good.  But I 
have symbolic capital (Grove et al. 1997) that makes it easier for me to cope with this 
disease.  No one important to me – family, friends, colleagues – has made me feel 
“discredited” (Goffman 1963:4).  I have crossed a bridge of shame and can now deal with 
this almost completely as a clinical condition.  But wait, that is not wholly true.  When I 
decided that I would tell the participants in this study that I, too, was living with HIV, I 
was open, as I usually am, to having them turn the tables on me.  Only one adolescent 
did, and while I answered her questions, I noticed some discomfort.  Unlike the 
perinatally infected individuals, I was responsible for my infection.  Shame resurfaces 
occasionally.  And so I found I could empathize with these young people, on the brink of 
adulthood, as they begin to navigate emotional and sexual relationships with their HIV in 
tow.  I knew the pressure of practicing safer sex as an adult, and I also knew the ease with 
which an adult can turn a momentary reckless eye, and HIV stares back.  I realized how 
much harder this can be for adolescents. 
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 Ten years after my diagnosis, I have forgotten one pill one time, and taken a dose 
late a handful of times.  I use an alarm for both my morning and my evening doses.  On a 
daily basis, my HIV is a virus that I control zealously, and my viral load is consistently 
undetectable.  I want to make sure that my therapy options remain open, so I am 
obsessively vigilant about preventing resistance.  I know that the virus may eventually 
become resistant to my current regimen no matter how adherent I am, but I do the only 
thing possible to ward off that evil.  This is what HIV means to me, and the very different 
meaning that the adolescents have grown up with and shaped anew as they entered 
adolescence is something that I struggled with during this study.  I am an adult virtually 
100% adherent to my antiretroviral medicines trying to understand the immense 
challenges of teenagers and young adults who are not.  
 I thought that my being HIV-positive might help connect us as fellow sufferers.  I 
thought it might make the participants more comfortable in the interview if they knew 
that this woman asking the questions had to take medicines like they did.  However, the 
world of adolescence is not one I inhabit, and they and I knew it.  HIV disease is a 
phenomenon to which each of us “brings to bear his or her lived experience, specific 
understandings, and historical background” (Finlay 2002:534), as this study has shown.  
Thus, my experience has been very different from the adolescents’,  but it afforded me a 
position of commonality with them regarding living with an incurable disease, and living 
with the knowledge that these medicines are going to be “our special friends” forever.  I 
occupied a space of “conscious partiality…a critical and dialectical distance between the 
researcher and his ‘objects’” (Mies 1983; quoted in Ellingson 1998:499) that allowed me 
to move into their HIV experience and back again into my researcher position.   
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 I tried to listen to the adolescents’ lives so that I could understand what 
challenged them most, and discover what paths they could follow to take control of their 
disease.  These findings can now be shared with the clinicians and other service providers 
who care for these young people, and recommendations for improving disease 
management can be proposed.  Finally, the understanding of living with AIDS must be 
shared with the world, that we might disable the stigma and learn to embrace each one of 
these adolescents – as well as 33 million others – as one of us. 
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CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS 
 
 This study of HIV disease management in medical ecological perspective among 
perinatally infected adolescents has illustrated the challenges that young people face in 
learning to cope with a lifelong chronic illness.  Since the advent of HAART in the mid-
1990s, a generation of children have grown into adolescence and adulthood.  For the 
adolescents in this study, all born before or just at the introduction of HAART, their 
survival into their teens and twenties is a future their mothers did not think possible when 
they were born.  Since then, these mothers and thousands of other parents, caregivers, and 
health care providers have been exploring and developing ways in which these children 
and young adults can best take control of their disease both medically and socially, can 
diligently manage a serious, incurable disease in order to remain healthy, and, at the same 
time, live a normal, untroubled childhood and adolescence.   
 The management of HIV disease remains complicated, despite great 
improvements in treatment, and the stigma that attaches to those living with the disease 
remains pronounced.  When these difficulties are encountered during the development of 
independence and maturity in adolescence, the process of gaining control in a healthy 
way can be daunting. What are the elements in this process that help or hinder the 
successful management of HIV, in particular, the successful adherence to HAART?  
What cultural and social influences impinge upon adolescents’ decisions about health-
related behaviors?  Though this study was primarily an exploratory ethnographic analysis 
with a very small sample of adolescent participants, it nonetheless provides a rare and 
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important glimpse of their perspectives on living with HIV.  This study has drawn some 
conclusions in answer to these questions, though it has also illustrated the uniqueness of 
each young person’s lived experience and his or her individual approach to making a 
place for HIV in his or her life. 
 Though the study was limited in scope, it has generated a number of 
recommendations that health care providers, social service providers, caregivers, and 
adolescents can explore, collaborate on, and implement in order that perinatally infected 
adolescents move smoothly toward adulthood in good health. 
Conclusions 
 The most important conclusion drawn from this research is the importance of 
early disclosure to the child of his or her HIV status.  Closely related to this, because it 
may in fact facilitate early disclosure, is the parent or other caregiver’s attitude of 
openness and confidence toward dealing with the challenges of HIV, in herself if she is 
the biological mother, and in the child’s life regardless of who the caregiver is.  Some of 
the adolescents in this study had lost parents to HIV or had been taken from parents who 
had substance abuse problems, but if they had been brought up by caregivers who faced 
HIV with equanimity and acceptance, then the adolescent had the opportunity to adapt to 
his or her own HIV more easily and competently.  The earlier in life that this process of 
identification, understanding, and adaptation began, the more likely it was that a place for 
HIV would be established in the adolescent’s life and be less of a disruption (Bury 1982).  
This would be a place where the importance of HIV treatment was prominent, but the 
HIV per se was not. 
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 Another key conclusion was the importance of a medical meaning of HIV in the 
adolescent’s life.  This would not only ensure the understanding of the implications of 
HIV treatment, but it would replace, or at least shift to a less powerful position, the more 
troubling social and cultural connotations of HIV.  HIV would be less the scary secret, 
and more the chronic nuisance.  If adolescents learned how to make the medications a 
routine part of their daily lives, they would be able to make HIV management a normal 
part of life.  Hence, they could feel more normal, more like other young people. 
 A third conclusion that is drawn from this study is the adolescent’s need for a 
better understanding of adherence, viral resistance, and HIV transmission risk.  This lack 
of understanding seems to be due in part to the failure to treat children and adolescents as 
capable participants in their care and treatment.  As the clinicians and the literature both 
point out, the simultaneous coddling and commanding of children does not give them the 
tools to begin making decisions and taking responsibility, and results in difficult and 
often unsuccessful transition to adult clinical care (Wiener et al. 2007).   
 In addition, being uninformed about the ramifications of adherence versus non-
adherence puts the adolescent at risk for therapy failure and poor health outcomes, and 
his or her sexual partners at greater risk for contracting HIV.  Because adolescents with 
perinatally-acquired HIV have been prescribed antiretroviral therapy from an early age, 
they are likely to have some resistant strains of HIV (Mullen et al. 2002).  It is also 
possible that they were infected with a resistant strain carried by their mothers 
(Delaugerre et al. 2007).  For this reason, adherence is extremely important; it makes a 
lower viral load and thus reduced risk of HIV transmission to partners more likely, and it 
also reduces the risk of further resistance to the adolescent’s current or future regimens.  
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The adolescent’s HAART and viral resistance history notwithstanding, it is of utmost 
importance for these adolescents to understand and practice good adherence, both for 
their own health and for current or future sexual partners. 
 Finally, this research points to the need for an exchange of chronic illness 
representations held by health care providers and adolescents.  Because many perinatally 
infected adolescents are today living lives relatively free of symptoms, opportunistic 
infections, and medication side effects, there may be a complacency in their attitudes 
toward adherence and toward the key health indicators, viral load and CD4 level.  This is 
also associated with their lack of comprehensive knowledge about HIV infection and its 
ramifications.  On the other hand, health care providers need to know the beliefs and 
behaviors in the adolescents’ lived experience of HIV that are nonnegotiable, and work 
with the patients to find a model of HIV disease management that conforms to both the 
medical and the social and cultural demands of practitioner and patient.  These 
imperatives need to be better understood, accepted, and integrated by both parties, if 
successful disease management and, therefore, favorable individual and public health 
outcomes, are to be achieved.   
Recommendations 
 The following recommendations are directed toward service providers, parents 
and other caregivers, and adolescents with perinatally acquired HIV disease.  The 
adolescents who are seen at the USF pediatric clinic have access to a variety of 
professionals in addition to the clinicians: social workers, medical case managers, mental 
health professionals, nutritionists, nurse educators.  Many of them also have access to 
support and social services though community-based case management agencies.  All of 
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these professionals in the HIV service delivery system have the potential to guide 
adolescents as they navigate the health care system, prepare for transition to adult care, 
and continue their daily management of their HIV disease.  These recommendations 
could be implemented in a number of the venues through which adolescents find care, 
treatment, and support: 
 1. Parents and caregivers of perinatally infected children should be counseled  
  about disclosure beginning before the child is of school age.  Their fears and  
  anxiety, as well as their lack of medical knowledge, should be addressed.   
  Disclosure should be delineated as a process (Lesch et al. 2007;Ledlie 1999;  
  Lipson 1993), with information benchmarks developed according to the  
  child’s age (and cognitive abilities), with identification of HIV by age 10. 
 2. The roles and responsibilities of parent/caregiver and child regarding   
  antiretroviral therapy should be clear-cut and age appropriate.  Caregivers  
  should be counseled on setting up a plan for the gradual delegation of   
  responsibility to the child, which includes the continual monitoring of children 
  and adolescents to ensure that they are adhering to their medications   
  successfully and not assuming full responsibility prematurely (Marhefka et al.  
  2008). 
 3. Counseling should be available and providers should work with biological  
  mothers (and other family members) to cope with their own HIV status, so as  
  to engender the openness that is necessary to accept the disease without fear  
  and shame before disclosing to the child.  It is important to know that   
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  assistance to both the infected child and the family may need to be ongoing  
  (Wilfert et al. 1999:165). 
 4. Adolescents must be given thorough, if basic, instruction on antiretroviral  
  therapy, adherence, resistance, the implications of HIV adherence and   
  resistance for transmission to sexual partners.  They should understand the  
  meaning of the viral load and the CD4 count, be encouraged to know their  
  most recent lab results, and know the names, dosages, and schedules of their  
  medications.  This clinical instruction should begin with children as soon as  
  they learn their HIV diagnosis, and before they are given responsibility for  
  medications.  The discussion should continue and become more detailed as  
  children and adolescents are given increasing responsibility. 
 5. Provider and patient models of HIV disease management (Hunt and Arar  
  2001:353) should be constructed, compared, interpreted, and integrated to  
  form a model of consensus that will promote success from the perspective of  
  both the provider and the adolescent patient.  This model can include a  
  cost/benefit examination of adherence and disease management, which  
  includes an “adaptive compromise” between providers and patients   
  (Armelagos et al. 1992:42).  Providers have to begin appropriate delegation of 
  responsibility to the child while understanding the adolescent’s real social and 
  cultural obstacles to good adherence.  Partnership must be forged early on and 
  continue throughout and be enhanced during adolescence, and the locus of  
  control, as well as responsibility for successes and failures, must be shared. 
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 6. Reminder tools should be presented to and encouraged among adolescent  
  patients.  Pill boxes, small keychain pill containers, alarms on cell phones and  
  watches, text messages, and other reminders that can be used wherever the  
  adolescent is and can be discreet are more likely to be used and to be   
  effective.  This will enable adolescents to integrate the medications into their  
  daily routines. 
 7. In keeping with nurse practitioner Ed’s endorsement, adolescent patients  
  should be encouraged and allowed to have friends, and especially sexual  
  partners, accompany them to their medical visits so that the disease and its  
  implications can be explained and demystified for the adolescents’ peer  
  networks.  This should be part of ongoing encouragement of adolescents to  
  share and talk about their disease with trusting peers. 
Suggestions for Future Research 
 As an exploratory study of perinatally infected adolescents’ lived experience with 
HIV disease, this research was limited to a biocultural examination of the proximate 
contextual factors that influenced their decisions and behaviors surrounding HIV disease 
management.  A number of issues were raised by this research that should be addressed 
in subsequent studies.   
 Mental health problems and treatment were not the focus of this research and 
were not discussed by the adolescents, but the clinicians in this study, as well as some 
studies documented in the literature on HIV-infected adolescents, acknowledged the 
prevalence of mental health diagnoses and their impact on successful disease 
management, especially medication adherence (Williams et al. 2006; Dodds et al. 2003; 
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Murphy et al. 2001).  Whether higher rates of psychiatric problems are due to HIV itself 
or to the socioecological environment (household and caregivers where HIV is present) is 
another question requiring further investigation (Williams et al. 2010).  Since mental 
health disorders in adolescents are also often underidentified (Murphy et al. 2005), more 
attention to mental health in adolescents and specific research on HIV-infected 
adolescents may shed light on whether and how mental health influences adherence 
outcomes. 
 The presence of psychiatric symptoms may also have an impact on substance use 
in adolescents (Williams et al. 2010).  One of the clinicians in this study maintained that 
among those adolescents who had problems with medication adherence, many also had 
substance use problems. Thus, with or without accompanying mental health disorders, the 
association of substance use with lower adherence to medications is another issue that 
merits further study.   
 Antiretroviral therapy today has vastly improved in terms of pill burden, 
complicated pill schedules and ability to tolerate the medications.  There is also a greater 
availability of alternative regimens as new drugs have been developed and approved.  
This means that adherence problems due to difficult regimens and side effects have been 
attenuated.  None of the participants in this study had serious problems with side effects, 
yet this may be one factor that affects optimum adherence (Kourrouski and Lima 2009).  
In particular, adolescents who have been on HAART since birth, may have already 
changed regimens several times, and have fewer options available to them.  Thus, an 
exploration of the history of adolescents’ drug regimens, resistance to certain drugs, and 
 218
the difficulties they are experiencing with their current medications may shed insight into 
the adherence issues of this particular population.   
 Given that the adolescents’ HIV disease management was situated in medical and 
social spheres of influence, in-depth observation of these environments would elucidate 
additional factors that affect decision making about adherence and disclosure, as well as 
the experience of both stigma and support.  Shadowing adolescents as they navigate their 
school, family, and clinical relationships, coupled with focus groups with adolescents, 
both HIV-positive and HIV-negative, would have the potential of illuminating the social 
conditions and cultural domains (Trotter 1997) that engender conceptions and perceptions 
of HIV, AIDS, adherence, stigma, and acceptance. Such up-close observation may also 
reveal the “situational temptations” (MacDonell et al. 2011) that adolescents face in their 
daily experience with HIV disease.  
Observation of and further in-depth interviews with clinicians and patients are 
necessary in order to discover and understand the impact of the clinician-patient 
interaction on adolescents’ acceptance of responsibility for disease management and their 
ability to fulfill that responsibility successfully.  This study showed very different 
interaction styles of the clinicians, and further study might determine the interaction 
styles that are most effective in connecting with adolescents, encouraging learning and 
the assumption of responsibility, and improving adherence and health outcomes.  
  The comprehensiveness of the USF pediatric system of HIV medical care allows 
patients’ multiple needs to be met at one location, yet further study would answer 
questions about whether adolescents’ dislike of long clinic visits is ultimately detrimental 
to their engagement in their own care and treatment.  It is also necessary, now that 
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perinatally infected children are reaching adulthood, to see how the pediatric model of 
care, in which the locus of responsibility rests heavily with the provider, affects 
adolescents’ and young adults’ readiness for transition to adult care (Foster et al. 2007; 
Wiener et al. 2007).  An examination of the efficacy of the transition preparation program 
at the pediatric clinic and the need for implementation of best practices are also needed, 
as adolescents may find the transition more difficult than anticipated (Fair et al. 2010) 
and many will not successfully transition despite preparation at the pediatric clinic 
(Barrett et al. 2010). 
 The survival of perinatally infected children into adulthood means that these 
individuals must confront their futures, which includes having children.  While the 
present study did not focus on future goals, a number of the participants mentioned the 
goals of continuing their education, getting a job, and having children.  Part of disease 
management, therefore, will mean preventing second-generation mother-to-child 
transmission, which has been referred to as “super-vertical” transmission (Mitchell et al. 
2008).  Adherence and viral suppression become increasingly important for young 
infected pregnant women, if they are to reduce the probability of transmission to their 
newborns.  This is especially important since second-generation perinatal transmission 
may involve virus that is resistant to certain antiretroviral drugs (Brogly et al. 2007). 
 Finally, given that many of the participants in this research disclosed their HIV 
status to very few friends, and most had little or no contact with other HIV-positive 
adolescents, a study of the barriers to social support among perinatally-infected 
adolescents is warranted.  The positive effects of this kind of peer support on disease 
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management, including adherence, and on other healthy behaviors require further study 
(Dodds et al. 2003). 
Coda 
 Caregivers and health care providers, and others who are aware of the 
adolescent’s diagnosis, must be given the tools to engender a narrative of hope in 
adolescents with perinatally acquired HIV.  Only one participant in this study had been 
given the opportunity to see her HIV status in a positive light and foresee a meaningful 
future:  
even though I’m just another person on this planet, like just realizing  
that I can make a difference, and that’s just kind of helped me a lot…  
I’m thinking like maybe, as a big picture, what that would mean would 
probably be like working for the WHO in like Africa and China and  
places like that, you know.  So I would be making a difference to people 
around the world, I guess, who are HIV positive or not. [Rachel]  
 
Adolescents with perinatally acquired HIV disease are now reaching the age of thirty, and 
it is incumbent upon those around them to guide them, from early childhood and through 
adolescence, to anticipate an adulthood of possibility and productivity.  This can be done 
during adolescence by encouraging them to push the boundaries of their disease and to 
plan for their futures.  Whether or not this entails work related to HIV and AIDS is, of 
course, up to each of them, but they need learn that with the proper knowledge and 
management of their HIV, this disease need not manage them. 
 I end with a passages from two anthropological works written about another 
chronic disease, epilepsy, which acclaim the power of social and cultural narratives:  
[N]arrative is uniquely suited to represent illness and reality as open  
to mystery, potency and change (Good et al. 1994:837).   
 
Possibilities for transformation in the conditions of the afflicted are 
kept alive.  Multiple perspectives and divergent interpretations are 
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encouraged.  Alternate sources of power for potential transformations  
are conjured; social actors reject the anticipated; hope is engendered 
(Kleinman et al. 1995:1320). 
 
The lived experience of adolescents with perinatally acquired HIV needs to spawn new 
narratives of power and reinvention, both for the adolescents’ personal growth and for  
society’s conversion, narratives which resist the orthodoxy of stigma that has governed 
HIV and AIDS for too long.  We must now draw on the lessons discovered in this study  
to facilitate the acceptance of HIV and consequent successful disease management 
among those living with this disease.  
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Appendix A: Adolescent Medication Questionnaire 
Adherence Issues among Adolescents Perinatally Infected with HIV 
 
Adolescent Medication Questionnaire 
 
Part 1: Personal Information 
 
Name: ________________________  ID Number: _____________ 
Age: _______ Date of Birth: ____/____/______ Gender:   Female□     Male□ 
Ethnicity:        Hispanic□ Non-Hispanic□  
Race:    Black□    White□    More than one□    Other (Specify) ________________ 
 
Part 2: Naming medications and describing medication schedule 
              
2.1 What medications do you currently take for your HIV disease? 
__________________________________________________________________ 
2.2 What other medications do you take, besides your HIV meds?  (If no other 
medications, write none.) 
__________________________________________________________________ 
2.3 Complete the table for your HIV medications only. 
Medication 
Name 
How many per 
day? 
When do you take 
it/them? 
Any specific instructions 
(with/without food, at a specific 
time, etc.) 
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Part 3: Medication Adherence 
3.1 Thinking about the last two weeks, how many days did you skip an HIV 
medication for any reason? 
0 □     1 □      2-3□   4 or more□  
3.2 If you skipped an HIV medication in the last two weeks, was it 
A single pill□   
A single medication (all of the pills for that day) □   
All of your HIV medications on that day □ 
 
3.3 What were the reasons that you skipped your medication in the past two weeks? 
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________  
3.4 What things make it difficult for you to take your medications as instructed? 
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________ 
3.5 How often would you say you skip a pill or pills overall? 
Once a month □  Twice a month □  3 or more times a month □ 
3.6  Does your doctor or nurse talk to you about taking your medications?   
Yes□ No □ 
What does he/she say about taking your medications? 
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________ 
3.7 Do you talk to your doctor or nurse about any problems or issues you have with 
your medications?  
Yes □ No □ 
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What does he/she say?  What does he/she tell you to do? 
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________ 
 
3.8 On a scale of 1 to 10, how well does your doctor or nurse understand your issues, 
challenges, problems, and experience with taking HIV medications? 
       1            2           3           4           5           6           7           8           9        10 
      /_______/______/______/______/______/______/______/______/_____/ 
1—Doesn’t understand at all -----------------------------10 Understands everything 
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Appendix B: Semi-structured Adolescent Interview Guide 
1. When were you told that your illness was HIV disease? Who told you?  What 
 were the circumstances? 
 
2. How did you feel when you learned your diagnosis? 
 
3. Tell me what it is like for you living with HIV.  (Probe for physical effects, 
 illnesses and  hospitalizations, change in medication regimen, social support, 
 social difficulties, stigma, goals and the future, medical care and providers, 
 family support/difficulties.) 
 
4. Describe a typical day in your life.  How do you spend your weekends and free 
 time?  (Probe for how often HIV is part of that day, how often they think about it, 
 etc.) 
 
5. What medicines do you take for HIV?  Describe your regimen – number of pills 
 per day, time of pill-taking, other instructions (with/without food, spacing of 
 different pills, refrigeration,  etc). 
 
6. What problems do you have that you feel are associated with taking your HIV 
 meds?  (Probe  for physical side effects, complicated regimen, keeping 
 medications hidden from others, fitting medication taking into schedule.) 
 
7. How difficult is it for you to take your pills every day and according to the 
 directions? 
 
8. Do you ever not take your HIV meds?  Under what circumstances? 
 
9. What does adherence mean to you? (Explain adherence.) 
 
10. Describe your relationship with your health care providers – doctor, nurse, social 
 worker, mental health professional. 
 
11. How would you rate your HIV health care? 
 
12. Have you disclosed your illness to your friends?  Others?  For those to whom you 
 have disclosed, how did you choose these people to share your diagnosis?  
 What were the circumstances?  How did the person react to this news?  For those 
 not disclosed to, why haven’t  you disclosed to these people? 
 
13. What is your family life like?  (Probe for household makeup, socioeconomic 
 situation.)  What other family members are positive? (Probe for health care, 
 medication regimens, attitudes toward HIV and medications of positive family 
 members.) 
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14. Do you have a boyfriend/girlfriend? How old is he/she?  Does he/she know about 
 your HIV?  Do your closest friends have boyfriends/girlfriends?  How important 
 is having a boyfriend/girlfriend to you? 
 
15. What does safer sex mean to you? 
 
16. (If participant has boyfriend/girlfriend) Are you in a sexual relationship with your 
 boyfriend/girlfriend?  (If yes) What does that mean?  Are you practicing safer  
 sex?  What does that entail? 
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Appendix C: Clinician Interview Guide 
All questions pertain to perinatally infected adolescents. 
1. How long is a typical care visit with an adolescent? 
2. What percentage of the visit time is comprised of you, the provider, talking or 
explaining? 
3. What percentage of the visit time is comprised of the adolescent patient speaking 
or explaining? 
4. Do you set aside any time during the visit to speak to the adolescent privately?   
5. How involved are your adolescents in their personal treatment and management 
of HIV? 
6. Do you conduct sexual histories with your adolescent patients? 
• All?  Which ones? 
• What is included in your sexual history? 
• Do you discuss sexual activity and risk with your patients?  What do you 
include in this discussion? 
 
7. How often do you talk to your adolescent patients about adherence? 
• What does adherence counseling include? 
• How involved are your adolescents in their individual treatment plan? 
• In your opinion, what is the biggest barrier to adherence among your 
adolescent patients? 
• In your opinion, what is the most important facilitator of adherence among 
your adolescent patients? 
 
8. What percentage of patients seen WITHIN THE PAST THREE MONTHS 
received the following screenings and/or assessments? 
 
  Mental Health Screening:  
  None    1-24%    25-49%    50-74%  75-100%      Don’t know 
  Alcohol & Substance Use Screening:  
  None    1-24%    25-49%    50-74%    75-100%    Don’t know 
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  Behavioral Risk Assessments:   
  None    1-24%    25-49%    50-74%    75-100%    Don’t know 
  STD Screening:   
  None    1-24%    25-49%    50-74%    75-100%    Don’t know 
9. What percentage of your patients seen WITHIN THE PAST THREE MONTHS 
has the following diagnoses? 
  Hepatitis C      %  Mental health disorder      %  
 
  Drug and/or alcohol problems      % Any STI      % 
 
  TB      % AIDS (Progressed to AIDS)      %  
 
  OI      %   Other complicating condition      %   What conditions?  
 
 
10. What percentage of your patients do you estimate consult with a traditional healer 
and/or complementary and alternative medicine (CAM) practitioner or engage in 
alternative medicine practices? 
 
11. A.  What do you see as the three major health care issues or needs among the 
adolescents you serve at this clinic? 
 
 1.                      
 2.                      
 3.                      
 
B.  Of their parent(s) or caretakers? 
 
 1.                      
 2.                      
 3.                      
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C.  What do you see as the three major non-health-related issued that affects the 
adolescent’s health and health care? 
  
 1.                      
 2.                      
 3.                      
 
12.  Describe the relationship between the adolescent patient and you, his or her 
health care  provider. 
 
13. What barriers do you experience in providing the best possible care to HIV-
infected adolescents? 
(Suggest the following, if necessary.) 
 [01] Limited Resources 
 [04] Lack of Provider Expertise 
 [05] Other Health Priorities 
 [06] Lack of Provider Interest 
 [07] Patients/Clients Not Aware of Services 
 [08] Issues of Confidentiality 
 [09] Issues of Cultural Competency 
 [10] Language Barriers 
 [88] Other specify ____________________ 
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Appendix D: Focus Group Protocol 
Before the focus begins: 
• Have copies of consent form.  Collect signed consent forms. 
• Have pens, sticky notes, dots, name tags, and voice recorder ready. 
• Set out snacks. 
Introducing the focus group activity: 
  
1.  Go over ground rules. 
 
• Confidentiality – keeping what is said in the group private.  Assure them that 
anything said during the focus group will not be shared with their parents or anyone 
at the clinic, except when the research is finished, and none of their identities will be 
shared.  It will be general things that I found out, or I will refer to you as a participant. 
 
• You can use your ID number instead of your name.  When you speak, say your 
number first. 
 
• Only one person speaks at a time. 
 
• Respect everyone’s input.  Remember that there may be differences of opinion and 
experience. 
 
2.  Explain research study. 
 This is a study in which I want to understand living with HIV and managing HIV 
in the everyday lives of perinatally infected adolescents, from their perspective.  We 
know medically what HIV is and how it is treated.  I, as an adult with HIV, understand 
some of the challenges that older women have when they’re living with this disease.  
Adolescents and young adults will deal with their challenges differently, and for those 
who were born with HIV, and have had to take medications and see the doctor regularly, 
and maybe have had other illnesses, and have family members with HIV, the experience 
will be different as well.  This study is an opportunity for youth to tell their stories, to 
share the challenges they face, to share with us ways in which they have managed well 
with the disease, the experiences that are their own and affect the way they deal with HIV  
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in their relationships with other people, in their health care, in their medication issues, in 
their family life. 
 We at FAN have perinatally infected youth who live in many different kinds of 
family and household situations.  One of the unique relationships for these youth, 
however, is that between them and their biological mothers.  Since all of you are infected 
with HIV and transmitted the virus to your child, there are no doubt interactions, 
attitudes, problems, benefits of this mother-child relationship that influence the health 
and wellbeing of your child, as well as the way in which your child approaches her/his 
HIV disease and life in general.   
 In a focus group such as this, we bring together a group of people who focus on a 
topic that is of interest to the researcher. There are several topics that I want you to think 
and talk about during this focus group. I will introduce a topic, and pose some general 
questions, and then you will take turns discussing the topic, responding to other people’s 
ideas, and together presenting your thoughts on those topics.  We may use the sticky 
notes and dots for some of the questions, so I may pose a question and have you write 
down some ideas, then put them in order of importance using the dots.  Then we will 
share what you’ve written as a group.  In a group discussion, it is important to hear from 
everyone, so I may need to cut in at some points in order to let other people speak. Since 
we will have only about 10 minutes per question, it will be important to try to limit your 
responses to a minute or two, if possible. 
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3.  Introduce Focus Group Topics/Questions for Discussion 
1. Talk about your diagnosis.  Did you disclose to family and friends? What were 
the reactions of your family and friends?  
  
2. Talk about how you feel today about being HIV+. 
 
3. What is the worst thing about having HIV? 
 
4. What is the best thing about having HIV? 
 
5. Talk about what it was like learning that your child was infected with the virus. 
 
6. When and how did you disclose your disease and his or her own disease to your 
child? 
 
7. At what age was the child told he/she had HIV – the word HIV was used. 
 
8. At what age did you want to disclose, i.e., did you have any misgivings about 
disclosing when you did? 
 
9. Discuss the strengths and weaknesses of your health care.  How happy are you 
with (how would you rate) your health care? 
 
10. Discuss the strengths and weaknesses of your child’s health care.  How happy are 
you with (how would you rate) your child’s health care? 
 
11. What do you know about HIV and your own health indicators relating to HIV 
(viral load, CD4 count, etc.)? 
 
12. How would you rate your adherence to your medications? 
 
13. What do you know about antiretroviral therapy – the drugs, the medication 
schedules, the effects, the side effects, the effectiveness, drug resistance, etc.? 
 
14. Discuss your child’s medication regimen and the responsibilities, roles, 
involvement of you and the child in the child’s taking of and adherence to the 
medications.  How much independence, and in what areas, does your child have 
in her/his management of HIV in her/his everyday life? 
 
15. In thinking about the management of HIV in your life and your child’s life, what 
do you do to stay healthy and to ensure your and your child’s longevity?  Include 
all things, not just your doctor visits and antiretroviral therapy. 
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Appendix E: Codes for Analysis 
 
Adolescents Interviews 
 
Adjustment 
Adolescent Responsibility/Independence 
Age of Disclosure 
Age of Disclosure-Early 
Age of Disclosure-Intermediate 
Age of Disclosure-Late 
Benefits/Social Supports 
Caregiver Involvement in Medication 
CD4 or VL Mention 
Cultural Factors 
Disclosure to Boy/Girlfriend/Sexual 
Partner 
Disclosure to Friends 
Disclosure to Others 
Family Stability 
Family Support 
Future Goals 
Health Status 
Length of Current Regimen 
Loss of Parent/HIV+ Parent 
Lying 
Medication Adherence 
Medication Name Knowledge 
Obstacles 
Peer Support 
Provider-Patient Relationship 
Psychosocial Issues 
Resistance 
Risky Behaviors 
Secrecy 
Sexual Activity 
Stigma 
Understanding of HIV/Resistance 
 
Clinician Interviews 
 
Accidental Disclosure 
Adherence 
Adolescent Engagement 
Adolescent Issues 
Alternative Therapies 
Barriers to Adherence 
Barriers to Care 
Developmental Delay 
Disclosure 
Legal Issues 
Medications 
Mental Health Problems 
Relationship with Patients 
Resistance and Labs 
Secrecy 
Sexual Activity 
STIs 
Substance Use 
 
 
 
 
 
 
Mothers’ Focus Group 
 
Child's Adherence 
Child's Independence 
Disclosure to Child 
Distrust 
Health Care and HC Providers 
Medications and Adherence 
Mother’s Own Diagnosis 
 
 263
Appendix F: Graphs of Adolescent Viral Loads 
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Appendix G: Graphs of Adolescent CD4 Counts/Percents 
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